Summary of Feed Carcinogenicity Study of 2-Amino-4-Chlorophenol in F344 Rats

September 2008

Japan Bioassay Research Center

Japan Industrial Safety and Health Association

PREFACE

The tests were contracted and supported by the Ministry of Health, Labour and Welfare of Japan. The tests were conducted by Japan Bioassay Research Center (JBRC) and the report was prepared by JBRC and peer reviewed by outside expert pathologist. Complete report was submitted to Ministry of Health, Labour and Welfare of Japan on September 30, 2008.

This English Summary was translated by JBRC from Japanese complete report.

Summary of Feed Carcinogenicity Study of 2-Amino-4-chlorophenol in F344 Rats

Purpose, materials and methods

2-Amino-4-chlorophenol (ACP, CAS No. 95-85-2) is a crystalline solid with a melting point of 137°C. It is insoluble in water.

The carcinogenicity and chronic toxicity of ACP (greater than 99.1% pure) were examined by feeding groups of F344/DucrlCrlj (Fischer) rats ACP-containing diets for 2 years (104 weeks). Each group of test animals consisted of either 50 male or 50 female rats. The dietary concentration of ACP was 0, 1280, 3200 or 8000 ppm (w/w). Both sexes were exposed to each concentration of ACP. The highest dose level was chosen so as not to exceed the maximum tolerated dose (MTD), based on both growth rate and toxicity in a previous 13-week toxicity study. The identity of the ACP used in these experiments was confirmed by both infrared spectrometry and mass spectrometry, and it was analyzed by gas chromatography before and after its use to affirm its stability. To ensure that the concentration of ACP in the diet remained constant, the concentration of APC in the diet was determined by high performance liquid chromatography at the time of preparation and on the 4th day after preparation; ACP-containing food was stored at room temperature. The animals were observed daily for clinical signs and mortality. Body weight and food consumption were measured once a week for the first 14 weeks and every 4 weeks thereafter. All animals, including those found dead or in a moribund state as well as those surviving to the end of the 2-year exposure period, underwent complete necropsy. Urinalysis was performed near the end of the administration period. For hematology and blood biochemistry at the terminal necropsy, surviving animals were fasted overnight and bled under deep ether anesthesia. Organs and tissues were removed, weighed and examined for macroscopic lesions at necropsy. The organs and tissues were then fixed and embedded in paraffin. Five µm thick tissue sections were prepared and stained with hematoxylin and eosin and examined microscopically. Incidences of neoplastic lesions were statistically analyzed by Fisher's exact test. Any positive dose-response trends of ACP induction of neoplastic lesions were analyzed by Peto's test. Incidences of non-neoplastic lesions and urinalysis were analyzed by the Chi-square test. Changes in body weight, food consumption, hematological and blood biochemical parameters, and organ weights were analyzed by Dunnett's test. The present studies were conducted in accordance with the Organisation for Economic Co-operation and Development (OECD) Good Laboratory Practice and with reference to the OECD Guideline for Testing of Chemicals 451 "Carcinogenicity Studies".

Results

There was no significant difference in survival rate between any ACP -fed group of either sex and their respective controls. There was a decrease in the body weights of all the ACP-fed rats, both male and female; however, except for the 8000 ppm-fed animals, body weights recovered before the end of the experimental period. Terminal body weights of the 8000 ppm-fed males and females were suppressed to 95% and 87% of their respective controls. Slightly decreased food consumption was observed sporadically in the 8000 ppm ACP-fed females. Yellow coloration of the fur was observed in all the ACP-fed rats of both sexes. The incidence of forestomach tumor (squamous cell carcinoma and papilloma) was increased in all ACP-fed male mice. The incidence of urinary bladder tumor was increased in the 8000 ppm ACP-fed males. The incidence of squamous cell papillomas in the forestomach was increased in the 8000 ppm-fed females. In addition, the following non-neoplastic lesions were observed: the incidence of forestomach squamous cell hyperplasia was increased in the males fed 3200 and 8000 ppm APC and in females fed 8000 ppm APC; slight changes of anemic parameters including red blood cell count were noted in females fed 3200 and 8000 ppm APC; and deposition of hemosiderin in the spleen and increased spleen weights were observed in the 8000 ppm-fed females.

Conclusions

There was clear evidence of carcinogenic activity of 2-amino-4-chlorophenol in male rats. There was some evidence of carcinogenic activity of 2-amino-4-chlorophenol in female rats, based on an increased incidence of squamous cell papillomas in the forestomach.

SELECTED TABLES

TABLE C 1	BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS MALE
TABLE C 2	BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS FEMALE
TABLE C 3	BODY WEIGHT CHANGES: MALE
TABLE C 4	BODY WEIGHT CHANGES: FEMALE
TABLE D 1	FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS: MALE
TABLE D 2	FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS: FEMALE
TABLE D 3	FOOD CONSUMPTION CHANGES: MALE
TABLE D 4	FOOD CONSUMPTION CHANGES: FEMALE
TABLE E 1	CHEMICAL INTAKE CHANGES: MALE
TABLE E 2	CHEMICAL INTAKE CHANGES: FEMALE
TABLE F 1	HEMATOLOGY: MALE
TABLE F 2	HEMATOLOGY: FEMALE
TABLE G 1	BIOCHEMISTRY: MALE
TABLE G 2	BIOCHEMISTRY: FEMALE

TABLE H 1	URINALYSIS: MALE
TABLE H 2	URINALYSIS: FEMALE
TABLE J 1	ORGAN WEIGHT, ABSOLUTE: MALE
TABLE J 2	ORGAN WEIGHT, ABSOLUTE: FEMALE
TABLE K 1	ORGAN WEIGHT, RELATIVE: MALE
TABLE K 2	ORGAN WEIGHT, RELATIVE: FEMALE
TABLE L 1	HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS: MALE: ALL ANIMALS
TABLE L 4	HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS: FEMALE: ALL ANIMALS
TABLE O 1	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: MALE
TABLE O 2	NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS: FEMALE
TABLE Q 1	HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER: F344/DuCrlCrlj MALE RATS
TABLE Q 2	HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER: F344/DuCrlCrlj FEMALE RATS
TABLE R	CAUSE OF DEATH OF RATS IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL

BODY WEIGHT CHANGES AND

SURVIVAL ANIMAL NUMBERS: MALE

STUDY NO. : 0579
ANIMAL : KNT F344/DuCFICFLj[F344/DuCF.j]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

	;	70.73100		reco bbin			3200 ppm		~	and none	
	Av. Wt.	No. of	Av. Wt.	% of	No. of	Av. Wt.	Jo %	No. of	Av. Wt.	% of	No. of
Week-Day on Study	V	Surviv. <50>		cont. <50>	Surviv.		cont. <50>	Surviv.		cont. <50>	Surviv.
0-0	_	50/50	1	100	50/50		100	50/50	- 1	001	50/50
1-7	156 (50)	20/20	156 (50)	100	50/50	156 (50)	100	50/50	152 (50)	26	50/50
2-7	_	50/50		66	50/50		66	20/20		96	50/20
3-7	_	50/50		86	50/50		66	20/20		95	50/50
4-7		50/50		86	50/50		66	50/50		95	50/50
22		20/20		97	50/50		8 6	50/50		95	50/20
2-9	_	50/50		26	50/50		66	50/50	246 (50)	92	50/50
2-2	_	20/20		26	20/20		66	50/50		95	20/20
28	_	20/20		26	20/20		66	20/20		95	20/20
2-6	_	20/20		6	20/20		66	20/20		92	50/50
107		50/50		26	20/20		66	20/20	291 (50)	92	50/50
11-7		50/50		26	20/20		66	20/20		92	50/50
12-7		50/50		26	50/50		66	20/20	302 (50)	92	50/50
13-7	325 (50)	50/50		26	20/20		86	50/50		94	50/50
14-7		50/50		96	50/50		86	50/50		5	50/50
2-81		50/50		26	50/50		001	50/50		96	50/50
22-7	368 (50)	50/50		26	50/50		100	50/50	353 (50)	96	50/50
26-7		20/20		26	20/20		100	50/50		96	50/50
30-7		50/50	383 (20)	64	20/20		100	50/50		96	50/50
34-7	403 (49)	49/20		6	20/20		100	50/50		16	50/50
38-7		49/20		96	20/20		100	50/50	397 (50)	96	50/50
42-7	422 (49)	49/50		26	49/50		100	50/50		96	50/50
46-7		49/50	_	26	49/50	433 (50)	101	50/50		96	50/50
2-05		49/50	423 (49)	26	49/50	438 (50)	· 101	50/50		26	50/50
54-7		49/50		62	49/50		101	20/20		26	50/50
28-7		49/50	431 (49)	26	49/50	447 (50)	101	50/50		26	50/50
2-29		49/50		26	49/50		101	49/50	431 (50)	26	50/50
2-99	449 (49)	49/50	437 (49)	26	49/50	455 (49)	101	49/50		96	50/50
2-07	451 (47)	47/50	439 (49)	26	49/50	455 (49)	101	49/50	434 (48)	96	48/50
74-7	452 (47)	47/50	441 (49)	86	49/50	457 (49)	101	49/50		96	47/50
7-87	452 (45)	45/50		86	49/50	460 (47)	102	47/50		96	47/50
82-7	448 (44)	44/50	440 (49)	86	49/50	457 (46)	102	46/50	_	26	47/50
2-98	444 (44)	44/50	439 (48)	66	48/50	456 (46)	103	46/50	_	96	47/50
206	440 (43)	43/50	437 (47)	66	47/50	453 (46)	103	46/50	_	96	44/50
94-7	431 (40)	40/20	436 (44)	101	44/50	441 (46)	102	46/50	_	96	43/50
7-86	427 (36)	36/20	422 (42)	66	42/50	441 (41)	103	41/50	412 (41)	96	41/50
102-7	414 (35)	35/20		100	40/20		104	41/50	_	96	39/20
104-7	(00)	00/60	(00) 111	5	01/00	(00)	,	, 00 1, 00			

BAIS 4

BODY WEIGHT CHANGES AND

SURVIVAL ANIMAL NUMBERS: FEMALE

STUDY NO. : 0579
ANIMAL : RAT F344/DuCFICFL;[F344/DuCF;]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

	<u>5</u>	Control	•	1280 ppm			3200 ppm			8000 ppm		
Week-Day on Study	Av. Wt.	No. of Surviv. <50>	Av. Wt.	% of cont. <50>	No. of Surviv.	Av. Wt.	% of cont. <50>	No. of Surviv.	Av. Wt.	% of cont. <50>	No. of Surviv.	
0-0	100 (50)	50/50	100 (20)	100	50/50	100 (20)	100	50/50	100 (50)	001	05/05	
1-7	112 (50)		111 (50)	66	50/50	_	66	50/50	109 (50)	97	50/50	
2-7	_			100	20/20	_	66	50/50		26	50/50	
3-7		50/50		66	50/50	130 (50)	86	50/50	126 (50)	95	50/50	
4-7			_	100	50/50		66	50/50		96	50/50	
22	_			66	20/20	144 (50)	66	20/20		95	50/20	
2-9	_			100	50/50		86	20/20		95	20/20	
2-7	_			100	20/20		66	50/50		95	50/50	
2-8	_			100	20/20		86	50/50		94	20/20	
2-6	_		161 (50)	100	20/20		66	20/20		92	20/20	
107				101	20/20		66	20/20		92	50/50	
11-7				101	20/20		66	20/20		92	50/50	
12-7				101	20/20		66	20/20		92	50/50	
13-7	171 (50)		172 (50)	101	20/20	_	66	20/20	163 (50)	92	20/20	
14-7		20/20		101	20/20	_	66	20/20		95	50/50	
18-7				101	20/20	_	66	20/20	169 (50)	93	50/50	
22-7				101	50/50	_	66	20/20		94	50/50	
26-7			192 (50)	100	50/50	_	86	20/20		93	50/50	
30-7				101	20/20	_	86	20/20		93	50/50	
34-7	200 (20)			101	50/50	196 (50)	86	50/50		93	50/50	
38-7		20/20		100	20/20	_	97	20/20		91	50/50	
42-7	211 (50)			100	50/50	206 (50)	86	20/20	194 (50)	85	50/50	
46-7				101	20/20	_	26	20/20		16	50/50	
20-2				100	50/50	_	96	20/20		06	50/50	
54-7		20/20	226 (50)	100	20/20	218 (50)	96	20/20		16	50/50	
287				101	49/50	_	97	20/20		92	50/50	
62-7	236 (50)		236 (49)	100	49/50	226 (49)	96	49/50	212 (49)	06	49/50	
2-99				101	49/50	_	96	48/20		90	49/50	
7-07				100	49/50	_	96	48/50		06	49/50	
74-7				100	48/50	_	95	47/50	230 (48)	68	48/50	
78-7		47/20	268 (48)	001	48/50	_	92	47/50		68	48/50	
82-7		47/50		100	48/50	_	94	47/50		88	48/50	
2-98				100	18/20	_	6	47/50	245 (44)	88	44/50	
2-06				66	47/50	_	94	47/50		88	44/50	
94-7				100	46/50	_	94	47/50	_	68	44/50	
2-86	288 (45)		_	101	46/50	_	95	47/50	_	68	42/50	
102-7		43/50		101	46/50	_	93	46/50	255 (41)	87	41/50	
104-7	293 (42)	42/50	294 (45)	100	45/50	273 (46)	93	46/20	254 (40)	87	40/50	

BAIS 4

(B10040)

BODY WEIGHT CHANGES: MALE

Group Name	Administrati											PAGE :	
	0-0	Administration week-day 0-0		2-7	3-7		4-7		22		L-9		Probability A same and
Control	129± 5	2 ∓951		8 干981	210±	රා	229±	σ	$246\pm$	Ξ	259土	Ξ	
1280 ppm	129 4 5	156 8	ж ж	185 ± 10	₹908	12	224±	13*	干682	14*	251±	15**	
3200 ppm	129± 5	156± 7		185.± 8	207±	∞	226±	Ō	242 ==	10	256±	11	
mdd 0008	129± 5	152士 8		179± 11≉≉	700∓	12**	218#	12**	$234\pm$	13**	$246\pm$	14**	
Significant difference : * :	*: P ≤ 0.05	* : P ≤ 0.01			Test of Dunnett	mett							

SEX : MALE														PAGE :
Group Name	Admini 7-7	Administration week-day	week-day 8-7		L-6		107		11-7		12-7		13-7	
Control	273±	13	±285	14	796 ±	15	305±	15	313+	15	318	15	325±	16
1280 ppm	∓292	17*	277	18*	786±	18**	795 ±	19**	303 ±	19**	308 ⊹	19**	314±	20 **
3200 ppm	∓692	12	782 ∓	14	293 ∓	14	302+	14	311±	15	315±	16	320±	16
8000 pm	259±	15**	271±	16**	282 ∓	16**	791∓	17**	298±	17***	302+	17**	307±	17**
Significant difference:	* : P & 0.05		0 0 N				Test of Dumatt	++						

STUDY NO. : 0579 ANIMAL : RAT F344/Duck-1Crlj[F344/Duck-j] UNIT : R REPORT TYPE : AI 104 SEX : MALE	j[F344/DuCrj]	Е		1	BODY WEIGHT CHANGES ALL ANIMALS	CHANGES	(SUMMARY)							PAC	PAGE: 3
Group Name	Adminis 14-7	istration	Administration week-day18-7		22-7		26-7		302	Personal control of the control of t	34-7		387		
Contro]	333±	17	$352\pm$	81	368±	18	384±	50	394±	21	403土	21	413±	22	
1280 ppm	$321\pm$	\$00**	343 ±	\$1 *	356 ±	\$0≉*	371±	20**	383 ±	20*	$391\pm$	*7.7	398 ±	23**	
3200 ppm	328±	16	351+	17	368	18	384±	61	394±	22	405±	21	413±	24	
8000 mdd	315±	17**	338+	16**	353 +	17**	368 ±	78 **	∓08€	19**	389±	19**	397±	19**	
Significant difference :	*: P ≤ 0.05		# : P ≤ 0.(10			Test of Dunnett	umett							
(HAN260)					And the second s										BAIS 4

Group Name Administration Administra	STUDY NO. : 0579 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] UNIT : # REPORT TYPE : A1 104 SEX : MALE	[F344/bucrj]			BO AL	DY WEIGHT L ANIMALS	CHANGES	BODY WEIGHT CHANGES (SUMMARY) ALL ANIMALS								PAGE: 4
ntrol 422 ± 22 430 ± 24 455 ± 23 440 ± 23 443 ± 24 446 ± 24 446 ± 24 446 ± 24 440 ± 25 440 ± 23 443 ± 24 443 ± 25 440 ± 23 441 ± 25 441 ± 25 441 ± 25 441 ± 25 441 ± 25 441 ± 25 441 ± 25 441 ± 25 441 ± 25 442 ± 25 442 ± 25 442 ± 25 442 ± 25 442 ± 25 442 ± 25 442 ± 25 442 ± 25 442 ± 25 442 ± 25<	Name	Adminis	tration	week-day		7777										
ntrol 422± 22 430± 24 443± 23 440± 23 440± 23 440± 24 440± 24 440± 24 440± 26 440± 26 440± 26 440± 27 440± 28 440± 28 440± 28 440± 28 440± 28 440± 28 440± 28 440± 28 440± 28 440± 28 450± 28 450± 27 28 440± 28 450± 28 27 28 450± 450± <th< th=""><th></th><th>427</th><th></th><th>46-7</th><th>1000 THE COLUMN TWO IS NOT THE COLUMN TWO IS</th><th>20-7</th><th>777100</th><th>54-7</th><th></th><th>58-7</th><th></th><th>229</th><th>TO A TO THE REAL PROPERTY AND AND AND AND AND AND AND AND AND AND</th><th>2-99</th><th></th><th></th></th<>		427		46-7	1000 THE COLUMN TWO IS NOT THE COLUMN TWO IS	20-7	777100	54-7		58-7		229	TO A TO THE REAL PROPERTY AND	2-99		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Control		22	430±	24	435土	23	440±	23	443±	24	446±	24	449±	26	PRINCIPAL REPORT OF THE PRINCI
0 ppm 424 ± 2 28 ± 2 433 ± 2 $29 + 443\pm2$ $29 + 447\pm2$ $29 + 447\pm2$ $29 + 447\pm2$ $29 + 451\pm2$ $26 + 455\pm2$ $27 + 420\pm2$ $22 + 420\pm2$ $23 + 430\pm2$ $23 + 431\pm2$ $24 + 431\pm2$ $24 + 432\pm2$ $25 + 431\pm2$ $24 + 431\pm2$.280 ppm		23*	416±	23*	423 ⊥	*2Z*	427±	23*	431 ±	\$2\$ *	433±	22*	437 ±	23	
0 ppm $406\pm 20*$ $414\pm 21*$ $420\pm 22*$ $435\pm 23*$ $431\pm 24*$ $431\pm 24*$ $432\pm 25*$ ificant difference; $*:P \le 0.05$ $**:P \le 0.01$ Test of Dunnett	3200 ppm		22	433 =	23	438+	24	443±	25	447 ±	28	451±	56	455 ±	27	
ificant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Dunnett	udd 000s	406±	30*≠	414±	21**	420 +	22 * *	425士	23**	430土	23*	431±	24**	432±	25 ∗ ∗	
ificant difference ; *:P≤0.05 *:P≤0.01 Test of Dunnett																
	gnificant difference ;	* : P ≤ 0.		. P	01			Test of Du	umett							
	90)															BAIS 4

SEX: MALE		VIVO CONTRACTOR CONTRA					The state of the s			American American Company		MANAGAMA AND AND AND AND AND AND AND AND AND AN			PAGE: 5
vroup Name	Admini: 70-7	stration	Administration week-day		78-7		82-7	TOTAL CONTRACTOR AND	2-98		L-06	MATERIAL STATE OF THE STATE OF	94-7		V
Control	451±	22	452#	24	452±	23	448±	23	444	33	440±	40	431±	38	
1280 ppm	439 ∓	73*	441 ±	24	442 -	25	440 ±	25	439±	78	437 ±	33	436 ±	69	
3200 ppm	455±	33	457 ±	39	∓09∓	29	457±	30	456±	30	453±	32	+41+	39	
wdd 0008	434±	%**C7	435#	24**	434±	S6 * *	433±	28*	428±	29*	422±	*87.	415±	35	
Significant Affermance .	۰ ×						£ 5.7.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.	,							

SIODI NO. : 0319 ANUMAL : RAT F344/DuCrlJfF344/DuCrJJ ANUNT : R REPORT TYPE : A1 104 SEX : MALE	j[F344/DuCr.j]		BODY WEIGHT CHANGES ALL ANIMALS	(SUMMARY) PAGE: 6
Group Name	Administration wook-day	nepek-day	MARIAGO, A PROPERTY OF THE PRO	
	2-86	102-7	104-7	
Control	427± 31	414 ± 39	410士 43	
1280 ppm	422 ± 42	413 1 48	414 ± 36	
0000				
szuu ppm	441 ± 33	4 32± 40	423± 40	
8000 midd 8	412士 37	397± 34	390 ∓ 38	
Significant difference :	*: P ≤ 0.05	. P 0.0 ∏ . ★		Test of Dumett
(HAN260)		Advantage page of the control of the		RAICA

BODY WEIGHT CHANGES: FEMALE

SEX: FEMALE Groun Name	Administ	tration	Administration wook-day							A Company of the Comp			THE REAL PROPERTY OF THE PERSON NAMED IN COLUMN NAMED IN COLUM	PAGE :	. go
	0-0	107227	1-7		2-7		3-7		4-7		2-2		29	THE REPORT OF THE PROPERTY OF	
Control	100∓	m	112±	4	122 ±	re	132±	9	139∓	2	146±	2	151 ±	8	
1280 ppm	100∄	m	1117	4	122 ±	വ	131±	ıc	139 ±	7	145 ±	7	151±	∞	
3200 µpm	100±	ec	1111	4	121 ±	വ	130+	rc	138±	9	144	7	148 ±	7	
mdd 0008	100±	m	109±	4**	118±	** 9	126±	* *9	133±	/* *	∓681	**	144±	* * 5	
													11.00		
Significant difference ;	*:P≤0.05		- P ≤ 0.01				Tost of Dumott	+							

SEX : FEMALE														PAGE:
Group Name	Adminis 7-7	stration	Administration week-day 8-7		L6		10-7		117		12-7		13-7	
Control	154±	თ	158±	10	+ 191	01	165±	Ξ	Ŧ291	Ξ	+ 691	Ξ	171±	=
1280 ppm	154±	∞	158± 1	10	161 ±	10	+ 991	10	∓891	10	170 ±	10	172.±	::
3200 ppm	153.±	_∞	155±	Φ	159 ±	6	163±	ō	+ 991	10	168±	10	170±	10
Mdd 0008	147±	**6	149± 1	10**	153±	11**	156±	#	158	11**	161 ±	12**	163±	12**
							A THE STATE OF THE	THE PROPERTY OF THE PROPERTY O						1
Significant difference :	*:P≤0.05		★ :P≤0.01				Test of Dunnett	mett						

STUDY NO. : 0579 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] UNIT : # REPORT TYPE : A1 104 SEX : FEMALE	[[F344/buCr.j]		B01.	BODY WEIGHT CHANGES ALL ANIWALS	CHANGES	(SUMMARY)							PAGE: 9
Group Name	Administration week-day_	ın week-day											
	147	18-7		722-7	700000110000000000000000000000000000000	26-7		30-7		34-7		38-7	
								THE RESIDENCE OF THE PROPERTY	Междуна жан ком ком макене желендере желе жалан қалақ ү қа	1 VO VOOL II A MANAGA AAN AAN AAN AAN AAN AAN AAN AAN AA	PARTY COLUMN TO MINE TO THE PARTY OF THE PAR		
Control	173土 12	181	21	+ 981	13	192±	13	196±	15	700∓	15	207±	21
1280 ppm	174 ± 11	182±	11	188 +	12	∓ 261	13	197 ≟	13	₹102	14	∓902	14
3200 µpm	172± 11	179±	11	184±	12	189.	13	193±	13	196±	14	201±	15
8000 ppm	164± 12**	169±	12**	174±	13**	178±	13**	182 ±	14**	186∄].⊈**	189±	16**
Significant difference :	*: P ≤ 0.05	# : P ≤ 0.0	01			Test of Dunnett	umett						

STUDY NO. : 0579 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] UNIT : g REPORT TYPE : A1 104	j[F344/DuCrj]	_		M K	BODY WEIGHT CHANGES ALL ANIMALS	CHANGES	(SUMMARY)								
SEX : FEMALE														PAG	PAGE: 10
Group Name	Admini 42-7	istration	Administration week-day 42-7 46-7	TO POST DATA NOVI PARA NAME OF THE PARA	50-7		54-7		58-7		2-29		L-99		
Control	2117	81	215±	81	221 ±	20	227±	21	229±	22	∓987	24	243±	26	
1280 ppm	211±	15	217±	15	∓127	16	226±	17	232 -	19	736±	20	246 ±	21	
3200 ppm	∓902	17	208±	17	212+	19*	218±	20	225±	22	∓922	23	234±	26	
8000 ppm	194±	16**	196±	18**	200∓	18**	706±	19**	210±	21**	212=	21**	219±	23**	
Significant difference :	*: P ≤ 0.05		. P ≤ 0.01	10			Test of Dunnett	umett							

SEX : FEMALE			-		MALLA									PAGE : 11
uroup name	Adminis 70-7	stration	Administration week-day 70-7		78-7		82-7		2-98		L-06		94-7	
Control	250±	27	559 ±	59	267±	30	273±	30	277±	30	285±	53	288±	31
1280 ppm	251 ⊥	22	760≟	24	∓892	24	272 ±	24	₹922	24	782 ∓	26	∓682	25
3200 µµm	539±	28	246±	28*	254±	29 *	257±	29*	261±	30*	±267±	31**	271±	31*
8000 ppm	$224\pm$	24**	730年	24**	238±	24**	241∓	\$2 5 **	245 ±	25**	251±	26**	726 ±	70**
Significant difference:	* : P & 0.05		 ₹				7							

STUDY NO. : 0579 ANIMAL : RAT F344/DuCrlJ[F344/DuCrJ] UNIT : R REPORT TYPE : A1 104	[F344/DuCrj	E.			BODY WEIG ALL ANDWAL	BODY WEIGHT CHANGES ALL ANIMALS	(SUMMARY)
SEX : FEMALE	Addison						PAGE : 12
Group Name	Admin 98-7	nistration 7	Administration week-day 98-7 102-7	Approximation in the contract of the contract	10	104-7	
Control	288±	34	293±	31	793±	32	
1280 ppm	- 262	27	795 ±	30	294 ±	34	
3200 ppm	273±	31*	273±	30**	273±	3I*	
8000 pm	∓957	24**	755 ±	\$* *	254±	+ 32#	
Significant difference :	* : P ≤ 0.05	0.05	* : P ≤ 0.	10.			Test of Dunnett
(HAN260)							BAIS 4

FOOD CONSUMPTION CHANGES AND

SURVIVAL ANIMAL NUMBERS: MALE

STUDY NO. : 0579
ANIMAL : RAT F344/DuCr.ICr.L.j.[F344/DuCr.j.]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

PAGE: 1

Av. FC. No. of Surviv. Surviv. (50) 13. 6 (50) 50/50 14. 1 (50) 50/50 15. 0 (50) 50/50 14. 6 (50) 50/50 14. 9 (50) 50/50 15. 2 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 5 (50) 50/50 16. 5 (50) 50/50 16. 5 (50) 50/50 16. 5 (50) 50/50 16. 6 (50) 50/50 16. 6 (50) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 6 (50) 50/50 16. 6 (50) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 6 (50) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 7 (60) 50/50 16. 7 (40) 49/50	(50) 94 (50) 95 (50) 95 (50) 95 (50) 95 (50) 97 (50) 97 (50) 97 (50) 97 (50) 95 (50) 9	No. of Surviv. 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50	(50) (50) (50) (50) (50) (50) (50) (50)	600. No. of Cont. Surviv. (50) 101 50/50 101 50/50 99 50/50 99 50/50 99 50/50 97 50/50 97 50/50 98 50/50 97 50/50 98 50/50 97 50/50 98 50/50 99 50/50 97 50/50 98 50/50 99 50/50 99 50/50 96 50/50		% on t. (50) (50) (50) (50) (50) (50) (50) (50)	No. of Surviv. 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50
Surviv. (50) (50) (13.6 (50) 50/50 (14.1 (50) 50/50 (15.0 (50) 50/50 (14.6 (50) 50/50 (14.9 (50) 50/50 (15.2 (50) 50/50 (15.4 (50) 50/50 (15.4 (50) 50/50 (15.4 (50) 50/50 (15.4 (50) 50/50 (15.4 (50) 50/50 (15.4 (50) 50/50 (16.4 (50) 50/50 (16.5 (50	(50) (50) (50) (50) (50) (50) (50) (50)	Surviv. 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50	550) 550) 550) 550) 550) 550) 550) 550)	, s	4. E.	6507. (500) 999 95 95 95 96 96 96 96 96	Surviv. 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50
(50) 13. 6 (50) 50/50 14. 1 (50) 50/50 15. 0 (50) 50/50 14. 6 (50) 50/50 14. 7 (50) 50/50 14. 9 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 16. 7 (50) 50/50 16. 7 (50) 50/50 16. 7 (50) 50/50 16. 7 (50) 50/50 16. 9	(50) (50) (50) (50) (50) (50) (50) (50)	50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50	(50) (50) (50) (50) (50) (50) (50) (50)		13.4 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	\$50011.	50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50
13.6 (50) 50/50 14.1 (50) 50/50 15.0 (50) 50/50 14.6 (50) 50/50 14.6 (50) 50/50 14.7 (50) 50/50 15.2 (50) 50/50 15.4 (50) 50/50 16.2 (50) 50/50 16.2 (50) 50/50 16.2 (60) 50/50 16.2 (60) 50/50 16.2 (60) 50/50 16.2 (60) 50/50 16.4 (49) 49/50	(50) (50) (50) (50) (50) (50) (50) (50)	50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50			E E E E E E E E E E E E E E E E E E E	99 99 99 99 99 99 99 99 99 99 99 99 99	50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50
14.1 (50) 50/50 15.0 (50) 50/50 14.6 (50) 50/50 14.7 (50) 50/50 14.9 (50) 50/50 15.2 (50) 50/50 15.4 (50) 50/50 16.2 (60) 50/50 16.2 (60) 50/50 16.2 (60) 50/50 16.2 (60) 50/50 16.2 (60) 50/50 16.2 (60) 50/50 16.4 (49) 49/50	(50) (50) (50) (50) (50) (50) (50) (50)	50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50			8 4 <td>9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9</td> <td>50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50</td>	9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50
15. 0 (50) 50/50 14. 6 (50) 50/50 14. 9 (50) 50/50 14. 9 (50) 50/50 15. 2 (50) 50/50 15. 4 (50) 50/50 16. 2 (50) 50/50 16. 4 (49) 49/50		50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50			4 4 4 4 4 4 4 5 4 5 4 5 5 6 6 6 6 6 6 6	95 95 95 95 95 95 95 95 95 95 95 95 95 9	50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50
15. 0 (50) 50/50 14. 6 (50) 50/50 14. 7 (50) 50/50 14. 9 (50) 50/50 15. 2 (50) 50/50 15. 4 (50) 50/50 16. 2 (50) 50/50 16. 4 (49) 49/50		50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50			44 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5	9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50
14. 6 (50) 50/50 14. 7 (50) 50/50 14. 9 (50) 50/50 15. 2 (50) 50/50 15. 4 (50) 50/50 16. 2 (50) 50/50 16. 2 (50) 50/50 16. 2 (50) 50/50 16. 2 (50) 50/50 16. 6 (50) 50/50 16. 7 (49) 49/50		50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50			4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50
14. 7 (50) 50/50 14. 9 (50) 50/50 15. 2 (50) 50/50 15. 4 (50) 50/50 15. 7 (50) 50/50 16. 2 (50) 50/50 16. 5 (50) 50/50 16. 6 (50) 50/50 16. 7 (49) 49/50		50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50			4 4 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	96 96 96 96 96	50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50
14.9 (50) 50/50 15.2 (50) 50/50 15.4 (50) 50/50 15.4 (50) 50/50 15.3 (50) 50/50 15.4 (50) 50/50 15.4 (50) 50/50 15.4 (50) 50/50 16.2 (60) 50/50 16.5 (50) 50/50 16.5 (50) 50/50 16.7 (49) 49/50		50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50			4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	2 6 6 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50
15. 2 (50) 50/50 15. 4 (50) 50/50 15. 7 (50) 50/50 16. 5 (50) 50/50 16. 5 (50) 50/50 16. 9 (50) 50/50 16. 16. 4 (49) 49/50		50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50			44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	2	50/50 50/50 50/50 50/50 50/50 50/50 50/50
15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 3 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 16. 2 (50) 50/50 16. 2 (50) 50/50 16. 5 (50) 50/50 16. 5 (50) 50/50 16. 6 (50) 50/50 16. 6 (50) 50/50 16. 6 (50) 50/50		50/50 50/50 50/50 50/50 50/50 50/50 50/50 50/50			14.7 15.1 14.8 14.8 14.8 14.8 15.1 15.1	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	50/50 50/50 50/50 50/50 50/50 50/50 50/50
15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 16. 2 (50) 50/50 16. 2 (50) 50/50 16. 5 (50) 50/50 16. 6 (50) 50/50 16. 6 (50) 50/50 16. 6 (50) 50/50		50/50 50/50 50/50 50/50 50/50 50/50			15.1 14.8 14.8 14.8 14.8 15.1 15.1	98 97 96 96 96	50/50 50/50 50/50 50/50 50/50 50/50
15. 4 (50) 50/50 15. 3 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 16. 2 (50) 50/50 16. 5 (50) 50/50 16. 5 (50) 50/50 16. 6 (50) 50/50 16. 6 (50) 50/50 16. 7 (49) 49/50		50/50 50/50 50/50 50/50 50/50			14.8 14.8 14.8 15.1 15.1	95 96 96 96 96	50/50 50/50 50/50 50/50 50/50
15. 3 (50) 50/50 15. 4 (50) 50/50 15. 4 (50) 50/50 15. 7 (50) 50/50 16. 2 (50) 50/50 16. 5 (50) 50/50 16. 0 (50) 50/50 16. 4 (49) 49/50		50/50 50/50 50/50 50/50 50/50	-		8 41 8 41 15 1 15 1	97 96 96 96 96	50/50 50/50 50/50 50/50
15. 4 (50) 50/50 15. 4 (50) 50/50 15. 7 (50) 50/50 16. 2 (50) 50/50 16. 5 (50) 50/50 16. 0 (50) 50/50 16. 4 (49) 49/50		50/50 50/50 50/50 50/50			14.8 15.1 15.5	96 96 96 97	50/50 50/50 50/50 50/50 50/50
15.4 (50) 50/50 15.7 (50) 50/50 16.2 (50) 50/50 16.5 (50) 50/50 16.0 (50) 50/50 16.4 (49) 49/50		50/50 50/50 50/50	14.8 (50)		14.8 15.1 15.5	96 96 96 07	50/50 50/50 50/50 50/50
15. 7 (50) 50/50 16. 2 (50) 50/50 16. 5 (50) 50/50 16. 0 (50) 50/50 16. 4 (49) 49/50		50/50 50/50	15.0 (50)		15. 1	96 96 97	50/50 50/50 50/50
16. 2 (50) 50/50 16. 5 (50) 50/50 16. 0 (50) 50/50 16. 4 (49) 49/50		20/20	-		15.5	96	50/50 50/50
16. 5 (50) 50/50 16. 0 (50) 50/50 16. 4 (49) 49/50						47	50/50
16. 0 (50) 50/50 16. 4 (49) 49/50		20/20	_		16.0	21	
16.4 (49) 49/50		50/50	15.4 (50)	/09 96	15.7	86	20/20
	(20)	20/20	-		15.7	96	50/50
16, 4 (49) 49/50	(20)	20/20	16.0 (50)	98 50/	15.7	96	50/50
16.2 (49)	(49)	49/50		97 50/	15.6	96	50/50
15.9 (49) 49/50	(49)	49/50	15.4 (50)	97 50/	15.3	96	50/50
(49) 49/50		49/50	15.5 (50)	97 50/	15.4	4	20/20
16.3 (49) 49/50		49/50			15.7	96	50/50
15.8 (49) 49/50		49/50		96 50/50	15.3	67	20/20
16.7 (49) 49/50		49/50	16.1 (49)		16.1	96	20/20
		49/50			15.5	96	20/20
16.4 (47) 47/50		49/50	15.7 (49)		15.8	96	48/50
16.8 (47)	_	49/50	15.8 (49)	94 49/	16.0	95	47/50
78-7 16.7 (45) 45/50 16.8	_	49/50	16.4 (47)	98 47/	16.5	66	47/50
16.7 (44)		49/50	15.9 (46)		16.0	96	47/50
86-7 16.4 (43) 44/50 16.2	(48) 99	48/50	15.9 (46)		15.9	26	47/50
90-7 16.0 (43) 43/50 15.6	_	47/50		96 46/50	15.2	95	44/50
(40) 40/50	_	44/50			15.3	86	43/50
15.7 (36) 36/50	_	42/50			14.9	8	41/50
15. 2 (35) 35/50	(40)	40/20	_	99 41/50	15.3	101	39/20
15.9	(38) 66	38/50	15.4 (39)	97 39/50	15.3	96	39/20

BAIS 4

(BI0040)

FOOD CONSUMPTION CHANGES AND

SURVIVAL ANIMAL NUMBERS: FEMALE

STUDY NO. : 0579

ANIMAL : RAT F344/DuCr.LCr.Lj[F344/DuCr.j]
UNIT : g

REPORT TYPE : A1 104
SEX : FEMALE

				0007			mdd ooss			endd none			
Week-Day on Study	Av. FC.	No. of Surviv. <50>	Av. FC.	% of cont. <50>	No. of Surviv.	Av. FC.	% of cont. <50>	No. of Surviv.	Av. FC.	% of cont. <50>	No. of Surviv.		
1-7	10.3 (5)	(50) 50/50	10.3 (50)	103	50/50	10.1 (50)	86	50/50	10.1 (50)	86.98	50/50		
3-7	_	(50) 50/50		103	50/50		104	50/50	9.8 (50)	96	50/50		
4-7	_			66	20/20		66	50/50		97	50/20		
2-9	-			100	50/50		66	20/20	9.9 (20)	86	20/20	2	
29			9.9 (50)	100	20/20		86	50/50	_	97	50/50		
2-2	_	(50) 50/50	9.6 (50)	66	20/20	9.7 (50)	100	20/20		26	20/20		
82	۲-		9.7 (50)	100	20/20		66	20/20	_	97	20/20		
2-6	_			100	20/20		86	20/20	_	97	20/20		
10-7	8.6	(50) 50/50		100	20/20		66	20/20	_	26	20/20		
11-7	_			102	20/20		100	20/20		86	20/20		
127	_ Ga			102	20/20	_	66	50/50		26	20/20		
13-7				103	20/20	_	66	20/20		86	50/50		
14-7				007	20/20		86	20/20		94	50/50		
7-81				105	20/20		100	20/20		100	50/50		
227				901	20/20	10.2 (50)	101	20/20		101	50/50		
26-7				103	20/20	_	100	20/20		92	50/50		
307				104	20/20	10.5 (50)	66	20/20		96	20/20		
34-7				105	20/20	_	86	50/50		94	50/50		
)X				108	20/20	_	101	20/20		95	50/50		
12-2				105	20/20	_	96	20/20		65	50/50		
46-7				109	20/20	_	96	20/20		88	50/50		
202				106	20/20	_	92	20/20		90	20/20		
54-7		20) 20/20	12.6 (50)	107	20/20	_	86	20/20		93	20/20		
58-7		(20) 20/20		105	49/50	_	86	20/20	10.9 (50)	95	20/20		
52-7				106	49/50	_	26	49/50		85	49/50		
299				111	49/50	12.2 (48)	66	48/50	11.3 (49)	95	49/50		
707	_		12.9 (49)	104	49/50	-	86	48/50	11.2 (49)	90	49/50		
74-7		(47) 47/50		105	48/50	12.8 (47)	96	47/50		68	48/50		
7-87	_			104	48/50	_	96	47/50	12.5 (48)	91	48/50		
82-7	_			101	48/50	_	93	47/50	11.9 (48)	88	48/50		
2-98	_			101	48/50	12.8 (47)	96	47/50	_	92	44/50		
2-06	_			101	47/50	_	93	47/50	_	16	44/50		
94-7	_			100	46/50		95	47/50	_	91	44/50		
2-86	_	(45) $45/50$	13.5 (46)	103	46/50	12.9 (47)	86	47/50	_	93	42/50		
720.	13.8 (4	(43) 43/50	14.0 (46)	101	46/50	12.7 (46)	65	46/50	12.3 (41)	68	41/50		
	,	(01)	(1:)										

BAIS 4

(BI0040)

FOOD CONSUMPTION CHANGES: MALE

oba · Malle Croum Mamo		A					PAGE :
db.	1-7 (4)	ween day (ellective)	3-7(4)	4-7(4)	5-7(4)	6-7(4)	7-7(4)
Control	13.6土 0.7	14.1± 0.7	15.0± 0.9	15.0± 0.8	14.6± 1.0	14.7± 1.0	14.9± 1.1
1280 ppm	13.7 ± 0.7	14.3± 1.0	14.5± 1.0*	14.5土 0.9*	14.2 ± 1.0	14.2 ± 1.1*	14.2± 1.1*
3200 ррт	13.8± 0.7	14.3± 0.8	14.8± 0.7	14.9± 0.8	14.6士 0.8	14.5± 0.9	14.4± 0.9*
8000 ppm	13.4 ± 0.8	13.7± 1.0	14.2± 0.9**	14.7 ± 0.9	14.2± 0.9	14.2 ± 0.9*	14.1± 1.0**
()(i) 1) EP (i)	10 00 00 00 00 00 00 00 00 00 00 00 00 0	, i		: :			

STUDY NO. : 0579 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] UNIT : R REPORT TYPE : A1 104 SEX : MALE	j[F344/buCr.j]	я M	FOOD CONSUMPTION CHANGES (SUMMARY) ALL ANIMALS	ES (SUMMARY)			PAGE : 2
Group Name	Administration 8-7(4)	Administration week-day(effective)	10-7(4)	11~7(4)	12-7 (4)	13-7(4)	14-7 (4)
Contro	15.2± 1.1	15.4± 1.1	15.4± 1.3	15.4± 1.5	15.3± 1.3	15.4± 1.5	15.4± 1.4
1280 ppm	14.7 ± 1.3	14.7 ± 1.2*	14.5± 1.0**	14.6± 1.1*	14.5± 1.1**	14.6 - 1.0	14.7 ± 1.2**
3200 ppm	14.9士 1.0	15.0± 1.0	14.9± 0.9	14.9 + 1.0	15.0 ± 1.0	14.8士 0.9	15.0± 1.0
8000 mdd	14.6± 1.0*	14.7 ± 1.0**	15.1± 1.1	14.7 ± 1.1	14.8± 1.1	14.8± 1.2	14.8± 1.1*
Significant difference ;	*: P \le 0.05	* : P ≤ 0.01		Test of Dunnett			
(HAN260)							BAIS 4

ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] UNIT : R REPORT TYPE : A1 104 SEX : MALE	.j[F344/DuCr.j]	AL AL	ALL ANIMALS				PAGE :
Group Name	Administration 18-7(4)	Administration week-day(effective) 18-7(4) 22-7(4)	26-7 (4)	30-7(4)	34-7 (4)	38-7(4)	42-7 (4)
Control	15.7± 1.5	16.2± 1.4	16.5± 2.0	16.0± 2.0	16.4± 1.8	16.4± 1.8	16.2± 1.7
1280 ppm	15.1± 1.3*	15.6土 1.2*	16.1± 1.5	15.7± 1.3	15.7 ± 1.5	15.8 ± 2.0	15.9 ± 1.5
3200 ppm	15.0± 1.0*	15.5± 1.1**	16.0± 1.0	15.4± 2.3	15.7± 1.3	16.0 ± 1.4	15.7± 1.3
mdd 0008	15.1± 1.3*	15.5± 1.3*	16.0± 1.5	15.7± 1.5	15.7± 1.4	15.7± 1.3	15.6± 1.4
Significant difference ;	.: 4 : ₩	10 °0 ×16 ± \$		Test of Dunnett			

Group Name Administration week-day(effective) 54-7(4) 58-7(4) 68-7(4) 66-7(4) 70-7(4) Control 15.9± L.9 15.9± L.8 16.3± L.7 15.8± L.6 16.7± L.5 16.2± L.4 16.4± L.5 1280 ppm 15.3± L.4 15.8± L.5 15.8± L.6 15.3± L.7 16.1± L.3 16.9± L.3 16.2± L.7 3200 ppm 15.3± L.2 15.5± L.2 15.7± L.1 15.3± L.3 16.1± L.3 15.9± L.3 15.7± L.4 8000 ppm 15.3± L.3 15.4± L.2 15.7± L.1 15.3± L.3 16.1± L.3 15.5± L.2 15.8± L.5 Significant difference: *: P ≤ 0.05 **: P ≤ 0.01 **: P ≤ 0.01 Test of Dunnett Test of Dunnett	STUDY NO. : 0579 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] UNIT : R REPORT TYPE : A1 104 SEX : MALE	j[F344/bucr.j]	F0C AU.	FOOD CONSUMPTION CHANGES (SUMMARY) ALL ANTMALS	JES (SUMMARY)			: BAGE
$ 5.9 \pm 1.9 15.9 \pm 1.8 16.3 \pm 1.7 15.8 \pm 1.6 16.7 \pm 1.5 16.2 \pm 1.4 16.4 \pm 1.5 15.8 \pm 1.7 16.0 \pm 1.5 16.2 \pm 1.4 16.2 \pm 1.5 16$	oup Name	Administration 46-7(4)	week-day(effective) 50-7(4)	54-7 (4)	58-7 (4)	62-7(4)	66-7(4)	70-7 (4)
$ 5.3 \pm 1.4 15.8 \pm 1.5 15.8 \pm 1.6 15.3 \pm 1.6 16.3 \pm 1.7 16.0 \pm 1.5 16.2 \pm 1.5 16.2 \pm 1.5 16.2 \pm 1.5 16.2 \pm 1.3 15.6 \pm 1.7 15.1 \pm 1.2 16.1 \pm 1.3 15.9 \pm 1.3 15.7 \pm 1.5 15.3 \pm 1.3 16.1 \pm 1.3 15.5 \pm 1.2 15.8 \pm 1.5 1$	Control	15.9± 1.9		16.3± 1.7		16.7± 1.5	16.2± 1.4	16.4± 1.5
$15.4\pm 1.2 \qquad 15.5\pm 1.3 \qquad 15.6\pm 1.7 \qquad 15.1\pm 1.2 \qquad 16.1\pm 1.3 \qquad 15.9\pm 1.3 \qquad 15.7\pm 1.5$ $15.3\pm 1.3 \qquad 15.4\pm 1.2 \qquad 15.7\pm 1.1 \qquad 15.3\pm 1.3 \qquad 16.1\pm 1.3 \qquad 15.5\pm 1.2 \qquad 15.8\pm 1.5$ $*: P \le 0.05 **: P \le 0.01$	1280 ppm	15.3 ± 1.4	ij					
15.3 ± 1.3 15.4 ± 1.2 15.7 ± 1.1 15.3 ± 1.3 16.1 ± 1.3 15.5 ± 1.2 15.8 ± 1.3 $*: P \le 0.05$ **: $P \le 0.01$	3200 ppm	15.4± 1.2	-			16.1± 1.3		
*: P ≤ 0.05 ★: P ≤ 0.01	mdd 0008	15.3 ± 1.3	≓	15.7± 1.1		16.1± 1.3	15.5± 1.2	
*:P≤0.05 **:P≤0.01								
	Significant difference :		* *: P ≤ 0.01		Test of Dunnett			

SEX : MALE Group Name	Administration	Administration week-day(effective)			The state of the s		
A CANALA	74-7 (4)	78-7 (4)	82-7 (4)	86-7 (4)	90-7 (4)	94-7 (4)	98-7 (4)
Control	16.8± 1.9	16.7± 1.7	16.7± 2.1	16.4± 1.8	16.0± 3.5	15.6士 2.2	15.7± 2.0
1280 ppm	16.4± 1.7	16.8± 2.0	16.4 ± 1.8	16.2± 1.7	15.6土 1.8	15.0士 2.0	15.2± 2.4
3200 ppm	15.8± 1.9*	16.4± 1.3	15.9± 1.3	15.9± 1.5	15.4± 1.7	14.4± 2.8	15.2 ± 2.1
8000 ppm	16.0± 1.5	16.5± 1.6	16.0± 1.6	15.9± 1.9	15.2± 2.3	15.3± 2.8	14.9± 1.7
				,			
Significant difference ;	*: P \\ 0.05 \\	** : P ≤ 0.01		Test of Dunnett			

STUDY NO. : 0579 ANIMAL : RAT F344/DuCrICrlj[F344/DuCrj] UNIT : R REPORT TYPE : AI 104 SEX : MALE	[F344/DuCr.j.]	FOOD CONSUMPTION CHANGES (SUMMARY) ALL ANIMALS	PAGE: 6
Group Name	Administration 102-7(4)	Administration week-day(effective)	
Control	15.2± 3.8	15.9± 2.6	
1280 ppm	15.3 ± 2.1	15.8⊥ 1.8	
3200 ppm	15.1± 2.3	15.4± 2.2	
8000 bpm	15.3 ± 2.1	15.3± 1.9	
Significant difference :	*: P ≤ 0.05	** : P \leq 0.01 Test of Dunnett	
(HAN260)			BAIS 4

FOOD CONSUMPTION CHANGES: FEMALE

Group Name	Administration	wool-day (offorting)					l'AGE
	1-7(4)	1-7(4)	3-7 (4)	4-7(4)	5-7 (4)	6-7 (4)	77 (4)
Control	10.3± 0.6	9.9± 0.7	10.1± 0.6	10.3± 0.7	10.1± 0.7	6.9 = 0.9	9.7± 0.8
1280 ppm	10.3± 0.6	10.2 生 0.6	10.4土 1.3	10.2± 0.8	10.1 ± 0.7	9.9± 0.9	9.6± 0.7
3200 ppm	10.1 ± 0.5	9.7± 0.7	$10.5\pm\ 2.1$	10.2± 0.6	10.0± 0.7	9.7 = 0.6	9.7± 0.7
8000 mdd 0008	10.1± 0.6	9.5± 0.7**	9.8± 0.7*	10.0± 0.9	9.9 ± 0.8	6.6 ± 0.9	9.4± 0.9
Significant difference;	*:P≤0.05	+ : P ≤ 0.01		Test of Dunnett			

STODI NO. : 0319 ANUMAL : RAT F344/DuCrlCrlj[F344/DuCrj] UNIT : R REPORT TYPE : AI 104 SEX : FEMALE	1j[F344/DuCr.j]	. 4	ALL ANIMALS	COMPLIANT)			PAG	PAGE :
Group Name	Administratior 8-7 (4)	Administration week-day(effective)	10-7 (4)	11-7(4)	12-7(4)	13-7(4)	14-7 (4)	
Contro]	9.7 ± 0.8	9.8 + 0.9	6.0 +8.6	9.6 ± 0.9	9.9士 1.7	9.7	10.0± 1.3	
1280 ppm	9.7± 0.7	9.8+ 0.8	9.8 = 0.8	9.8 ± 0.8	10.1± 1.1	10.0 ± 1.2	10.0 ± 0.9	
3200 ррт	8.0 ∓9.6 3.0 ±9.8	2.0 干9.6	9.7 ± 0.7	9.6+ 0.8	9.8 + 0.9	9.6± 0.8	9.8 + 0.9	
8000 ppm	9.4± 0.8	9.5± 0.9	9.5± 0.9	9.4士 0.9	9.6± 0.8	9.5 = 0.9	9.4± 1.0**	
Simificant difference	* • •	10 U V a . \$						

(HAN260)

SIGDT NO. : 0319 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] UNIT : g REPORT TYPE : A1 104 SEX : FEMALE	j[F344/DuCr.j]	ALI ALI	FOUR CHANGES (SUMMARK) ALL ANIMALS	ES (SUMMARY)			PAGE: 9
Group Name	Administration	Administration week-day(effective)					
	18" (4)	(†)) – ZZ	26-7 (4)	30-7 (4)	34-7 (4)	38-7 (4)	42-7(4)
Control	9.7± 0.7	10.1± 1.1	10.6± 1.1	10.6士 1.3	10.8± 1.3	11.2± 1.6	11.0± 1.6
1280 ppm	10.2 ± 1.5	10.7 ± 1.4	10.9± 1.6	11.0± 1.6	11.3土 1.7	12.1± 2.2*	11.5士 2.1
3200 ppm	9.7 1.1	10.2 ± 1.8	10.6± 1.5	10.5± 1.6	10.6± 1.4	11.3 ± 2.1	10.6十 1.5
8000 pm	9.7 ± 1.0	10.2± 2.4	10.1 ± 1.0*	10.2 ± 1.3	10.1± 1.1**	10.6 ± 1.6	10.1± 1.2*
Significant difference ;	*: P ≤ 0.05	** : P ≤ 0.01		Test of Dunnett			
(HAN260)							BAIS 4

Group Name	Administration	Administration week-day(effective)	- Address - Addr	4			l'AGE : 10
	46-7(4)	50-7(4)	54-7(4)	58-7 (4)	62-7(4)	66-7 (4)	70-7(4)
Control	11.3± 1.7	12.1± 1.8	11.8± 1.7	11.5± 1.6	12.5± 2.0	12.3± 1.6	12.4± 1.7
1280 ррт	12.3 ± 2.7	12.8 - 1.2	12.6± 2.4	12.1± 2.1	13.2 ± 2.1	13.6± 2.4*	12.9 ± 1.9
3200 upm	10.9± 2.0	11.5± 1.9	11.6 ± 1.9	11.3士 1.8	12.1± 2.0	12.2 ± 2.2	12.1± 1.9
8000 mdd 0008	10.1± 1.1**	10.9± 1.7*	11.0 ± 1.4*	10.9± 1.3	11.5± 1.6*	11.3 1.5*	11.2 ± 1.3**
Significant difference:	*:P ≤ 0.05 *	★ :P≤0.01		Test of Dunnett			

PAGE: 11					v	
	98-7(4)	13.1± 2.5	13.5± 1.8	12.9± 2.0	12.2± 1.3**	
	94-7 (4)	13.4± 1.6	13.4 ± 1.9	12.7± 1.9	12.2± 1.6**	
	90-7 (4)	13.8± 2.2	13.9士 2.7	12.9± 2.0*	12.5± 1.3**	
BES (SUMMARY)	86-7(4)	13.4± 1.7	13.6± 2.5	12.8± 1.9	12.3 ± 1.1**	
FOOD CONSUMPTION CHANGES (SUMMARY) ALL ANIMALS	82-7 (4)	13.5± 1.6	13.7 ± 2.1	12.5± 1.8*	11.9士 1.6**	
R &	Administration week-day(effective)	13.7± 1.5	14.3± 2.2	13.2 ± 2.2	12.5± 1.4**	
Ducrlcrlj[F344/Ducrj]	Administration 74-7(4)	13.4± 1.7	14.1± 2.1	12.8± 2.1*	11.9± 1.1**	
STUDY NO. : 0579 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] UNIT : R REPORT TYPE : A1 104 SEX : FEMALE	Group Name	Control	1280 ppm	3200 ppm	8000 mdd	

Test of Dunnett **★**: P ≤ 0.01 Significant difference : $*:P \leq 0.05$ (HAN260)

BATS 4

Group Name Administration week-day(effective) Administration week-day(effective) Control 13.8± 1.9 13.6± 1.9 13.6± 2.4 1280 ppm 14.0± 2.2 13.6± 2.4 2.4 8000 ppm 12.7± 2.1* 12.1± 2.0** Significant difference: **: P ≤ 0.05 **: P ≤ 0.01 Test of Dumett	ANIMAL : RAT F344/DuCr1Cr1;[F344/DuCrj] UNLT : g REPORT TYPE : AI 104 SEX : FEMALE	j[F344/buCr.j]	ALL ANTMALS
13.8 \pm 1.9 13.6 \pm 1.9 14.0 \pm 2.2 13.6 \pm 2.4 12.7 \pm 2.1* 12.6 \pm 2.4 12.3 \pm 1.5** 12.1 \pm 2.0**	Group Name	Administration 102-7(4)	
14.0± 2.2 13.6± 2.4 12.7± 2.1* 12.6± 2.4 12.3± 1.5** 12.1± 2.0** *: $P \le 0.05$ **: $P \le 0.01$	Gontrol	13.8± 1.9	
12.7± 2.1* 12.6± 2.4 12.3± 1.5** 12.1± 2.0** *:P≤0.05 **:P≤0.01	1280 ppm		
12.3± 1.5** 12.1± 2.0** *: P ≤ 0.05 **: P ≤ 0.01	3200 ррш	12.7± 2.1*	
*:P ≤ 0.05 * : P ≤ 0.01	8000 mdd	12.3 1.5**	
*:P≤0.05			
	Significant difference ;	*: P ≤ 0.05	

TABLE E 1

CHEMICAL INTAKE CHANGES: MALE

42

PAGE: 2					
PAG	14	0.000 ± 0.000	0.058 ± 0.004	0.146± 0.008	0.376± 0.020
	13	0.000 ± 0.000	0.060 ± 0.003	0.148± 0.008	0.384± 0.021
	12	0.000± 0.000	0.061 ± 0.003	0.152± 0.007	0.391± 0.021
(SUMMARY)	11	0.000 ± 0.000	0.062 ± 0.003	0.153± 0.007	0.394± 0.021
CHEMICAL INTAKE CHANGES (SUMMARY) ALL ANIMALS	10	0.000土 0.000	0.063 ± 0.003	0.158± 0.007	0.415 ± 0.020
OHE ALL	weeks)	0.000 ± 0.000	0.066 ± 0.003	0.163± 0.007	0.418 ± 0.016
j[F344/DuOr.j.]	Administration (weeks)8	0.000± 0.000	0.068 ± 0.004	0.169± 0.007	0.431 ± 0.015
STUDY NO.: 0579 ANIMAL: RAT F344/DuCr.ICr.Ij[F344/DuCr.j] UNIT: R/kg/day REPORT TYPE: A1 104 SEX: MALE	Group Name	Control	1280 ppm	3200 ppm	mdd 0008

43

STUDY NO. : 0579 ANIMAL : RAT F344/DuCrlcrlj[F344/DuCrj] UNIT : g / kg / d a y REPORT TYPE : A1 104 SEX : MALE	344/DuCrj]			CHEMIO ALL AI	CHEMICAL INTAKE CHANGES ALL ANIMALS		(SUMMARY)							PA	PAGE :
Group Name	Adminis 18	Administration (weeks)	eeks)		26		30		34		38		42		7000
Control	0.000	0.000	0.000±	0.000	0.000±	0.000	0,000±	0,000	0.000 ± 0.000	0.000	€ 000 +	0.000	0.000±	0.000	A STATE OF THE BOARD AND A STATE OF THE STAT
1280 ppm	0.056± 0.004	0.004	0.056⊥	0.004	0. 056 ± (0.005	0.053±	0.004	0.052 ± 0.005	0.005	0.051士 0.006	0.006	0.050±	0.004	
3200 ppm	0.137 ± 0.006	0.006	$0.134\pm$	0.007	0.133±	0.006	0.124±	0.017	0.124±	0.009	0.124±	0.014	0.118±	0.009	
8000 ppm	0.357± 0.027	0.027	0.350±	0.023	0.348±	0.029	$0.331\pm$	0.028	0.323±	0.027	0.317±	0.027	0.307±	0.026	

STUDY NO.: 0579 ANIMAL: RAT F344/DuCrlCrlj[F344/DuCrj] UNIT: K/kg/day REPORT TYPE: A1 104 SEX: MALE	[F344/DuCr.j]	W W	CHEMICAL INTAKE CHANGES ALL ANTMALS	(SUMMARY)			PAGE: 4
Group Name	Administration (weeks)46	(weeks)50	54	58	29	99	70
Control	0.000 士 0.000	0.000士 0.000	0.000 + 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000± 0.000
1280 ppm	0.047 ± 0.004	0.048 == 0.005	0.047 ± 0.005	0.045 ± 0.005	0.048 ± 0.005	0.047 = 0.004	0.047 = 0.005
3200 ppm	0.114± 0.007	0.113 ± 0.008	0.112± 0.011	0.108 ± 0.007	0.114 ± 0.009	0.112生 0.007	0.111± 0.008
8000 ppm	0.296 ± 0.024	0.294 ± 0.023	0.296 ± 0.021	0.285 ± 0.025	0.300 ± 0.026	0.288 ± 0.024	0.292 ± 0.033

STUDY NO.: 0579 ANIMAL: RAT F344/DuCr1Cr1;[F344/DuCrj] UNIT: R/kg/day REPORT TYPE: A1 104 SEX: MALE	F344/DuCrj]	ALI ALI	CHEMICAL INTAKE CHANGES (SUMMARY) ALL ANIMALS	(SUMMARY)			PAGE: 5
Group Name	Administration (weeks)	(weeks)	88	98	06	94	86
Control	0.000 ± 0.000	0.000 = 0.000	0.000 ∓ 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000± 0.000
1280 ppm	0.048 ± 0.005	0. 049 ± 0. 006	0.048 ± 0.005	0.047 ± 0.005	0.046 ± 0.005	0.044 ± 0.006	0.046 ± 0.006
3200 ppm	0.111 ± 0.011	0.114 ± 0.010	0.112 = 0.007	0.112± 0.011	0.109± 0.011	0.104 ± 0.018	0.110± 0.014
8000 mdd	0.295 ± 0.031	0.304 ± 0.034	0.297± 0.036	0.298± 0.038	0.289 ± 0.047	0.298± 0.083	0.292± 0.039

46

(HAN300)

PAGE: 6						
(SUMMARY)						
CHEMICAL INTAKE CHANGES (SUMMARY) ALL ANIMALS						
	104	0.000 ± 0.000	0.049 ± 0.006	0.117 ± 0.015	17± 0.043	
	on (weeks)_				$0.317\pm$	
STUDY NO. : 0579 ANIMAL : RAT F344/DuCrICrlj[F344/DuCrj] UNIT : R/Kg/day REPORT TYPE : A1 104 SEX : MALE	Administration (weeks)	0.000 ± 0.000	0.048 ± 0.009	0.112 ± 0.016	0.309 ± 0.045	
STUDY NO. : 0579 ANIMAL : RAT FE UNIT : R / kg REPORT TYPE : AI 1 SEX : MALE	Group Name	Control	1280 ppm	3200 upm	8000 ppm	

TABLE E 2

CHEMICAL INTAKE CHANGES: FEMALE

PAGE: 7	A A A A A A A A A A A A A A A A A A A				
PA		0.000	0.004	0.009	0.027
	L	0.000+	0.080 ±	0.203±	0.514±
		0.000	0.006	0.008	0, 030
	9	0.000 ∓	0.085 ±	0.209+	0.536±
		0.000	0.004	0.008	0.028
	5	0.000±	0.089±	$0.221\pm$	0.565±
		0.000	0.005	0.009	0.035
(SUMMARY)	4	0.000 ± 0.000	0.094 ± 0.005	0.236± 0.009	0.603± 0.035
E CHANGES		0.000	0.013	0.055	0.033
CHEMICAL INTAKE CHANGES (SUMMARY) ALL ANIMALS	ę.	0.000±	0.102.±	0.258±	0.624±
CHE		0.000	0.006	0.012	0.035
	(weeks)	0.000 ±	0. 107 ±	0.257±	0.648±
_	Administration (Weeks)	0.000	0.005	0.011	0.032
F344/DuCr.j.	Admini 1	0.000 = 0.000	0.118 ± 0.005	0.291± 0.011	0.742± 0.032
STUDY NO. : 0579 ANYMAL : RAT F344/DuCrlCrlj[F344/DuCrj] UNIT : g/kg/day REPORT TYPE : Al 104 SEX : FEMALE	70				
ANIMAL : RAT F344/DuCrl UNIT : g /kg/ d a y REPORT TYPE : Al 104 SEX : FEMALE	O	Control	1280 ррт	nudd	8000 ppm
STUDY NO. : 0579 ANIMAL : RAT F UNIT : g // k REPORT TYPE : A1 SEX : FEMALE	Group Name	Сол	1280	3200 ppm	8000

(HVN300)

PAGE :				000 00	0.004	0.012	. 0.026
		14	TO THE REAL PROPERTY OF THE PR	0.000±	0.074=	0.182±	0.457±
			W. W	0.000	0.075 ± 0.007	0.011	0.028
		13	Vid 10	€0000	0.075±	0.180±	0.465±
				0.000	0.008	0.012	0.022
		12		0.000±	0.076±	0. 186±	0.475±
				0.000	0.004	0.010	0.024
(SUMMARY)		11		0.000± 0.000	0.074± 0.004	0.185± 0.010	0.477 ± 0.024
3 CHANGES				0.000	0.003	0.009	0.027
CHEMICAL INTAKE CHANGES ALL ANTMALS		10		0.000年	0.076 ±	0.189±	0.489±
				0.000	0.003	0.009	0.025
	Administration (weeks)	6		0.000±	0.078±	0.193±	0.498±
	stration			0.000	0.004	0.010	0.022
STUDY NO. : 0579 ANUMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] UNIT : K/kg/day REPORT TYPE : A1 104 SEX : FEMALE	Admini	&		0.000 □ 0.000	0.079 ± 0.004	0.197± 0.010	0.505 ± 0.022
STUDY NO. : 0579 ANIMAL : RAT F344/I UNIT : R/Kg/d REPORT TYPE : AI 104 SEX : FEMALE	Group Name			Control	1280 ppm	3200 ppm	8000 mdd

CHEMICAL INTAKE CHANGES (SUMMARY)
ALL ANIMALS

ALL ANIMALS

STUDY NO.: 0579
ANIMAL : KAT F344/DuCrl; j[F344/DuCr]]
UNIT : K / kg / d a y
REPORT TYPE : AI 104
SEX : FEMALE

SEX : FEMALE							PAGE: 9
Group Name	Administration (weeks)	(weeks)	. 56	30	34	38	42
Control	0.000 + 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000± 0.000
1280 ррт	0.072 ± 0.008	0.073± 0.009	0.073 ± 0.009	0.072 ± 0.008	0.072 ± 0.009	0.075 ± 0.012	0. 070 ± 0. 011
3200 ppm	0.174土 0.015	0.177± 0.026	0.179± 0.021	0.174 ± 0.021	0.173 ± 0.016	0.180 ± 0.029	0.165± 0.018
8000 ppm	0.457 ± 0.035	0.467± 0.101	0.452 ± 0.031	0.448 ± 0.048	0.434± 0.034	0.451± 0.061	0.417 ± 0.040

51

(HAN300)

STUDY NO.: 0579 ANIMAL: RAT F344/DuCc.ICr.I.j[F344/DuCr.j] UNIT: R / kg / d a y REPORT TYPE: AI 104 SEX: FEMALE	:344/buCr.j]		CHEMICAL INTAKE CHANGES (SUMMARY) ALL ANTMALS	(SUMMARY)			PAGE: 10
Group Name	Administration (weeks) 46 50	(weeks)	54	58	62	99	70
Control	0.000 ± 0.000	0.000 = 0.000	0.000 □ 0.000	0.000 ∓ 0.000	0.000± 0.000	0.000 ± 0.000	0.000± 0.000
1280 ррт	0.072± 0.015	0.074 ± 0.011	0.071生 0.011	0.067 ± 0.010	0.071± 0.010	0.0714 0.013	0.066 ± 0.009
3200 ppm	0.168 ± 0.027	0.173 ± 0.024	0.169± 0.022	0.163 ± 0.020	0.172 ± 0.025	0.166 ± 0.025	0.163 ± 0.022
8000 ppm	0.414± 0.033	0.438± 0.066	0.427 ± 0.041	0.418± 0.052	0.436± 0.054	0.413± 0.047	0.403± 0.051

(SUMMARY)	
CHEMICAL INTAKE CHANGES ALL ANIMALS	
STUDY NO. : 0579 ANIMAL : RAT F344/bucr1Cr1j[F344/bucrj] UNIT : R/Kg/day REPORT TYPE : A1 104	SEX : FEMALE

oga · remale							PAGE: 11
Group Name	Administration (weeks)	(weeks)		A A A A A A A A A A A A A A A A A A A		territoria de la constanta de	
	74	78	82	86	06	94	86
Control	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 ± 0.000	0.000 □ 0.000	0.000 ± 0.000	0.000± 0.000
1280 ррт	0. 070 ± 0. 008	0.068± 0.009	0.064 ± 0.010	0.063 ± 0.011	0.063 ± 0.012	0.060 ± 0.009	0.060 ± 0.008
3200 ppm	0.167 ± 0.025	0.168 ± 0.025	0.156 ± 0.022	0.157 ± 0.021	0.155 ± 0.022	0.151 ± 0.022	0.152 ± 0.023
8000 ppm	0.416 ± 0.049	0.422 ± 0.057	0.398± 0.056	0.405 ± 0.049	0.402 ± 0.046	0.384 ± 0.051	0.383± 0.046

PAGE : 12							
(SUMMARY)		THE REAL PROPERTY OF THE PROPE					
CHEMICAL INTAKE CHANGES (SUMMARY) ALL ANIMALS							
	(weeks)		0.000 ∓ 0.000	0.059± 0.010	0.148± 0.027	0.383 ± 0.064	
crlj[F344/Ducrj]	Administration (weeks)		0.000 ± 0.000	0.061 ± 0.009	0.150± 0.026	0.387 ± 0.047	
STUDY NO.: 0579 ANIMAL: RAT F344/DuCrICrij[F344/DuCrj] UNIT: R/kg/day REPORT TYPE: AI 104 SEX: FEMALE	Group Name		Control	1280 ppm	3200 ppm	mdd 0008	

TABLE F 1

HEMATOLOGY: MALE

STUDY NO. : 0579 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] MEASURE. TIME : 1 SEX : MALE	44/DuCrICrl. REPORT 1	nCrlCrlj[F344/DuCrj] REPORT TYPE : Al			HEM	HEMATOLOGY (SUMMARY) ALL ANIMALS (105W)	MMARY) OSW)								, E	.
Group Name	NO. of Animals	RED BLOOD CELL 1 O ⁶ / µl	O CELL	HEMOCLOBIN g / d2	JBIN	HEMATOCRIT	RIT	MCV f &		мсн р в	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	MCHC g / d2		PLATELET 1 0³ ∕ μℓ	rage . ET ET	1
Control	33	7.56±	L. 25	12.9+	 4.	35.9±	5.4	47.9±	4.9	17.1±	1.6	35.7±	1.8	∓7 9 6	217	
1280 ppm	38	8.14± 1	1.14	13.8±	2.4	38. 0 ±	5.2	46.8 🕂	2. 4	16.9 ±	1.4	36.1±	2.0	∓926	285	
3200 ppm	68	8. 43 + 0	0.74**	14.5±	1. 2**	39. 7 ±	2.9**	47.1±	1.5	17.2+	0.7	36.6±	0.7	#288	131	
mdd 0008	38	7.88士 0	0.89	13.4±	1.9	37.2±	4.1	47.4±	3.0	17.1	1.7	35.9±	1.7	1018±	224	
Significant difference :	fference ;	* : P ≤ 0.05		* : P S 0. (10	PARTITION OF A SAME I MARKET M		Test of Dunnett	nett							PATEA

	PAGE: 2						BA1S-4
HEMATOLOGY (SUMMARY) ALL ANIMALS (105W)							Test of Dunnett
							* : P ≤ 0.01
/DuCrj]	A1	RETICULOCYTE %	5.6± 4.9	4.0± 2.7*	3.4± 1.0**	4.7 ± 2.2	. ≤ 0.05
lCr1 j[F344/	REPORT TYPE : A1		5	4.	e,	4	*
79 F344/DuCr. 	REP	NO. of Animals	33	38	39	38	difference
STUDY NO. : 0579 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] MFASIRF TIME : 1	SEX : MALE	Group Name	Control	1280 ppm	3200 ppm	8000 ppm	Significant difference ; * : P \leq 0.05 (HCL070)

PAGE: 3		8± 22	3± 15	1 + 1	1 = 2	
	OTIIER	20	n	1	-	
	A de la constanta de la consta	Ξ	10	7	σ,	
	LYMPIO	40∓	38 ±	42±	41 ±	
		69	83	*	23	
	MONO	1+	+ 9	+	2 +	
		0	0	0	0	M (1800) (1900)
	BASO	+1 0	⊕0	†! 0	+10	nett
		7	53	1	Т	Test of Dunnett
ARY) W)	EOSINO	+1	2 ±	+ 2	2+	Test
HEMATOLOGY (SUMMARY) ALL ANIMALS (105W)	(%)	12	11	2	တ	
HEMATOLO ALL ANIM	Differential WBC (9	45±	∓19	$49\pm$	$51\pm$	
	fferentia	1	-	0		0.01
	Di. N-BAND	+1	1	+0	†I 0	VI ≵
li i	717	13.41	13. 09	1.85	1.59**	0.05
/DuCrlCrlj[F344/DuC REPORT TYPE : A1	₩BC 1 0³ ∕ μβ	9.83± 13.41	9.26± 13.09	+29.9	8.02±	Vil □ *
79 F F344/DuCrlCr] : 1 REPORT	NO. of Animals	33	38	36	88	Significant difference ; * : P \leq 0.05
STUDY NO.: 0579 ANUMAL: RAT F344/PuCr1Cr1;[F344/PuCr]] MEASURE. TIME: 1 SEX: MALE REPORT TYPE: A1	Group Name	Control	1280 ppm	3200 ppm	8000 ppm	Significant

(HCL070)

TABLE F 2

HEMATOLOGY: FEMALE

50.6± 2.3 18.8± 0.9 37.1± 1.1 671± 146 50.6± 2.3 18.8± 0.9 37.1± 1.1 691± 163 50.9± 1.6** 18.8± 0.4 37.0± 0.8** 748± 181** Test of Dunett	STUDY NO. : 0679 ANIMAL	CELL HEWOGLOBIN		ATOLOGY (SUMMAR) ANIMALS (105W) HEMATOCRIT %	MMARY) 05W) RIT		MCV f R		MCB p g		MCHC g / dg		PLATELET 1 0³ ∕ µℓ	PAGE:
7.1 50.6± 2.3 18.8± 0.9 37.1± 1.1 694± 2.8 50.9± 1.6** 18.8± 0.4 37.0± 0.8** 748± 1.4** 51.5± 0.9** 19.0± 0.3* 36.8± 0.3** 771± Test of Dunnett	42 8.03± 0.78 15.0± 1.6	0.78 15.0±	1.6		40.0±	3.6	49.9±	1.6	18.7±	0.7	$37.4\pm$	1.1	∓129	146
2.8 50.9± 1.6** 18.8± 0.4 37.0± 0.8** 748± 1.4** 51.5± 0.9** 19.0± 0.3* 36.8± 0.3** 771± Test of Dunnett	44 7.81± 0.92 14.6± 1.8	0.92 14.6±	1.8		39. 4 ±	4.1	50.6土	2.3	18.8 🛨	6.0	37. 1 ±	1.4	€94±	163
1.4** 51.5± 0.9** 19.0± 0.3* 36.8± 0.3** 771± Test of Dunnett	46 7.91± 0.66* 14.9± 1.2	0.66* 14.9士	1.2		40.5+	2.8	50.9±	1.6**	18.8+	0.4	37.0±	0.8**	748±	181**
Test of Dunnett	39 7.62± 0.31** 14.5± 0.5**	0.31** 14.5±	0.5**		39.3∓	1. 4**	51.5±	0.9**	19.0干	0.3*	36.8±	0.3**	771±	83**
	Significant difference ; *: P ≤ 0.05 **: P ≤ 0.01	∨i d ¥			THE CASE OF THE CA		Test of Dun	nett		NI MIN NA VARIANTANA MANANANA NA				

STUDY NO. : 0579 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]	F344/DuCrlCrlj	[F344/DuCr.j]	HEMATOLOGY (SUMMARY) ALL ANIMALS (105W)	
SEX : FEMALE	REPORT TYPE : AI	YPE : A1		PAGE: 5
Group Name	NO. of Animals	RETICULOCYTE %		
Control	42	3.0+ 1.7		
1280 ppm	44	$4.1\pm$ 5.2		
3200 ppm	46	3.6± 2.4**		
8000 ppm	36	4.2 ± 0.5**		
Significant	Significant difference ;	*: P ≤ 0.05	** : $P \le 0.01$ Test of Dunnett	
(HCL070)				BAIS4

STUDY NO. : 0579 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] MFASIRE TIME : 1	9 F344/DuCrlCrl 1	l j [F344/Du(li X			HEMATOLOG	HEMATOLOGY (SUMMARY) ALL ANIMALS (105W)	<u></u>									
SEX : FEMALE		REPORT TYPE : A1														PAGE :	9
Group Name	NO. of Animals	WBC 1 0³ ∕ μβ	TT	Dif N-BAND	Differential WBC N-SEC	WBC (%)		EOSINO		BASO		MONO		LYMPHO		OTHER	
Control	42	3.09	1.48	<u>+1</u>		43±	11	#1 +1	_	#0	0	2+	င္၀	48±		+1	ę,
1280 mad	14	3.34 ⊹	1.81	<u>+1</u>		43 -	=	<u>+ </u>		+I		+ 	. 8	±74	: :	, c	
3200 mgd 3200	46	3.27±	1.85	+1	-	41+	11	5 +1		+10	0	2+1	. 2	25 +	10	+1	
mqq 0008	39	3.39±	1.58	1+	_	37±	10	2+		+ 0	0	ю †	63	25 ±	*6	+1	4
Significant	Significant difference ;	* P 0.05	. 0.05	± . P 0.01	0.01		MANDANDAN AND AND AND AND AND AND AND AND	Test	Test of Dunett		ALE SEE OF THE SECOND STREET, SEE		THE REAL PROPERTY AND ADDRESS OF THE PERSON NAMED IN COLUMN TWO ADDRESS				
(920 120)		ł															DATE A

TABLE G 1

BIOCHEMISTRY: MALE

STUDY NO. : 0579 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] MAASIIPF TIMF : 1	F344/DuCrlCrl	lj[F344/DuCrj	1			BIOCHEMISTRY (SUMMARY) ALL ANIMALS (105W)	JMMARY) 5W)									
SEX : MALE		REPORT TYPE : A1													PAGE :	
Group Name	NO. of Animals	TOTAL P.	TOTAL PROTEIN g / dl	ALBUMIN g / dl		A/G RATIO		T-BILIRUBIN mg/dl	BIN	GLUCOSE mg/dl		T-CHOLESTEROL mg/d2	STEROL	TRIGLYCERIDE mg/dl	JERI DE	
-	Ş	- t :		:	:				Addition	Wyderman arms and a second and		TO THE				
Control	33	6.7∄	0.4	2.7=	o. 2	0.7±	0.1	0.19± 0	0.14	144+	50	195±	7.9	106±	2 2	
1280 ppm	38	€.7±	0.4	2.8 :	0.3	0.7	0. 1	0.15± 0	0.03	145 🛨	17	181 ±	52	₹ 26	42	
3200 ppm	39	€.8	0.4	2.8	0.2	0.7±	0.1	0.16± 0	0.03	147 ±	21	201	55	109+	25	
mdd 0008	38	∓9.9	0.3	2.8	0.3	0.7±	0.1	0.15± 0	0.03	149±	17	219±	85	140±	100	
Significant	Significant difference ;	*: P ≤ 0.05	. 05	** : P ≤ 0.01			**************************************	Test of Dunnett	11¢			THE THE PROPERTY OF THE PROPER			MARKET LINE AND THE PROPERTY OF THE PROPERTY O	
(HCL074)	***************************************															BAIS 4

STUDY NO. : 0579 ANIMAL : RAT F344/DuCrICrlj[F344/DuCrj] MEASURE. TIME : 1 SEX : MALE REPORT TYPE : AI	F344/DuCrlCrlj 1 REPORT T	[[F344/DuCrj YPE: AI	_			BIOCHEMISTRY (SUMMARY) ALL ANIMALS (105W)	(SUMMAR) 105W)	Q							PAGE	c
Group Name	NO. of Animals	PHOSPHOLIPID mg/d2	LIP1D	AST I U / £	ø	ALT I U / g	8	LDH I U / &	8	ALP I U / g	8	G-GTP I U / g	8	CK I U / g		1
Control	33	284±	113	- - 68	85	40±	28	149十	87	+ 881	80	†1 9	5	126 ±	42	
1280 ppm	38	261 ±	69	∓62	27	34 1+	13	141 ±	45	∓961	56	9	m	117土	55	
3200 ppm	39	786±	33	**************************************	83	32±	13	132±	20	170∓	09	***	ιĠ	112±	47	
8000 ppm	38	308∓	113	73 ±	28	32#	13	126±	35	∓961	186	14+	** /	114±	54	
Significant (HCL074)	Significant difference; *:P ≤ 0.05	. P ≤ 0.	. 05	* : P ≤ 0.01	Tamping a second as a second		*NAME OF COLUMN ASSESSMENT OF THE STREET	Test of Dunnett	nnett						TV9	BAIS 4

STUDY NO. : 0579 ANIMAL : RAT F344/DuCr1Cr1j[F344/DuCrj] MEASURE. TIME : 1	F344/DuCrlCrlj 1	[F344/DuCrj	0		BI	BIOCHEMISTRY (SUMMARY) ALL ANIMALS (105W)	UMMARY) 5W)								
SEX : MALE		REPORT TYPE : A1													PAGE: 3
Group Name	NO. of Animals	UREA NITROGEN mg/d2	TROGEN	CREATII mg/d2	ININE R	SODIUM m Eq∕2		POTASSIUM m.Eq∕2	ŪM Ī	CHLORIDE m Eq / 2		CALCIUM mg/dl		INORGAN mg/d2	INORGANIC PHOSPHORUS
				CONCENSION OF THE PROPERTY OF				The state of the s	We provide the state of the sta	AND ANALYSIS OF THE PROPERTY O					
Control	33	19.4	4.7	一0.6十	0.1	143±	-	3.8+	0.5	∓901	-	10.7±	0.4	4.3+	0.5
1280 ppm	38	18.7 ±		0.6 ⊞	0. 1	143±	=	3.9 ±	0.3	106 ±	87	10.6土	0.3	4.3 ±	0.4
3200 ppm	36	19.8士	3.4	0.6+	0.1	142±	-	3.9+	0.3	∓901	23	10.7±	0.4	4.2+	0.6
8000 mad	38	25.0±	20.8*	0.7±	0.3	142±	-	4.1+	0.2**	∓901	7	10.6±	0.6	5.0±	3.0*
Significant	Significant difference ; * : P \leq 0.05	*:P ≤ 0	1. 05	** : P ≤ 0.	01			Test of Dunnett	nett						

(HCL074)

TABLE G 2

BIOCHEMISTRY: FEMALE

				ALE ANIMALS (105#))5W)								PAGE :
Group Name NO. of Animals	TOTAL PROTEIN g / d2	ALBUMIN 8 / dl		A/G RATIO	0]	T-BILIRUBIN mg/de	KUBIN	GLUCOSE mg/dl		T-CHOLESTEROL mg/dl	STEROL	TRIGLYCERIDE mg/dl	ERIDE
Control 42	6.9土 0.5	3.6 #	0.4	1.1+	0.1	0.14±	0.04	143±	14	132±	44	87±	77
1280 ppm 44	6.9 ± 0.5	3.6±	0.1	1.1	0.1	0.14 ±	0.03	143 ±	21	130 :∓:	32	71=	53
3200 ppm 46	7.0 + 0.4	3.6±	0.2	1.1+	0.1	0.13±	0.02	146±	14	T30	28	÷89	53
8000 ppm 39	7.1 0.3	3.8±	0.3**	1.1+	0.1*	0.14±	0.02	145±	26	∓981	23	54土	28
Significant difference ; *	* : P \ 0.05	★ :P≤0.01]			Test of Dunnett	nett		OF NOORS POORSALAN LINE A				

STUBY NO. : 0579 ANIMAL : RAT F344/DuCklCklj[F344/DuCkj] WFASIRE. TIME : I	9 F344/DuCrlCrl; 	j[F344/DuCrj	_		.B.	BIOCHEMISTRY (SUMMARY) ALL ANIMALS (105W)	SUMMARY) 05W)									
SEX : FEMALE	REPORT 1	REPORT TYPE : A1													PAGE:	
Group Name	NO. of Animals	PHOSPHOLIPID mg/dl	CIPID	AST I U / g	AND CONTRACT OF THE PROPERTY O	ALT I U / g		LDH I U / 2		ALP I U / 2	8	6-6TP 1 U / 2		CK IU/2	8	
Control	42	243±	78	114±	68	48±	23	∓181	29	118	89	2#	2	#128	23	
1280 ppm	44	239土	57	113土	53	47 -	24	± 102	105	∓901	29	7	-	102 ±	64	
3200 ppm	46	- 539+	55	104±	40	42±	17	∓98ĭ	92	116	107	2+	1	84+	28	
mdd 0008	39	$252\pm$	37	93±	36	41+	61	157±	29	93 + 1	56	4 †1	** 9	79士	17	
Significant	Significant difference; *:P ≤ 0.05	.0 4 *	. 05	# : P 0.01				Test of Dunnett	nett	AND LEVER WAS TAKED AS A SECOND AS A SECON					an executive and an executive constant of the executive constant of th	
(HCL074)				- 1							And					BAIS 4

STUDY NO. : 0579 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] MEASURE. TIME : 1) F344/DuCr1Cr1 1	.j[F344/DuCrj	. 		BIG	BIOCHEMISTRY (SUMMARY) ALL ANIMALS (105%)	JMMARY) 5W)									
SEX : FEMALE	REPORT	REPORT TYPE : A1													. PA	PAGE: 6
Group Name	NO. of Animals	UREA NITROGEN mg/d&	TROGEN	CREATININE mg/de	INE	SODIUM mEq∕2		POTASSIUM m.Eq./ &	UM E	CHLORIDE m Eq / 2	3 o	CALCIUM mg/dl	W	INORGAN mg/dl	ANIC PH	INORGANIC PHOSPHORUS
							TOTAL AND THE PROPERTY OF THE	A STATE OF THE STA	007 11100000000000000000000000000000000	And the district was a management of the state of the sta						THE RESIDENCE VIOLENCE IN THE PROPERTY OF THE
Control	42	19.1+	17.5	+9.0	0.6	142±	-	3.7±	0.5	104±	53	10.7±	9.0	4.4±	:3 :3	
1280 ppm	44	16.7±	5.3	0.5±	0.1	142土	2	3.7±	0.4	105 ±	63	10.6±	0.5	3.9⊥	0.8	
3200 ppm	46	16.4±	2.5	0.5+	0.1	142+	-	3.7+	0.4	105±	ç3	10.6±	0.4	4.0+	9.8	
8000 ppm	39	16.4	2.0	0.5±	0.1	142±	63	3.7±	0.4	104±	T.	10.6±	0.3	3.9±	0.7	
Significant	Significant difference ;	* : P ≤ 0.05	. 05	* : P ≤ 0.01	T T T T T T T T T T T T T T T T T T T			Test of Dunnett	nett							***************************************
(HCL074)																BAIS 4

TABLE H 1

URINALYSIS: MALE

NO. of pH Protein. Animals 5.0 6.0 6.5 7.0 7.5 8.0 8.5 CHI - ± + 2+ 3+ 4+ CHI		
	Glucose Ketone body Bilirubin $-\pm +2 + 3 + 4 +$ CHI $-\pm +2 + 3 + 4 +$ CHI $-\pm 2 + 3 +$	CIII
CONTROL 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 30 3 0 0 0 0 32 0 0	
1280 ppm 38 0 1 5 11 15 6 0 0 0 0 23 15 38 0 0	0 0 0 0 33 5 0 0 0 0 38 0 0	
3200 ppm 39 0 1 4 5 14 15 0 * 0 0 0 0 26 13 39 0 0	0 0 0 0 35 4 0 0 0 0 39 0 0 0	
8000 ppm 39 0 3 1 15 17 3 0 0 0 1 23 15 39 0	0 0 0 0 66 0 0 0 0 0 8 98 0 0 0 0 0	,

Group Name Animals $-\pm + 2 + 3 + CIII$ $\pm + 2 + 3 + 4 + CIII$ Countrol 33 33 0 0 0 0 33 0 0 0 0 1280 ppm 39 37 0 1 0 1 39 0 0 0 0 8000 ppm 39 36 0 0 1 2 39 0 0 0 0 Significant difference ; $\star : P \le 0.05$ $\star \star : P \le 0.05$ $\star \star : P \le 0.05$ $\star \star : P \le 0.05$	STONT NO O.13 ANIMAL : RAT F344/DuCr.ICr.Ij[F344/DuCr.j] MEASURE. TIME : 1 SEX : WALE REPORT TYPE : AI	F344/DuCr.ICr. 1 REPORT	:4/DuCrlCrlj[F344/DuCrj] REPORT TYPE : Al	CALINIAL	PAGE :
33 0 0 0 0 0 38 0 0 0 0 0 0 39 0 0 0 0 0 0 0 0 0 0 0 0	Group Name	NO. of Animals	0ccult blood - ± + 2+3+ G	Urobilinogen UI ± + 2+3+4+ CIII	
38 0 0 0 0 0 39 0 0 0 0 0 39 0 0 0 0 0 0 0	Control	33		0 0	
39 0 0 0 0 0 39 8 4*: P ≤ 0.01	1280 ppm	38		0 0	
39 0 0 0 0 0 *** ** : P ≤ 0.01	3200 ppm	36	37 0 1 0 1	0 0	
** : P ≤ 0.01	mdd 0008	36	36 0 0 1 2	0 0	
	Significant	difference	*: P ≤ 0.05	** : P ≤ 0.01	Test of CHI SQUARE

TABLE H 2

URINALYSIS: FEMALE

Outp Name NO. of Animals pH animals Animals 5.0 6.0 6.5 7.0 7.5 8.0 8.5 GII Colored in the protein Colored in the pody and a significant difference; Colored in t	NO. of Animals 43	8. 5.	2+ 3+ 4+	2+ 3+ 4+	3+ 4+	Bilirubin — + 2+ 3+ CHI
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	43 0 2 45 0 2	9 16 12 3	0			PONNA see all talk of the second seco
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	45 0 2	13 6 13 2		0 0 0 0	0 0 0	0 0
$\begin{array}{cccccccccccccccccccccccccccccccccccc$				0 0 0 0	0 0 0	0 0
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	46 0 1	2 9 28 4	-	0 0 0 0	0 0 0	1 0
* : P ≤ 0.05 ** : P ≤ 0.01	40 0 4	8 12 9		0 0 0 0	0 0 0	0 0
			Test	of CHI SQUARE	ANALYS AND ANALYS ANALYS AND ANALYS ANALYS AND ANALYS ANALYS AND ANALYS AND ANALYS AND ANALYS AND ANALYS AND ANALYS AND A	

Group Name NO. of Animals Occult blood Animals Urobilinogen ± + 2+ 3+ CII Image: The proof Animals Urobilinogen = + 2 + 3 + 4 + CII Cultrol 43 39 0 1 0	SEX : FEMALE	NELONI	KEFUKI LIFE . AI			PACE :
43 39 0 1 0 3 43 0	roup Name	NO. of Animals	0ccult blood ± + 2+ 3+ G	Urobilinogen ± + 2+ 3+ 4+	CII	7
45 46 45 1 0 0 46 46 0 0 0 46 0 0 0 40 39 0 0 0 1 40 0 0 0	Control	43	39 0 1 0 3	0		
46 45 1 0 0 0 46 0 0 0 0 40 39 0 0 0 1 40 0 0 0	1280 ррш	45	_	0 0		
40 39 0 0 0 1 40 0 0 0	3200 ppm	46		0 0		
	8000 ppm	40	39 0 0 0 1	0 0 0		

TABLE J 1

ORGAN WEIGHT, ABSOLUTE: MALE

PAGE:						
	EYS	0.282	0.312	0.370*	0.555*≠	
	KIDNEYS	2.967±	2.966±	3.139±	3.348±	
	LUNGS	± 0.583	€ 0.196	£ 0.119	E 0.125	
	TO	1.524±	1.427 ±	1.395±	1.373土	
	HEART	- 0.110	4 0.075	± 0.080	± 0.131	
RY)		1.248±	$1.261 \pm$	1.273±	1.280±	
LUTE (SUMMA (1054)	TESTES	2. 157	1.294	1.076	1.331	
ORGAN WEIGHT:ABSOLUTE (SUMMARY) SURVIVAL ANIMALS (105W)	ATT.	3. 452±	3.045 ±	3.062±	$3.227\pm$	***************************************
ORGAN	ADRENALS	0.157	0.583	0.023	0.020*	
	ADR	$0.102\pm$	0. 179 ±	0.077	0.072±	
	Body Weight	43	35	38	38	***************************************
[F344/DuCr.j]	Body	∓06€	394⊡	403±	371±	
rg r F344/DuCrlCrlj il	NO. of Animals	33	38	39	39	
STUDY NO.: 0579 ANIMAL: RAT F344/DucricrijfF344/Ducrjj REPORT TYPE: A1 SEX: MALE UNIT: g	Group Name	Control	1280 ppm	3200 ppm	8000 ppm	

(IKCL040)

BAIS 4

Test of Dunnett

 \Rightarrow : P \leq 0.01

Significant difference ; * : P \leq 0.05

SPLEEN LLYER
ANIMAL - KAI 16344/DUCFICELJU:344/DUCFJJ REPORT TYPE : AL SEX : MALE UNIT: g Group Name NO. of SPLE Group Name NO. of SPLE Animals Control 33 1.457± 1280 ppm 38 1.071± 3200 ppm 39 1.125± 80000 ppm 39 1.125±

TABLE J 2

ORGAN WEIGHT, ABSOLUTE: FEMALE

. HDAG						
	EYS	0. 165	0. 183	0.156	0.186	TO THE RESIDENCE OF THE PROPERTY OF THE PROPER
	KIDNEYS	1.841±	1.854 ±	1.812±	1.834±	THE RESERVE OF THE PROPERTY OF
	SS	0, 066	0.130	0.071	0.166	
	TUNGS	0.953±	0.950 ±	0.925±	0.939±	***************************************
	T	0.083	0.076	0.079	0.055	
	HEART	0.905土	0.885 ±	0.869±	0.866±	
ORGAN WEIGHT:ABSOLUTE (SUMMARY) SURVIVAL ANIMALS (105W)	IES	0. 295	1.084	0.307	0. 137	
ORGAN WEIGHT:ABSOLUTE (SURVIVAL ANIMALS (105W)	OVARIES	0. 183±	0.361±	0.187±	0.151±	V(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(1)(
ORGAN WE SURVIVAL	IALS	0.010	0.010	0. 182**	0,007**	
	ADRENALS	0.076±	0.073 ==	⊕0.096	₹690 '0	mi mam an appendante des des son sendo modes an accomo
	ight	33	32	31*	31**	And Add about the second secon
44/DuCrj]	Body Weight	277±	780 - 1	559∓	240∓	THE REAL PROPERTY OF THE PROPE
STUDY NO. : 0579 ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj] REPORT TYPE : A1 SEX : FEMALE UNIT: g	NO. of Animals	42	45	46	40	
STUDY NO. : 057. ANIMAL : RAT REPORT TYPE : A. SEX : FEMALE UNIT: g	Group Name	Control	1280 ppm	3200 ppm	8000 ppm	A Constitution of the Cons

(IICI,040)

BAIS 4

Test of Dunnett

 \star : P \leq 0.01

Significant difference ; * : P \leq 0.05

(HCL,040)

TABLE K 1

ORGAN WEIGHT, RELATIVE: MALE

ORGAN WEIGHT:RELATIVE (SUMMARY) SURVIVAL ANIMALS (1057)

PAGE: 1

STUDY NO.: 0579
ANIMAL : RAT F344/Ducricrijf344/Ducrijl
REPORT TYPE : AI
SEX : MALE
UNIT: %

Group Name	NO. of Animals	Body Weight (g)	cht ADRENALS	TESTES	LIBART	TUNGS	KIDNEYS
Control	33	390± 43	0.027 ± 0.041	0.883土 0.539	0.323土 0.036	0.395土 0.156	0.773± 0.140
1280 ррш	38	394± 35	0.046 ± 0.153	0.775 ± 0.337	$0.322\pm\ 0.033$	$0.364\pm\ 0.054$	$0.759\pm\ 0.119$
3200 ppm	38	403± 38	0.019 ± 0.006	0.760± 0.263	$0.319\pm\ 0.037$	0.351± 0.068*	0.783± 0.093
8000 mad	36	371± 38	0.020 ± 0.007	0.861 ± 0.337	0.350± 0.059	0.379± 0.097	0.927± 0.282***
Significant	difference ;	Significant difference ; * : P \leq 0.05	** : P ≤ 0.01	Tes	Test of Dunnett		

(HCL,042)

BAIS 4

Group Name NO. of SPLJEN LIVER BRAIN Animals Coutrol 33 0.376± 0.385 3.055± 0.455 0.536± 0.064	
33 0.376 \pm 0.385 3.055 \pm 0.455	
	. 064
1280 ppm 38 0.275 ± 0.086 2.907 ± 0.413 0.531 ± 0.048	. 048
3200 ppm 39 $0.259\pm0.043*$ 2.926 ± 0.310 0.522 ± 0.057	250
8000 ppm 39 0.305 \pm 0.034 3.150 \pm 0.408 0.567 \pm 0.082*	. 082*

(HCL042)

BAIS 4

TABLE K 2

ORGAN WEIGHT, RELATIVE: FEMALE

PAGE: 3						
	KIDNEYS	$0.674\pm\ 0.097$	$0.668\pm\ 0.076$	0.708± 0.090*	0.778± 0.153**	
	LUNGS	0.349± 0.050	0. 341± 0. 040	$0.362\pm\ 0.049$	0.399± 0.107**	
c	HEART	0.332± 0.056	$0.319\pm\ 0.035$	0.339士 0.040	0.365± 0.041**	Test of Dunnett
ORGAN WEIGHT:RELATIVE (SUMMARY) SURVIVAL ANIMALS (105W)	OVARIES	0.065± 0.095	$0.123\pm\ 0.366$	0.071± 0.101	0.064± 0.060	Test
ORGAN Y SURVIV	ADRENALS	0.028± 0.005	0.026 ± 0.004	0.040± 0.087	0.029 ± 0.006	‡ : P ≤ 0.01
[344/DuOr.j.]	Body Weight (g)	277± 33	280 ∓ 32	259± 31*	240± 31**	* : P ≤ 0.05
F344/DuCrlCrljf	NO. of Animals	42	45	46	40	Significant difference ;
STUDY NO. : 0579 ANIMAL : RAT F344/DuCrlcrlj[F344/DuCrj] REPORT TYPE : Al SEX : FEMALE UNIT: %	Group Name	Control	1280 ppm	3200 ppm	mdd 0008	Significant

(HCL,042)

BATS 4

Group Name NO. of Animals SPLEEN LIVER BRAIN Control 42 0.233± 0.122 2.532± 0.415 0.691± 0.101 1280 ppm 45 0.231± 0.143 2.455± 0.356 0.680± 0.074 3200 ppm 46 0.219± 0.050 2.457± 0.196 0.738± 0.100** 8000 ppm 40 0.294± 0.053** 2.739± 0.427** 0.791± 0.116** Significant difference ; *: P ≤ 0.05 **: P ≤ 0.05 **: P ≤ 0.01	NUTMAL : RAT F344/buck-ICk-lj[F344/buck-j] REPORT TYPE : A1 SEX : FEMALE UNIT: %	F344/DuCrlCrlj	F344/DuCr.j]	SURVIVAI	ORNIVAL ANIMALS (105W)	PAGE:
0. 233 ± 0. 122 2. 532 ± 0. 415 0. 691 ± 0. 101 0. 231 ± 0. 143 2. 455 ± 0. 356 0. 680 ± 0. 074 0. 219 ± 0. 050 2. 457 ± 0. 196 0. 738 ± 0. 100*** 0. 294 ± 0. 053 ** 2. 739 ± 0. 427 ** 0. 791 ± 0. 116*** *: P ≤ 0. 05 **: P ≤ 0. 01	Group Name	NO. of Animals	SPLBEN	LIVER	BRAIN	
0. 231 ± 0.143 2. 455 ± 0.356 0. 680 ± 0.074 0. 219 ± 0.050 2. 457 ± 0.196 0. 738 ± 0.10084 0. $294\pm 0.053**$ 2. $739\pm 0.427**$ 0. $791\pm 0.116**$ *: P ≤ 0.05 **: P ≤ 0.01	Control	42	0.233± 0.122	2.532± 0.415	0.691± 0.101	
0. 219 ± 0.050 2. 457 ± 0.196 0. 738 ± 0.10044 0. $294\pm0.053**$ 2. $739\pm0.427**$ 0. $791\pm0.116*4$ * : P \leq 0. 05 ** : P \leq 0. 01	1280 ppm	45	$0.231\pm\ 0.143$	$2.455\pm\ 0.356$	$0.680\pm\ 0.074$	
0.294± 0.053** 2.739± 0.427** 0.791± 0.116*** *: P ≤ 0.05 **: P ≤ 0.01	3200 ppm	46	0.219 ± 0.050	$2.457\pm\ 0.196$	0.738± 0.100**	
*: P ≤ 0.05 **: P ≤ 0.01	8000 ppm	40	0.294± 0.053**	2.739± 0.427**	0.791土 0.116**	
	Significant	difference ;			Test of Dunett	

TABLE L 1

HISTOPATHOLOGICAL FINDINGS:

NON-NEOPLASTIC LESIONS: MALE: ALL ANIMALS

(HPT150)

STUDY NO. : 057 ANLMAL : RAT REPORT TYPE : A1 SEX : MAL	: 0579 : RAT F344/DuCrICrL;[F344/DuCr.j] : All	HISTOPA ALL ANI	HISTOPATHOLOGICAL FINDINGS :N ALL ANIMALS (0-105W)	HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)		PAGE :
Organ	Findings	Group Name No. of Animals on Study Grade (%)	Control 50 2 3 4 7 (%) (%) (%)	1280 ppm 50 3 4 (%) (%) (%) (%)	3200 ppm 50 (%) (%) (%) (%) (%)	8000 ppm 50 1 2 3 4 (%) (%) (%) (%)
(Integumental	[Integumentary system/appandage]					
skin/app	mineralization	1 (2)	<50> (0) (0) (0) (0) (0)	(50) (0) (0) (0)	<00 (0) (0) (0) (0) (0)	<50> 1 0 0 0 (2) (0) (0) (0)
	inflammation	(i) (i)	2 0 0 0 (4) (4) (6) (6)	(0)(0)(0)(0)(0)	(0) (0) (0) (0) (0)	(0)(0)(0)(0)(0)
	squamous cell hyperplasia	(O)	(0)(0)(0)(0)(0 1 0 0 (0) (0) (0) (0)	(0) (0) (0) (0)	0 1 0 0 (0) (0) (0)
	epidermal cyst	(0 0	(0)(0)(0)(0 1 0 0 (0) (0) (0)	0 1 0 0 (0) (0) (0) (0)	0 1 0 0 (0) (0) (0)
	sebaceous hyperplasia	(0 0	(0)(0)(0)(0)((0) (0) (0) (0)		0 1 0 0 (0) (0) (0)
	ulcer:squamous epithelium	(0) (0)	(0)(0)(0)((0)(0)(0)(0)(0)	0 1 0 0 (0) (0) (0)	(0) (0) (0) (0)
subcutis	henorrhage	(0)	(0) (0) (0) (0) (0) (0) (0) (0) (0) (0)	<50> 0 1 0 0 (0) (2) (0) (0)	(0) (0) (0) (0) 0 0 0 0 0 0 0 0	<pre></pre>
	librosis:[ocal	(f) (g)	1 0 0 (2) (2) (3) (4)	0 1 0 0 (0) (0) (0) (0)	0 2 0 0 (0) (0) (0) (0)	(0)(0)(0)(0)
Grade < a > b (c) Significant	Grade 1: Slight 2: Moderate 3: Nowber of animals examined at the site b : Number of animals with lesion (c) c: b / a * 100 c: b / a * 100 significant difference; *: P \leq 0.05 **: P \leq 0.	3 : Marked 4 : Severe e site P ≤ 0.01 Test of Clii Square	re are			

(SUMMARY)	
LESIONS	
: NON-NEOPLASTIC L	
FINDINGS	
HISTOPATHOLOGICAL	

ALL ANIMALS (0-105W) STUDY NO. : 0579 ANIMAL : RAT F344/DuCrICrli[F344/DuCri]

	Group Name No. of Animals on Study	Control 50	1280 ppm 50	3200 ppm 50	8000 ppm 50
Organ	Grade Findings.	(%) (%) (%) (%)	(%) (%) (%)	(%) (%) (%) (%)	(%) (%) (%) (%)
(Respiratory system)	system)				
nasal cavit	thrombus	<50> 0 1 0 0 (0) (2) (0) (0)	(50) (0) (0) (0) (0)	(0) (0) (0) (0) (0)	<pre></pre>
	eosinophilic change:olfactory epithelium	14 5 0 0 (28) (10) (0) (0)	16 5 0 0 (32) (10) (0) (0)	12 3 0 0 (24) (5) (0) (0)	9 6 0 0 (18) (18) (0) (0)
	eosinophilic change:respiratory epithelium	1 0 0 0 (2) (3) (3) (4)	5 0 0 0 0 (10) (10)	2 0 0 0 (4) (4) (6) (6) (6)	2 0 0 0 (4) (4) (6) (6) (6)
	inflammation:foreign body	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	16 1 0 0 (32) (8) (0) (0)	19 2 0 0 (38) (4) (0) (0)	12 0 0 0 (24) (24) (30) (30) (30)
	respiratory metaplasia:olfactory epithelium	2 0 0 0 (4) (4) (6) (6) (6)	1 0 0 0 0 (2) (2) (3) (4)		
	respiratory metaplasia:gland	8 0 0 0 (16) (16) (16) (19) (19)	7 0 0 0 0 (14) (14) (15) (15)	6 0 0 0 (12) (12) (13) (13) (13) (14)	9 0 0 0 (18) (18) (19) (19) (19)
lung	congestion	<50> 0 0 0 0 (0) (0) (0)	(0) (0) (0) (0) 0 0 0 0 0 0 0 0	(0) (0) (0) (0) 0 0 0 0 0 0 0 0	(50) 0 1 0 (0) (2) (0) (0)
	edema			0 1 0 0 (0) (0) (0)	
Grade (a > b b (c)	Grade 1: Slight 2: Moderate 3: Marked (a) a : Number of animals examined at the site b : Number of animals with lesion (c) c: b/a*100	4 : Severe			

STUDY NO. : 057 ANIMAL : RAT REPORT TYPE : A1 SEX : MAL	: 0579 : RAT F344/DuCr.ICr.L.j.[F344/DuCr.j.] : AL : MALE	HISTOPATHOLOGICAL FINDI ALL ANIMALS (0-105W)	HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)		PAGE :
Organ	Findings	Group Name Control No. of Animals on Study 50 Grade 1 2 3 (%) (%) (%) (%)	1280 ppm 50 4 4 (%) (%) (%) (%) (%) (%)	3200 ppm 50 1 2 3 4 (%) (%) (%)	8000 ppm 50 3 4 (%) (%) (%) (%)
(Respiratory system)	system)				
lung	inflammetory infiltration	<50> 1 1 0 (2) (2) (0) ((0)(0)(0)(0) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	<50> 0 2 0 0 (0) (4) (0) (0)	<pre></pre>
	bronchiolar-alveolar cell hyperplasia	oia 0 2 0 (0) (4) (0) (0 1 0 0 0 0 0 0 0 0 (2) (3) (0) (0)	1 0 0 0 (2) (2) (3) (4) (5)	3 0 0 0 (0) (0) (0)
(Hematopoietic system)	ic system)				
воне шаттом	granulation	(50) 3 1 0 (6) (2) (0) ($\begin{array}{cccccccccccccccccccccccccccccccccccc$	<pre></pre>	(0) (0) (0) (0) 0 0 0 0 0 0 0 0
	increased hematopolesis	7 0 0 (14) (14) (15) (15) (17)	0 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	(0)(0)(0)(91)	9 0 0 0 0 (18) (18) (19) (19)
lymph node	lymphadenitis) (0) (0) (0) 0 0 0 0 0 (0) (0) (0	$\begin{pmatrix} \langle 56 \rangle \\ 0 & 0 & 1 & 0 & 0 \\ 0) & (& 0) & (& 2) & (& 0) & (& 0) \end{pmatrix}$	<pre></pre>	<50> 0 1 0 0 (0) (2) (0) (0)
spleen	congestion	<50> 0 1 0 (0) (2) (0) ((500) (0) (0) (0) (0) (0) (0) (0)	<50> 0 1 0 0 (0) (2) (0) (0)	<pre></pre>
Grade < a > b (c) Significant	Grade 1: Slight 2: Moderate 3: N < a > a : Number of animals examined at the site b : Number of animals with lesion (c) c: b / a * 100 Significant difference : *: P \leq 0.05 **: P \leq 0.	3: Marked 4: Severe site P ≤ 0.01 Test of Chi Square			
(IIPT150)					BA

SEX : MAL	: MALE				PAGE
Organ	Findings	Group Name Control No. of Animals on Study 50 Grade (%) (%) (%) (%)	1280 ppm 50 1 2 3 4 (%) (%) (%)	3200 ppm 50	8000 ppm 50 x 4 (%) (%) (%) (%)
(Hematopoic	(Hematopoietic system)				
spleen	necrosis:focal	$ \begin{array}{ccccccccccccccccccccccccccccccccccc$	(0) (0) (0) (0) (0) (0)	(0) (0) (0) (0) 0 0 0 0 0 0 0 0	(0) (0) (0) (0) 0 0 0 0 0 0 0 0
	deposit of hemosiderin	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	4 3 0 0 (8) (8) (9) (0)	6 3 0 0 (12) (6) (0) (0)	6 1 0 0 (12) (12) (13) (13)
	fibrosis:focal		(0)(2)(0)(0)	1 0 0 0 0 (2) (2) (3) (4) (6)	(2) (0) (0) (0)
	extramedullary hematopoiesis	3 0 0 0 (0) (0) (0)	2 1 0 0 (0) (10) (10) (10) (10)	(2) (8) (0) (0)	5 1 1 0 (10) (2) (2) (0)
	engorgement of erythrocyte		(0)(0)(0)(0)(0)		3 0 0 0 0 0 0 0 0
{Circulatory system}	ry system)				
heart	thrombus	(0) (0) (0) (0) (0) (0) (0) (0)	(0) (0) (0) (0) 0 0 0 0 (0) (0) (0)	(0) (0) (0) (0) 0 0 0 0 0 0 0 0	<pre></pre>
	myocardial fibrosis	21 0 0 0 (42) (42) (60) (60)	20 2 0 0 (40) (40) (40) (9)	18 0 0 0 (36) (36) (0) (0) (0)	19 1 0 0 (38) (38) (3) (0) (0)
Grade <a>> a> b	Grade 1: Slight 2: Moderate 3: N < a > a: Number of animals examined at the site b : Number of animals with lesion c: b / a * 100 c: b / a * 100 Significant difference; * *: P \equiv 0.5 **: P \equiv 0.5	3: Marked 4: Severe le site P ≦ 0.01 Test of Chi Square			

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)	-ICrli[F344/bucri] ALL ANIMALS (0-105W)
--	---

SEX	: MALE					PAGE :
0rgan	Findings	Group Name No. of Animals on Study Grade 1	Control 50 2 3 4 (%) (%) (%)	1280 ppm 50 1 2 3 4 (%) (%) (%) (%)	3200 ppm 50 1 2 3 4 (%) (%) (%) (%)	8000 ppm 50 1 2 3 4 (%) (%) (%)
(Digestive system)	system)					
hooth	dysplasia	0)	<50> 0 0 0 (0) (0) (0)	(0) (0) (0) (0) 0 0 0 0 0 0 0 0	<00> (0) (0) (0) (0) (0) (0)	(0) (0) (0) (0) (0) (0) (0) (0) (0) (0)
tongue	inflammatory infiltration	0)	<50> (0) (0) (0) (0)	<50> 0 0 0 0 0 0 0 0 0 0 0 0	(0)(0)(0)(0) 0 0 0 0 0 0 0 0	<50> 0 0 1 0 (0) (0) (2) (0)
	squamous cell hyperplasia	0)	(0) (0) (0)		0 1 0 0 (0) (0) (0)	
	artoritis	0)	(0) (0) (0)	(0)(0)(0)(0)(0)		1 0 0 0 (0) (0)
stomach	erosion:forestomach	(O)	<50> (0) (0) (0) (0)	<pre></pre>	<50> 1 0 0 0 (2) (0) (0) (0)	<50> (0) (0) (0) (0)
	ulcer:forestomach	5 (10)	(0) (0) (0)	0 1 0 0*	3 0 0 0 (0) (0)	2 1 0 0 (4) (2) (0) (0)
	liyperplasia:forestomach	(2)	3 0 0 (9) (9)	2 1 0 0 (4) (2) (6) (6)	10 4 0 0*	13 24 8 0 *** (26) (48) (16) (0)
Grade < a > b b (c)	Grade 1: Slight 2: Moderate 3: A < a > a: Number of animals examined at the site b : Number of animals with lesion c: b / a * 100	3 : Marked 4 : Severe at the site	a			

(HPT150)

STUDY NO. : 0572 ANLMAL : RAT REPORT TYPE : AL SEX : MAL	: 0579 : RAT F344/buCrICrI;[F344/buCr.j] PE : Al : MALE	HISTOPATHOLOGICAL FI ALL ANIMALS (0-105W)	LOGICAL FINDINGS :N S (0-105W)	HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)		PAGE :
Organ	Findings	Group Name No. of Animals on Study Grade (%)	Control 50 4 (%) (%) (%)	1280 ppm 50 1 2 3 4 (%) (%) (%)	3200 ppm 50 4 (%) (%) (%) (%)	8000 ppm 50 1 3 4 (%) (%) (%)
{Digestive system}	e system)					
stomach	erosion:glandular stomach) (21) 9	<50> (0) (0) (0) (0)	<pre></pre>	<50> 4 0 0 0 (8) (0) (0) (0)	<50> 1 0 0 0 (2) (0) (0) (0)
	ulcer:glandular stomach	1 (2) (0 0 0	(0)(0)(0)(0)(0)		
	hyperplasia:glandular stomach	1 (2) (0 0 0	2 0 0 0 (4) (4) (6) (6)	(0)(0)(0)(0)(0)	
	mineralization:glandular stomach) (0)	(0) (0) (0 0	(0)(0)(0)(0)(0)		0 1 0 0 (0) (0) (0)
Liver	herniation) (14)	<50> 0 0 0 0) (0) (0)	<50> 7 0 0 0 (14) (0) (0) (0)	<50> 7 0 0 0 (14) (0) (0) (0)	<50> 5 0 0 (10) (0) (0) (0)
	peliosis-like lesion) (0)	0 0 0 0	(0)(0)(0)(0)(0)	(0)(0)(0)(0)(0)	1 0 0 0 (2) (2) (3) (4)
	necrosis:central	1 (2) (0 1 0 0) (2) (0)	0 2 0 0 (0) (4) (0) (0)	(2) (2) (2) (0)	1 2 0 0 (2) (4) (0) (0)
	necrosis:focal	1 (2) ((0) (0) (0	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	(0) (0) (0) (0)	0 1 0 0 (0) (0) (0)
Grade < a > b b (c) Significat	Grade 1: Slight 2: Moderate 3: N $\langle a \rangle$ a: Number of animals examined at the site b : Number of animals with lesion c: b $/ a \approx 100$ as 100 c: b $/ a \approx 100$ Significant difference; $ a \approx 10$ Significant difference; $ a \approx 10$ Significant difference $ a \approx 10$ Significant dif	3: Marked 4: Severe site ≤ 0.01 Test of Chi Square				
-						

PAGE: 6

5 0 0 (10) (0) (0) (0 (0) (0) (0) 0 (0) (0) (0) 1 0 0 (2) (2) (0) (8000 ppm 50 7 1 0 (14) (2) (0 25 83 - S
 1
 2
 3
 4

 (%)
 (%)
 (%)
 (%)
 00 5 1 0 0 (10)(2)(0)(0) 3 0 0 0 (0) (0) (0) 00 1 0 0 (2) (2) (0) (3200 ppm 50 1 0 0 (2) (0) (0) HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W) 00 0 0
 1
 2
 3
 4

 (%)
 (%)
 (%)
 (%)
 (2) (0) (0) (0) 6 0 0 0 0 (12) (12) (13) (13) (14) 2 0 0 0 (0) (0) (0) 1280 ppm 50 1 0 0 ((2) (0) 2 0 0 (4) (4) (6) 2 3 4 (%) (%) (%) 00 0 0 2 0 0 0 (4) (6) (0) (0) 00 0 0 0 1 0 (0) (2) (0) (7 1 0 (14) (2) (0) (3 1 0 (6) (2) (0) (Control 50 3 0 0 (0) (0) No. of Animals on Study Grade Group Name STUDY NO. : 0579
ANLMAL : RXT F344/DuCrICrI;[F344/DuCrj]
REPORT TYPE : A1
SEX : MALE acidophilic cell focus basophilic cell focus clear cell focus fatty change granulation Findings (Digestive system) Organ liver

00

00

) 0 0

00

00

00

0 0

3 1 0 (6) (2) (0) (

00

0 1 0 (0) (2) (0)

00

0 0

PAGE:

4 8

0 0 1 0 0	(0) (0) (2) (0) (0)
0 0 0	(0) (0) (0)
0 0 0 0	(0) (0) (0) (0)
0 0 0 0	(0)(0)(0)(0)
hepatocellular hypertrophy:contral	

00

 $\overline{}$

6 43 0 (12) (86) (0)

00 $\overline{}$

7 42 0 (14) (84) (0)

00

7 41 0 (14) (82) (0)

bile duct hyperplasia

spongiosis hepatis

3 : Marked Grade 1: Slight 2: Moderate 3: Ma < a > a : Number of animals examined at the site b b : Number of animals with lesion (c) c:b/a*100 Significant difference; *:P \leq 0.05 **:P \leq 0.0

Test of Chi Square

**: P ≤ 0.01

(IIPT150)

(SUMMARY)	
LES10NS	
: NON-NEOPLASTIC	
INDINGS	

STUDY NO. : 057 ANIMAL : RAT REPORT TYPE : A1 SEX : MAL	: 0579 : RAT F344/bucr.ICrl.j[F344/bucr.j] : Al : MALE	HISTOPATHOLOGICAL FINDINGS :N ALL ANIMALS (0-105W)	HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)		PAGE :	∞
Organ	Findings	Group Name Control No. of Animals on Study 50 Grade 1 2 3 4 (%) (%) (%) (%)	1280 ppm 50 1 2 3 4 (%) (%) (%)	3200 ppm 50 1 2 3 4 (%) (%) (%)	8000 ppm 50 1 2 3 4 (%) (%) (%) (%)	
(Digestive system)	ystem)					
liver	focal fatty change	(0) (0) (0) (0) 0 0 0 0 0 0 0 0 0 0 0 0	(0) (0) (0) (0) 0 0 0 0 0 0 0 0 0	<pre></pre>	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
bile duct	duct ectasia	<50> 0 1 0 0 (0) (2) (0) (0)	(0) (0) (0) (0) 0 0 0 0 0 0 0 0	(0) (0) (0) (0) 0 0 0 0 0 0 0 0	(0) (0) (0) (0) 0 0 0 0 0 0 0 0 0	
pancreas	atrophy	. (50) 19 5 0 0 (38) (10) (0) (0)	<pre></pre>	<50> 13 3 0 0 (26) (6) (0) (0)	<50> 23 1 0 0 (46) (2) (0) (0)	
	arterilis	0 1 0 0 (0) (3) (0) (0)				
	islet cell hyperplasia	$\begin{array}{cccccccccccccccccccccccccccccccccccc$		$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	0 1 0 0 (0) (0) (0) (0)	
(Urinary system) Kidney	.tem} clironic nephropathy	<50> 14 20 10 0 (28) (40) (20) (0)	<50> 16 24 8 0 (32) (48) (16) (0)	(50) (9 24 15 0 (18) (48) (30) (0)	(50) 9 22 14 1 (18) (44) (28) (2)	
Grade (a) b (c) Significant (Grade 1: Slight 2: Moderate 3: $k < a > a > Number of animals examined at the site b b. Number of animals with lesion (c) c: b / a * 100 Significant difference; k : P \le 0.05 **: P \le 0.05$	3: Marked 4: Severe the site : P ≤ 0.01 Test of Chi Square				

BAIS4

(IIPT150)

97

Standard Standard	STUDY NO. ANIMAL REPORT TYPE SEX	: 0579 : RAT F344/DuCrICrLj[F344/DuCrj] : Al : MALE	HISTOPATHOLOGICAL FINDINGS : ALL ANIMALS (0-105W)	HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)	KO	PAGE
State Stat	Organ		Control 50 1 2 3 6) (%) (%)	1280 ppm 50 2 3 (%) (%)	3200 ppm 50 2 3 (%) (%)	(2)
The properties of the content of t	(Urinary sy.	ons.			· ·	***************************************
The system The	kidney	mineralization:pelvis	<pre></pre>) (0) (0) (0 0 0 0 0) (0) (0	<50> 1 0 0 2) (0) (0) ((50) (0 (0) (0 (0) (0) (0) (0) (0) (0) (0)
atypical tubule byserplasia pelvis $ (0) (2) (0) (2) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0$		mineralization:cortex	0 (0)	1 0 (2) (0) (0 0 0	0 (0)
State Stat		urothelial hyperplasia:pelvis	1 0 (2) (0) (0 (0)	0 1 (0) (2) (0 (0)
State Stat		atypical tubule hyperplasia	0 0 0	0 0 0 0	1 0 0 2 2) (0) (0) ((0) (0)
rine system Sight 2 : Moderate 3 : Marked 4 : Severe 5 : Number of animals with lesion c : 1	urin bladd	inflammatory polyp	<50> 0 0 (0) (0) (<50> 0 0 0 0) (0) (0)	<50> 0 1 0 0) (2) (0) (<50> 0 (0) (
cyst cyst cyst cyst cyst cyst cyst cyst		nodular hyperplasia:transitional epithelium	0 (0)	0 1 0 0) (2) (0) (0 0 0	1 1 2) (2) (
cyst cyst (0) (2) (3) (4) (50) (0) (50) (0) (50) (0) (50) (0) (50) (0) (6) (6) (7) (9) (9) (9) (9) (9) (9) (9) (9) (9) (9	(Бидостіпе	system)				
1: Slight 2: Moderate 3: Marked a: Number of animals examined at the site b: Number of animals with lesion c: b / a * 100 c:	pituitary	cyst	<50> 1 0 (2) (0) ((50) 2 1 0 4) (2) (0) (<50> 2 0 (4) (0) ((50) (0 (0) (0) (0) (0) (0) (0) (0) (0) (0
	Grade <a>> b (c) Significant	2: Moderate 3: Marked of animals examined at the site of animals with lesion *100 *100 *100 *100 *100 *100 *100 *10	4 : Severe st of Cli Square			

STUDY NO. : 0572 ANIMAL : RAT REPORT TYPE : A1 SEX : MALI	: 0579 : RAT F344/buCrlCrlj[F344/buCrj] : A1 : MALE	HISTOPATHOLOGICAL FINDINGS ALL ANIMALS (0-105W)	HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105%)	W	PAGE	떮
Control of the contro		Group Name Control No. of Animals on Study 50	1280 ppm	3200 ppm	mdd 0008	
Organ	Findings	1 2 %) (%)	(%) (%) (%) (%)	(%) (%) (%) (%)	e %	44 86
(Endocrine system)	(mon s As					
pituitary	hyperplasia	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	<pre></pre>	<pre></pre>	<50> 6 9 0 ((12) (18) (0) (0 0
	Rathke pouch	$\begin{pmatrix} 1 & 0 & 0 & 0 \\ (2) & (0) & (0) & (0) \end{pmatrix}$	(2) (0) (0) (0)	2 0 0 0 (4) (4) (6) (6)	1 0 0 () () ()	00
	aberrant craniopharyngeal tissue		0 1 0 0 (0) (0) (0) (0)			00
tlıyroid	ultimibranchial body remanet	<50> 1 0 0 0 (2) (0) (0) (0)	(50) (0) (0) (0) (0)	<50> 1 0 0 0 (2) (0) (0) (0)	<50\$ 0 0 0 () (0) (0) (()	0 0
	follicular hyperplasia	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	(0)(0)(0)(0)		2 0 0 (4) (4) (6) (7)	00
	C-oell hyperplasia	9 3 0 0 (18) (6) (0) (0)	8 3 0 0 (16) (16) (19)	15 2 0 0 (30) (4) (0) (0)	15 4 0 (00
adrenal	necrosis	<50> 0 0 1 0 (0) (0) (2) (0)	(0) (0) (0) (0) 0 0 0 0 (0) (0) (0)	<pre></pre>	<250> 0 0 0 0 (0) (0) (0)	00
Grade <a>> b	Grade 1: Slight 2: Moderate 3: <pre></pre>	3: Marked 4: Severe site ≤ 0.01 Test of Chi Square				

STUDY NO. : 057 ANIMAL : RAT REPORT TYPE : A1 SEX : MAI	: 0579 : RMT F344/bucricrij[F344/bucrj] : A1 : MALE	HISTOPATHOLOGICAL FINDINGS :N ALL ANIMALS (0-105W)	HISTOPATHOLOGICAL FINDLNGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)		PAGE: 11
Organ	Findings	Group Name Control No. of Animals on Study 50 Grade (%) (%) (%) (%)	1280 ppm 50 4 4 (%) (%) (%) (%)	3200 ppm 50 1 2 3 4 (%) (%) (%)	8000 ppm 50 3 4 (%) (%) (%) (%)
(Endocrine system)	system)				
adrenal	hyperplasia:cortical cell	<50> 0 2 0 0 (0) (4) (0) (0)	(0) (0) (0) (0) 0 0 0 0 0 0 0 0	<50> (0) (4) (0) (0) (0)	(0) (0) (0) (0) 0 0 0 0 0 <0\$>
	hyperplasia:medulla	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	2 2 0 0 (4) (4) (0) (0)	2 2 0 0 (4) (4) (0) (0)	2 3 0 0 (4) (6) (0) (0)
	focal fatty change:cortex	1 0 0 0 (2) (3) (4) (5)	1 0 0 0 (2) (2) (0) (0)	2 0 0 0 (4) (4) (6) (6) (6)	1 0 0 0 (2) (3) (4) (5)
(Reproductive system)	ve system}				
testis	mineralization	$\langle 50 \rangle$ $\begin{array}{cccccccccccccccccccccccccccccccccccc$	(50) (0) (0) (0)	<pre></pre>	(50) 1 0 0 0 (2) (0) (0) (0)
	arteritis	5 3 0 0 (10) (10) (10) (10)	4 1 0 0 (8) (8) (7) (9) (9)	9 0 0 0 (18) (18) (18) (19) (19)	4 3 0 0 (8) (8) (9) (0)
	interstitial cell hyperplasia	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	12 0 0 0 0 (24) (24) (0) (0) (0)	6 2 0 0 (12) (4) (0) (0)	15 1 0 0 (30) (2) (0) (0)
epididymis	arteritis	(0) (0) (0) (0) 0 0 0 0 0 0 0 0 0	(0) (0) (0) (0) 0 0 0 0 0 0 0	(0)(0)(0)(0) 0 0 0 0 0 0 0 0 0 0 0	<50> 0 1 0 0 (0) (2) (0) (0)
Grade < a > b (c) Significant	Grade 1 : Slight 2 : Moderate 3 :) <a> a : Number of animals examined at the site b : Number of animals with lesion (c) c : b / a * 100 Significant difference : * : P \le 0.05 ** : P \le 0.	3: Marked 4: Severe le site P ≤ 0.01 Test of Chi Square			
(HPT150)					BAIS4

STUDY NO. : 057 ANIMAL : RAT REPORT TYPE : A1 SEX : MAL	: 0579 : RAT F344/DuCrICrI;[F344/DuCr;] : A1 : MALE	V TVV	ALL ANIMALS (0-105%)	NOCS : NOT	HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105#)		PAGE: 12
Organ	Pindings	Group Name No. of Animals on Study Grade	Control y 50 1 2 3 (%) (%) (%)	4 (%)	1280 ppm 50 1 2 3 4 (%) (%) (%)	3200 ppm 50 1 2 3 4 (%) (%) (%) (%)	8000 ppm 50 1 2 3 4 (%) (%) (%) (%)
(Reproductive system)	system)						
epididymis	spermatogenic granuloma	•	(50) 0 1 0 0) (2) (0) (0 (0	(0)(0)(0)(0) 0 0 0 0 0 0 0 0	<pre></pre>	(6) (0) (0) (0) (0)
prostate	inflammation		<50> 0 4 0 0) (8) (0) (0 (0	(0) (6) (0) (0)	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	(0) (0) (0) (0) 0 0 0 0 (20)
	hyperplasia	6 (12)	0 0 9 (3) (3)	0 (0	3 0 0 0 0 (9) (9)	6 1 0 0 (12) (2) (0) (0)	6 0 0 0 0 (12) (12) (13) (14) (15)
mammary gl	galactocele	Č	<50> 0 1 0 0) (2) (0) (0 (0	(0) (0) (0) (0) 0 0 0 0 0 0 0 0	(0) (0) (0) (0) 0 0 0 0 0 0 0 0 0 0 0	<pre></pre>
(Special sen	[Special sense organs/appendage]						
eye	cataract	10 (20)	(20) (0) (0) (0) (0) (0)	0 0	<550> 7 0 0 0 (14) (0) (0) (0)	(12) (0) (0) (0)	<50> 13 0 0 0 (26) (0) (0) (0)
	retinal atrophy	(2	13 7 0 (26) (14) (0) (0 (0	2 4 2 0 ** (4) (8) (4) (0)	1 2 2 0 **	2 8 3 0 ** (4) (16) (6) (0)
Grade 1 : Slight (a) b a : Number b b : Number (c) c : b / a * Significant difference ; (IPT150)	2: Moderate of animals examined at the of animals with lesion 100 *: P ≤ 0.05 **: P	3 : Marked 4 : Severe site ≤ 0.01 Test of Chi Square	luare				BAIS4

	MALE					PAGE :
Organ	Findings	Group Name No. of Animals on Study Grade	Control 1 2 3 4 (%) (%) (%) (%)	1280 ppm 50 1 2 3 4 (%) (%) (%) (%)	3200 ppm 50 1 2 3 4 (%) (%) (%)	8000 ppm 50 1 2 3 4 (%) (%) (%) (%)
ecial sense ora	(Special sense organs/appendage)					
eye ke	keratitis)	<50> (0) (0) (0) (0) (0)	(0)(0)(0)(0) 0 0 0 0 0 0 0 0	<50> (50) (7) (9) (10) (10) (10) (10) (10) (10) (10) (10	<00 (0) (0) (0) (0) (0)
й	squamous cell metaplasia∶cornea		1 0 0 0 2) (0) (0) (0)		(0)(0)(0)(0)(0)	(0)(0)(0)(0)(0)
nasolacr d	inflammation		<50> 1 0 0 0 2) (0) (0) (0)	<pre> <50> 2 0 0 (4) (0) (0) (0)</pre>	<50> 1 0 0 0 (2) (0) (0) (0)	(0) (0) (0) (0) 0 0 0 0 0 0 0 0 0
(Musculoskeletal system)	system)					
muscle	atrophy	C	<pre></pre>	(0)(0)(0)(0) 0 0 0 0 0 0 0	<50> 0 0 0 0 (0) (0) (0)	(50) (0) (2) (0)
bone	osteosclerosis	<u> </u>	(0) (0) (0) (0 0 0 0 0 0 000 0 000	<50> 1 0 0 0 (2) (0) (0) (0)	<50> (0) (0) (0) (0) (0) (0) (0) (0) (0) (0)	(0) (0) (0) (0) (0) (0) (0) (0) (0) (0)
(Body cavities)						
mediastinum he	hemorrhage		<20> (0) (0) (0) (0) (0) (0) (0) (0) (0) (0)	<50> 0 1 0 0 (0) (2) (0) (0)	(0) (0) (0) (0) 0 0 0 0 0 0 0 0	<pre></pre>
Grade 1: (<a> a> a (<a> b (<a> c (<a> c<a> c<a> c<a> c<a> c<a> c<a> (<a> c<a> c<a> c<a> c<a> c<a> c<a> c<a> c	1: Slight 2: Moderate 3: Na Number of animals examined at the site b: Number of animals with lesion c: b / a * 100	3 : Marked 4 : Severe site	vere			

STUDY NO. : 0579 ANIMAL : RAT F344/DuCrICrIj[F344/DuCrj] REPORT TYPE : Al	HISTOPATHOLOGICAL FINDINGS :1 ALL ANIMALS (0-105W)	HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)	Y)	
SEX : MALE				PAGE: 14
	Group Name Control No. of Animals on Study 50	1280 ppm 50	3200 ppm	8000 ppm
OrganFindings	(%)	(%) (%) (%) (%)	(%) (%) (%) (%)	$\frac{1}{(\%)}$ $\frac{2}{(\%)}$ $\frac{3}{(\%)}$ $\frac{4}{(\%)}$
(Rody cavities)				
retroperit	(409)	(20) (50)	<20\$	<20\$>
1060				
Grade 1 : Slight 2 : Moderate <a> a : Number of animals examined at th	3 : Marked 4 : Severe he site			
b b : Number of animals with lesion (c) c : b / a * 100 Significant difference ; * : P \le 0.05 **: P \le 0.	ion ** : $P \le 0.01$ Test of Chi Square			
(HPT150)				BA1S4

TABLE L 4

HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC

LESIONS: FEMALE: ALL ANIMALS

STUDY NO. : 057 ANIMAL : RAI REPORT TYPE : AI SEX : FEX	: 0579 : RAT F344/DuCr1Cr1;[F344/DuCr;] : A1 : FEMALE	E S	LL ANIMALS (0-105W)	HLSTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)	(4)	PAGE: 15
Organ	Findings	Group Name No. of Animals on Study Grade	Control Cudy 50 1 2 3 4 (%) (%) (%) (%)	1280 ppm 50 1 3 4 (%) (%) (%) (%)	3200 ppm 50 1 2 3 4 (%) (%) (%) (%)	8000 ppm 50 x 4 (%) (%) (%) (%)
(Integumenta	(Integumentary system/appandage)					
skin/app	squamous cell hyperplasia		<50> (0) (0) (0) (0) (0)	<50> 0 1 0 0 (0) (2) (0) (0)	<50> 0 1 0 0 (0) (2) (0) (0)	<pre></pre>
	scab		0 0 0 0 0		0 0 0 0 0	1 0 0 0 (2) (2) (3) (4) (5)
	epidermal cyst		0 1 0 0 (0) (0) (0)			(0)(0)(0)(0)(0)
{Respiratory system}	system)					
nasal cavit	thrombus		<pre></pre>	(0) (0) (0) (0) 0 0 0 0 0 (0) (0) (0)	(0)(0)(0)(0) 0 0 0 0 0 0 0	(0) (0) (0) (0) 0 0 0 0 0 0 0 0
	goblet cell hyperplasia				0 1 0 0 (0) (0) (0)	(0) (0) (0) (0)
	eosinophilic change:olfactory epithelium	an.	8 32 2 0 (16) (64) (4) (0)	12 33 2 0 (24) (66) (4) (0)	13 30 1 0 (26) (60) (2) (0)	18 18 1 0 * (36) (36) (2) (0)
	eosinophilic change:respiratory epithelium	lium	16 0 0 0 0 (32) (32) (0) (0) (0)	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	14 0 0 0 (28) (28) (3) (4) (5)	1 0 0 0 ** (8)(0)(0)(0)
Grade <a>b b cc) Significant	Grade 1: Slight 2: Moderate 3::	Warked .01 Test	4: Severe of Chi Square			
(IIPT150)						BAIS4

	: FEMALE					PAGE :
		Name Animals on Study	Control 50 4 4	1280 ppm 50 1 2 3 4		8000 ppm 50 1 2 3 4
organ	rinaings	(%)	(%)	(%) (%)		(%)
(Respiratory system)	system)					
nasal cavit	inflammation:foreign body	0) (0)	<50> 0 0 0 0) (0) (0)	<pre></pre>	<50> 1 0 0 0 (2) (0) (0) (0)	<50> 1 0 0 (2) (0) (0) (0)
	respiratory metaplasia:gland	8 0 (16) (0	(0) (0) (0	5 0 0 0 (10) (10) (10) (10)	0 0 0 6	6 0 0 0 (12) (12) (13) (13) (13) (14)
lung	congestion	0 (0)	<50> 0 0 0 0) (0) (0)	<50> 0 0 0 0 (0) (0) (0)	<50> 0 1 0 (0) (2) (0) (0)	(0) (0) (0) (0) 0 0 0 0 0 0 0 0
	едешя	0) (0)	(0) (0) (0	1 0 0 0 0 (2) (2) (3) (4) (4)	(0)(0)(0)(0)(0)	
	accumulation of foamy cells	1 0 (2) (0 0	(0) (0) (0	(0)(0)(0)(0)	(2) (0) (0) (0)	
	bronchiolar-alveolar cell hyperplasia	1 0 (2) (0 0	(0) (0) (0	(2) (0) (0) (0)	1 0 0 0 (2) (3) (4) (5)	2 0 0 0 (4) (5) (6) (6)
	inflammation:foreign body	0) (0) .	0 0 0			1 0 0 0 (0) (0) (0)
(Hematopoietic system)	c system)					
bone marrow	granulation	5 (10) (00)	<50> (0) (0) (0) (0)	(50) 1 2 0 0 (2) (4) (0) (0)	<pre></pre>	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
Grade < a > b b (c)	1 : Slight 2 : Moderate 3 : Marked a : Number of animals examined at the site b : Number of animals with lesion c : b / a * 100	ed 4 : Severe				

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)	ALL ANIMALS (0-105W)	
STUDY NO. : 0579	ANIMAL : RAT F344/DuCrlCrlj[F344/DuCrj]	REPORT TYPE : A1

	Group No. of Grade	Name Con Animals on Study 50	1280 ppm 50 2 3	3200 ppm 50 1 2 3 4	8000 ppm 50
Organ	Findings) (%) (%)	(%) (%) (%)	(%)	(%) (%) (%)
(Hemalopoietic system)	system)				
bone marrow	increased hematopoiesis	<50> 4 0 0 0 (8) (0) (0) (0)	<50> 6 0 0 0 (12) (0) (0) (0)	<50> 2 0 0 (4) (0) (0) (0)	<50> 4 0 0 (8) (0) (0) (0)
spleen	congestion	<50> 0 1 0 0 (0) (2) (0) (0)	(0) (0) (0) (0) (0)	(0) (0) (0) (0) 0 0 0 0 0 0 0 0	(0)(0)(0)(0) 0 0 0 0 0 0 0 0
	deposit of hemosiderin	21 13 0 0 (42) (26) (0) (0)	24 15 0 0 (48) (30) (0) (0)	23 20 0 0 (46) (46) (40) (0) (0)	24 20 0 0 * (48) (40) (0) (0)
	extramedullary hematopoiesis	10 1 0 0 (20) (20) (3) (4)	14 4 0 0 (28) (3) (0) (0)	9 2 0 0 (18) (4) (0) (0)	13 6 0 0 (26) (26) (12) (0) (0)
	engorgement of erythrocyte		(0)(0)(0)(0)	(0)(0)(0)(0)	5 0 0 0 (10) (10) (10)
(Circulatory system)	ystem]				
heart	myocardial fibrosis	<50> 9 0 0 0 (18) (0) (0) (0)	(10) (0) (0) (0) (0) (10) (10) (10) (10)	<050> 6 0 0 0 (12) (0) (0) (0)	(14) (0) (0) (0)
Grade 1 : Slight (a 2) a : Number b b : Number (c) c:b/a*	2: Moderate of animals examined at the of animals with lesion 100	3: Marked 4: Severe			

STUDY NO. : 057 ANIMAL : KA1 REPORT TYPE : A1 SEX : FER	: 0579 : RAT F344/DuCrICrij[F344/DuCrj] : A1 : FEWALE	HISTOPATHOLOGICAL FINDINGS :N ALL ANIMALS (0-105W)	HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)		PAGE : 18
Organ	Findings	Group Name Control No. of Animals on Study 50 Grade 1 2 3 4 (%) (%) (%) (%)	1280 ppm 50 1 2 3 4 (%) (%) (%) (%)	3200 ppm 50 1 2 3 4 (%) (%) (%) (%)	8000 ppm 50 1 2 3 4 (%) (%) (%)
(Digestive system)	system)				
ənâuoj	arteritis	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	(50) (0) (0) (0) (0)	<pre></pre>	(0) (0) (0) (0) (0) (0) (0) (0)
stomach	ulcer:forestomach	<50> 0 1 0 0 (0) (2) (0) (0)	<50> 1 0 0 0 (2) (0) (0) (0)	<50> 1 0 0 0 (2) (0) (0) (0)	<50> 1 2 0 0 (2) (4) (0) (0)
	hyperplasia:forestomach	2 0 0 0 (4) (4) (6) (6) (7)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	5 4 0 0 (10) (8) (0) (0)	16 24 0 0 ** (32) (48) (0) (0)
	erosion:glandular stomach	1 0 0 0 (2) (3) (4) (6) (6)	1 0 0 0 (2) (2) (3) (4)	1 0 0 0 (2) (3) (6) (6)	1 0 0 0 (2) (3) (4) (6)
	hyperplasia:glandular stomach		1 0 0 0 (2) (2) (3) (4)		(0)(0)(0)(0)
	mineralization:glandular stomach	0 1 0 0 (0) (2) (0) (0)	(0)(0)(0)(0)	(0)(0)(0)(0)(0)	(0)(0)(0)(0)(0)
liver	hemiation	<50> 6 0 0 0 (12) (0) (0) (0)	(0) (0) (0) (91) 8 0 0 0 8 (0) (0) (0)	<50> 7 0 0 0 (14) (0) (0) (0)	<50> 9 0 0 0 (18) (0) (0) (0)
Grade < a > b (c) Significant	Grade 1 : Slight 2 : Moderate 3 : N < a > a : Number of animals examined at the site b b : Number of animals with lesion (c) c : b / a * 100 Significant difference ; * : P \leq 0.05 ** : P \leq 0.	3 : Marked 4 : Severe he site P ≤ 0.01 Test of Chi Square			

(IIPT150)

STUDY NO. : 0574 ANIMAL : KAT REPORT TYPE : A1 SEX : FEM	: 0579 : RAT F344/buCrlCrlj[F344/buCrj] : A1 : FEMALE	HISTOPATHOLOGICAL FI ALL ANIMALS (0-105W)	AL FINDINGS :NC 105W)	HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)		PAGE :
Organ	Findings	Group Name Con No. of Animals on Study 50 Grade (%) (%)	Control 50 3 4 (%) (%)	1280 ppm 50 (%) (%) (%)	3200 ppm 50 1 2 3 4 (%) (%) (%) (%)	8000 ppm 50 (%) (%) (%) (%)
(Digostive system) liver	system) naliosis—like lesion		c	<50> 0	< 50 >	<50> 0
	necrosis:focal			(2) (0) (0) (0) 2 0 0 0 (4) (0) (0) (0)		(0) (0) (0) (0) (0) (0) (0) (4) (0) (0) (0) (0) (0) (0) (0) (0) (0) (0
	fatty change		6 0	2 0 0 4) (0) (0) (
	granulation	13 1 (26) (20) (1 0 2) (0)	10 1 0 0 (20) (20) (30) (40)	11 0 0 0 (22) (32) (3) (3) (4)	7 0 0 0 0 (14) (14) (15) (15) (15)
	clear cell focus	2 0 (4) (0) (0 (0)			
	basophilic cell focus	25 0 (50) (0) (0 0	28 0 0 0 0 (56) (56) (60) (60)	20 3 0 0 (40) (6) (0) (0)	23 1 0 0 (46) (2) (0) (0)
	bile duct hyperplasia	0 18 0 (0) (90)	(0) (0)	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	10 0 0 0 0 (20) (20) (30) (30)	5 2 0 0 4 (10) (10) (10)
	focal fatty change	1 0 (2) (0) ((0) (0)	(2) (0) (0) (0)	(0) (0) (0) (0) (0)	1 0 0 0 (2) (3) (4) (6) (6) (6)
Grade	2 : Moderate of animals examined at of animals with lesion : 100	3: Marked 4: Severe le site				
Significant (IIPT150)	Significant difference , * · f ≥ 0.00 **·· f (IPT150)	0.01 1	A CONTRACTOR AND A CONT			B

ANTMALL : KALL REPORT TYPE : AL SEX : FEM	FEMALE					PAGE :
Organ	Findings	Group Name No. of Animals on Study Grade	Control 150 1 2 3 4 (%) (%) (%)	1280 ppm 50 1 2 3 4 (%) (%) (%)	3200 ppm 50 (%) (%) (%) (%)	8000 ppm 50 1 2 3 4 (%) (%) (%) (%)
(Digestive system)	system)					
pancreas	atrophy		<50> 1 1 0 0 2) (2) (0) (0)	<pre></pre>	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	<pre></pre>
	islet cell hyperplasia	J	1 0 0 0 2) (0) (0) (0)		1 0 0 0 (2) (2) (3) (4)	0 1 0 0 (0) (0) (0) (0) (0)
(Vrinary system)	stem}					
kidney	cyst	Ü	<50> (0) (0) (0) (0)	(0) (0) (0) (0) (0) (0) (0) (0)	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	(0) (0) (0) (0) 0 0 0 0 0 0 0 0
	chronic nephropathy	Č	28 5 0 1 56) (10) (0) (2)	29 4 1 0 (58) (8) (2) (0)	30 5 0 0 (0) (0)	29 6 1 0 (58) (12) (2) (0)
	dilatation:tubular lumen		(0)(0)(0)(0		1 0 0 0 (2) (2) (3) (4)	(0)(0)(0)(0)
	atypical tubule hyperplasia	Č	1 0 0 0 2) (0) (0) (0)		(0)(0)(0)(0)	
	dilated pelvis		0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	(0)(0)(0)(0)	0 1 0 0 (0) (0) (0)	0 1 0 0 (0) (0) (0) (0)
Grade <a>> b (c) Significant	Grade 1: Slight 2: Moderate 3: N <a> a: Number of animals examined at the site b: Number of animals with lesion c: b/a * 100 Significant difference; *: P ≤ 0.05 **: P ≤ 0.	larked 4: 01 Test of Chi	Severe Square			

4S (SUMMARY)	
:NON-NEOPLASTIC LESION	
HISTOPATHOLOGICAL FINDINGS :N	ALL ANIMALS (0-105W)

STUDY NO. ANIMAL REPORT TYPE SEX	: 0579 : RAT F344/DuCr1Cr1;[F344/DuCrj] : A1 : FEMALE	HISTO ALL A	HISTOPATHOLOGICAL FINDING ALL ANIMALS (0-105W)	HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)		PAGE: 21
Organ	Findings	Group Name No. of Animals on Study Grade	Control 7 50 1 2 3 4 (%) (%) (%) (%)	1280 ppm 50 1 2 3 4 (%) (%) (%) (%)	3200 ppm 50 4 (%) (%) (%) (%)	8000 ppm 50 1 2 3 4 (%) (%) (%) (%)
(Endocrine system)	ystem)					
pituitary	angiectasis		<50> 1 0 0 0 2) (0) (0) (0)	<50> 1 0 0 (2) (0) (0) (0)	<50> 1 1 0 0 (2) (2) (0) (0)	<50> 0 1 0 0 (0) (2) (0) (0)
	cyst		1 0 0 0 2) (0) (0) (0)	2 2 0 0 (4) (4) (6) (6)	2 1 0 0 (4) (2) (0) (0)	2 0 0 0 (4) (4) (6) (6)
	hyperplasia	(91)	8 4 0 0	12 9 0 0 (24) (24) (18) (0) (0)	6 8 0 0 (12) (15) (0) (0)	7 9 0 0 (14) (15) (18) (18) (19) (19)
	Ratlike pouch	" <u>C</u>	2 0 0 0 4) (0) (0)		(0)(0)(0)(0)(0)	1 0 0 0 (2) (2) (3) (4) (5)
thyroid	C-cell hyperplasia	15 (30)	<50> 5 4 0 0 0) (8) (0) (0)	<50> 9 2 0 0 (18) (4) (0) (0)	(16) (10) (0) (0) 8 5 0 0 8 (10) (0) (0)	<50> 10 4 0 0 (20) (8) (0) (0)
adrenal	peliosis-like lesion		<pre></pre>	<50> 1 0 0 0 (2) (0) (0) (0)	<50> 1 0 0 0 (2) (0) (0) (0)	<pre></pre>
	necrosis:focal			(0)(0)(0)(0)(0)	1 0 0 0 (2) (3) (0) (0)	(0) (0) (0) (0)
Grade < a > b (c) Significant	Grade 1: Slight 2: Moderate 3: 1	3: Marked 4: Severe e site P ≤ 0.01 Test of Chi Square	ere uare			
(IIPT150)						BAIS4

STUDY NO. : 057 ANIMAL : RAI REPORT TYPE : A.I SEX : FEW	: 0579 : RAT F344/buCr1Crlj[F344/buCrj] : A1 : FEMALE	HISTOPATHOLOGICAL FINDINGS ALL ANIMALS (0-105W)	HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)		-
Organ	Pindings	Group Name No. of Animals on Study Grade (%) (%) (%) (%) (%)	1280 ppm 50	3200 ppm 50	8000 ppm 50 1 2 3 (%) (%)
(Endocrine system)	system)				
adrenal	hyperplasia:medulla	(0) (0) (0) (0) (0)	<pre></pre>	<pre></pre>	(50) 1 0 0 (2) (0) (0)
	focal fatty change:cortex	2 0 0 0 (4) (4) (6) (6) (7)	3 0 0 0 0 (0) (0)	(0)(0)(0)(0)	2 1 0 (4) (2) (0)
{Reproductive system}	ve system}				
ovary	cyst	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	<pre></pre>	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	(50) 2 0 0 (4) (0) (0) -
uterus	dilatation	(0)(0)(0)(0) 0 0 0 0 0 0 0 0	(50) (0) (0) (0) (0)	(0) (0) (0) (0) 0 0 0 0 0 0 0 0	<50> 0 1 0 (0) (2) (0) 1
	decidual change	0 2 0 0 (0) (4) (0) (0)	0 1 0 0 (0) (0) (0)	(0)(0)(0)(0)	0 0 0
	cystic endometrial hyperplasia	1 0 0 0 (2) (3) (4) (5)	3 0 0 0 0 0 0 0	3 0 0 0 (0) (0) (0)	0 1 0 (0) (2) (0)
Grade < a > b (c) Significant	Grade 1: Slight 2: Moderate $\langle a \rangle$ a Number of animals examined at the b: Number of animals with lesion (c) c: b / a * 100 Significant difference: *: P ≤ 0.05 **: P	3 : Marked 4 : Severe e site P ≤ 0.01 Test of Chi Square			

(0) (0) (0) ** 0 0 0 800**0 ppm** 50 က 88 <20> 2 8 - 36 <u>~</u> ~ 4 8 3200 ppm 50 2 3 (%) (%) <20> - 8 HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105%) 4 % (8) (8) (2) (0) 1280 ppm 50 co (%) <200 2 88 - 8 4 8
 7
 4
 0
 0

 (14) (8) (0) (0)
 Control 50 2 (%) <200 ક્ર No. of Animals on Study Grade Group Name STUDY NO. : 0579
ANIMAL : RAT F344/DuCrICrlj[F344/DuCrj]
REPORT TYPE : A1
SEX : FEMALE osteosclerosis Findings_ (Musculoskeletal system) Organ pone

PAGE: 24

4 %

ı		
	(HPT150)	

BAIS4

Grade 1: Slight 2: Moderate 3: Marked 4: Severe $\langle a \rangle$ a : Number of animals examined at the site b : Number of animals with lesion (c) c: b/a*100 Significant difference; *: P \leq 0.05 **: P \leq 0.01 Test of Chi Square

TABLE O 1

NEOPLASTIC LESIONS-INCIDENCE AND

STATISTICAL ANALYSIS: MALE

J. ANALYSIS
STATISTICA
NS-INCIDENCE AND
C LESTONS
NEOPLASTI

Group Name					
	Control	1280 ppm	3200 ppm	8000 mdd	
	SITE : subcutis TUMOR : fibroma				
Tumor rate					
Overall rates(a)	9/50(18.0)	6/50(12.0)	7/50(14.0)	3/50 (6.0)	
Aujusteu (ares (u) Torminal rates (c) Statistical analysis	8/33 (24. 2)	13. 10 5/38(13. 2)	13.04 5/39(12.8)	2. 56 1/39(2. 6)	
Peto test					
Standard method(d)	P = 0.2448				
Prevalence method(d)	P = 0.9951				
Cochran-Armitave test(e)	F = 0.9039 P = 0.0924				
Fisher Exact test(e)		P = 0.2883	P = 0.3929	P = 0.0606	
Jumor rate	TUMOR : fibroma, fibrosarcoma				
Overall rates(a)	9/50 (18.0)	6/50(12.0)	8/50(16.0)	3/50/ 6.0)	
Adjusted rates(b)	24.24	13. 16	13.33	2.56	
Terminal rates(c)	8/33(24.2)	5/38 (13.2)	5/39(12.8)	1/39(2.6)	
Statistical analysis					
Standard method(d)	P = 0.2632				
Prevalence method(d)	P = 0.9950				
Combined analysis(d)	P = 0.9667				
Cochran-Armitage test(e)	P = 0.0991				
Fisher Exact test(e)		P = 0.2883	P = 0.5000	P = 0.0606	
	SITE : lung				DOMOTORY DATE IN PROPERTY AND ASSAULT AND A TOTAL ASSAULT AND A TOTAL ASSAULT
		enoma			
lumor rate Agosmall votom(a)	1/50(0)	3/50(6.0)	0 (20 (0 0)	(0 6)05/1	
Adjusted rates(h)	3 03		(0.00)00 /0		
Terminal rates(c)	1/33(3.0)	3/38(7.9)	0/38(0.0)	1/39 (2.6)	
Statistical analysis					
Peto test					
Standard method(d)					
Prevalence method(d)	P = 0.7281				
Combined analysis(d)					
Coontan-Armitage test(e) Fisher Exact test(e)	V = 0.3752	P = 0.3087	P = 0 5000	P = 0.7525	

NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL ANALYSIS

Group Name	Control	1280 ppm	3200 ppm	mdd 0008	
	SITE : spleen TUMOR : mononuclear cell leukemia	nia			
Tumor rate					
Overall rates(a) Adjusted rates(b)	9/50(18.0) 18 18	3/50(6.0)	0/50(0.0)	1/50(2.0)	
Torminal rates(c)	6/33(18.2)	1/38(2.6)	0/39(0.0)	0.0 00.0)	
redistical analysis Peto test					
Standard method(d)	P = 0.8721				
Prevalence method(d)	P = 0.9997 D = 0.6003				
Cochran-Armitage test(e)	F = 0.9992 P = 0.0067**				
Fisher Exact test(e)		P = 0.0606	P = 0, 0013**	l' = 0.0078**	
	SITE : stomach TUMOR : squamous cell papilloma				
Tumor rate					
Overall rates(a)	0/50(0.0)	2/50(4.0)	11/50(22.0)	39/50 (78.0)	
Adjusted rates(b)	0.0		23.08	92.31	
Terminal rates(c)	0/33(0.0)	2/38(5.3)	9/39 (23.1)	36/39 (92.3)	
retistical analysis Peto test					
Standard method(d)) = d				
Prevalence method(d)	P < 0.0001**?				
Combined analysis(d)	P =				
Cochran-Armitage test(e)	P < 0.0001**				
Fisher Exact test(e)		P = 0.2475	P = 0, 0003**	P < 0.0001**	
	TUMOR : squamous cell carcinoma				
fumor rate					
Overall rates(a)	0/50(0.0)	0/50(0.0)	0/50(0.0)	12/50(24.0)	
Adjusted rates(b)	0.0			27.27	
Terminal rates(c)	0/33(0.0)	0/38(0.0)	0/39(0.0)	9/39(23.1)	
Statistical analysis Peto test					
Standard method(d)	P ==				
Prevalence method(d)	P < 0.0001**?				
Combined analysis(d)	D ==				
Cochran-Armitage test(e)	P < 0, 0001**	5 2 1 G	2 2 2	++1000 C = C	,
risher Exact test(e)		3	Ė	1. 0.000,44	

ANALYSIS
STATISTICAL
QVV
LESTONS-INCLDENCE
NEOPLAST1C

SITE : TUMOR : 0/50(0/33(0/3)(0/33(0/3)(0/3	stomach squamous cell papilloma, squamous cell carcinoma 0.0) 0.0) 0.0) 2/50(4.0) 5.26 0.0) 2/38(5.3) 0]**?	3200 ppm 11/50(22. 0) 23. 08 9/39(23. 1) P = 0.0003***	8000 ppm 43/50(86.0) 95.12 37/39(94.9) P < 0.0001**	
SITE : TUMOR : 0/50(0/33(0/3)(0/3)(0/3)(0/3)(0/3)(0/3)(0/3)(0/3)(0/3)(0/3)(0/3)(0/3)(0/3)(0/3	na, squamous cell carcinoma 2/50(4.0) 5.26 2/38(5.3) P = 0.2475 a 4/50(8.0) 9.76	11/50 (22. 0) 23. 08 9/39 (23. 1) P = 0.0003***	43/50(86.0) 95.12 37/39(94.9) P < 0.0001**	
0/50(0/33(0/33(1)	2/50(4.0) 5.26 $2/38(5.3)$ $P = 0.2475$ $4/50(8.0)$ 9.76	11/50 (22. 0) 23. 08 9/39 (23. 1) P = 0.0003***	43/50 (86. 0) 95. 12 37/39 (94. 9) P < 0.0001**	
0/50(0/33(0/33(1)	2/50(2/38(P = 0.24' 4/50(11/50 (22. 0) 23. 08 9/39 (23. 1) P = 0.0003**	43/50(86.0) 95.12 37/39(91.9) P < 0.0001**	
0/33(1)	2/38 (P = 0.24:	23. 08 9/39 (23. 1) P = 0. 0003**	95. 12 37/39(94. 9) P < 0.0001**	
D/33(1)	2/38(P = 0.24:	9/39 (23. 1) P = 0.0003***	37/39(91.9) P < 0.0001**	
St(e) P =	P = 0.24.		P < 0.0001**	
st (e) P < 0.06 st (e) P < 0.06 StTE : TUMOR : 1/50(1/33(1) P = 0.32 st (e) P = 0.63	P = 0.24.		P < 0.0001**	
SITE : TUMOR : 1/50(1/33(1/33(1)	P = 0, 24.		P < 0.0001**	
SITE : TUMOR : 1/50(1/33(1/33(1)	P = 0.24		P < 0.0001**	
SITE : TUMOR : 1/50(1/33(1) P = 0.32 1) P = 0.32 st (e) P = 0.63	P = 0.24		P < 0.0001**	
SITE : TUMOR : 1/50(1/33(1/33(1)	4/50 (
1/50(1/33(1/33(1/33(1)	4/50(8.0) 9.76			
1/30(1/33(1/33(1/33(1/3) P = 0.327 1/3) P = 0.633 1/3) P = 0.633	4/50(8.0) 9.76			
1/33(P =	9.76	1/50(2.0)	3/50(6.0)	
1) P = 0.32 (1) P = 0.32 (2) st (e) P = 0.63		2.56		
J) H) St(e)	2/38(5.3)	1/39(2.6)	3/39(7.7)	
11				
The second secon				
	P = 0.1811	P = 0.7525	P = 0.3087	
SITE : liver				
TUMOR : hepatocellular adenoma	hepatocellular adenoma, hepatocellular carcinoma			
Tumor rate				
Overall rates(a) 1/50(2.0)	4/50(8.0)	3/50(6.0)	3/50(6.0)	
Adjusted rates(b) 3.03		7.69		
1/33(2/38(5.3)	3/39(7.7)	3/39(7.7)	
is				
Peto test				
Standard method(d) P =				
Prevalence method(d) $P = 0.3401$				
Δ,				
Cochran-Armitage test(e) $P = 0.6534$				
	P = 0.1811	P = 0.3087	P = 0.3087	

	,
ž	_
5	1
>	•
7	2
2	2
4	
	,
=	4
ζ.	
- 2	
દ	•
Ξ	
- 5	
CTATICATO	
5	
9	
N N	
^	
2	•
`-	
5	3
=	2
7	,
ž	۶
=	-
٠,	
ž	ź
SIMIC	2
5	7
Ľ,	3
-	
C	٥
7	
5	2
A Idra	1
2	5
=	

Group Name	1	0001			
	TO 721100	indd oost	9200 ppm	mad nnns	
	SITE : pancreas TUMOR : islet cell adenoma				
Fumor rate					
Overall rates(a)	2/50(4.0)	4/50(8.0)	6/50(12.0)	3/50(6.0)	
Adjusted rates(b)	6.06		14.63	7. 69	
Terminal rates(c)	2/33(6.1)	3/38(7.9)	5/39(12.8)	3/39(7.7)	
Statistical analysis					
eto test Standard method(d)	<u> </u>				
Prevalence method(d)	P = 0.4782				
Combined analysis(d)	p =				
Cochran-Armitage test(e)	P = 0.8932				
Fisher Exact test(e)		P = 0, 3389	P = 0.1343	P = 0.5000	
	SITE : pancreas TUMOR : islet cell adenoma,is	pancreas islet cell adenoma,islet cell adenocarcinoma			
lumor rate					
Overall rates(a)	2/50(4.0)	4/50(8.0)	6/50(12.0)	3/50(6.0)	
Adjusted rates(b)	6. 06	60.6	14. 63	7.69	
Terminal rates(c)	2/33(6.1)	3/38(7.9)	5/39 (12.8)	3/39 (7.7)	
Statistical analysis					
Peto Lest	1				
Standard method (d)					
Prevalence method(d)	F = 0.4782				
Combined analysis(d)	F =				
Cochran-Armitage test(e)	P = 0.8932				
risner Exact test(e)		l' = 0.3389	P = 0.1343	P = 0.5000	
					THE RESIDENCE OF THE PROPERTY
	TUMOR : transitional cell carcinoma	cinoma			
lumor rate Omorall rates(a)	0 (20 (0 0)	0 (20 (0 0)	0 (0 0)	7 /00/ 2	
Admeted rates(b)			(0.0) (0.0)	17.00 14.0)	
forminal rates(c)	0.33 (0 0)	0 0)88/0	0.0	7/30(17 0)	
Statistical analysis				1001 1001	
Peto test					
Standard method(d)	= d				
Prevalence method(d)	P < 0.0001**				
Combined analysis(d)	P =				
Cochran-Armitage test(e)	P < 0.0001**				
[No. Law Dec. of Acces (1)		:	:		

Group Name Control L280 pms S200 pms S200 pms)09/			
SITE : urinary bladder TUMOR : transitional cell papilloma, transitional cell carcinoma 0/50(0.0))09/	1280 ppm	3200 ppm	8000 mdd
(c) 0/50(0.0) 0/38(0.0) 0/38(0.0) 0/33(0	0/50(0.0)	sitional cell carcinoma		
Dividit 0.00	0,50 (0.0)			
D	0,0			7/50(14. 0)
P =	0/33(0.0)			7/30(17.95
p = st (a) p < 0.0001** p < 0.0001** p < 0.0001** SITE : pituitary gland TUMOR : adenoma 13/50(26.0) 13/50(20.0) 13/50(21.2) p = 0.9135 p = 0.9135 p = 0.9939 st (e) p = 0.0979 p = 0.0979 SITE : thyroid TUMOR : C-cell adenoma 8/50(16.0) p = 0.9933 1) p =				(/ 93 (11. 9)
1)				
SITE pituitary gland TUMOR adenoma TJA3 (21. 2)	< 0.0001**			
SITE : pituitary gland TUMOR : adenoma 13/50(50.0) 23.53 7/33(21.2) P = 0.9135 P = 0.9135 SITE : thyroid TUMOR : C-cell adenoma 8/50(16.0) P = 0.9933 1) P = 0.9933 1/50(14.0) 1/50(14.0) 1/50(14.0) 1/50(14.0) 1/50(14.0) 1/50(14.0) 1/50(14.0) 1/50(14.0) 1/50(14.0) 1/50(14.0) 1/50(14.0) 1/50(14.0) 1/50(14.0) 1/50(14.0) 1/50(14.0) 1/50(14.0)				
SITE : pituitary gland TUMOR : adenoma 13/50(26.0) 13/50(26.0) 13/50(20.0) 13.16 7/33(21.2) P = 0.9135 st (e) P = 0.9135 st (e) P = 0.9699 st (e) P = 0.979 P = 0.3176 P = 0.3176 IWON : C-cell adenoma 8/50(16.0) 7/50(14.0) P = 1)				
SITE : pituitary gland TUMOR : adenoma 13/50(26.0) 23.53 7/33(21.2) P = 0.9135 P = 0.9135 st(e) P = 0.9979 SITE : thyroid TUMOR : C-cell adenoma 8/50(16.0) P = 0.993 1) P = 0.938*	-	P = N. C.		P = 0, 0062**
TUMOR : adenoma 13/50(20.0) 13/50(20.0) 13.50 7/33(21.2) P = 0.9135 P = 0.9135 Strip P = 0.0979 STIP : thyroid TUMOR : C-cell adenoma 8/50(16.0) P = 0.9933 1) P = 0.9933 1) P = 0.9933 1) P = 0.9308 13.16 5/38(13.2) 13.16 13.16 5/38(13.2) 13.16 13.17 13.16 13.17 13.16 13.17	• •			
13/50(20.0)				
13.0 (20.0) 13.0 (20.0) 13.16 13.2 (20.0) 13.16 13.2 (20.0) 13.16 13.2 (20.0) 13.16 13.2 (20.0) 13.2 (20.0	3/50(36.0)	(0 06 / 00 / 0)	(0,00,00)	(0.01,001,0
T/33 (21. 2)	3/30(Z0. 9) 33 F3	10/30(20.0)	12/50(24. 0)	6/50(12.0)
P = 0.9135 1) P = 0.8906 st(e) P = 0.0979 p = 0.979 SITE : thyroid TUNOR : C-cell adenoma 8/50(16.0) 7/50(14.0) P = 1) P = 1) P = 0.993 1) P = 1) P = 0.993 1) P = 0.993	7 (22 (-21-2)	15. It	20.93	10.26
P = 0.9135 P = 0.8906 p = 0.8906 p = 0.9669 st(e)	(100 (41.4)	0/ 90 (19. 7)	6, 59 (20. 5)	4/39(10.3)
P = 0.9135 P = 0.8906 Streek				
J	= 0.9135			
1)	= 0.8906			
st(e) P = 0.0979 P = 0.3176 P = 0.3176 P = 0.500 SITE : thyroid TUMOR : C-cell adenoma 8/50(16.0)	= 0.9669			
SITE : thyroid TUMOR : C-cell adenoma 8/50(16.0)	= 0.0979			
SITE : thyroid TUMOR : C-cell adenoma \$\sigma 50(16.0) 7/50(14.0) 3/50(16.0) 17.33(21.2) 7/33(18.4) 2/39(19.4) 2/39(19.4) 2/39(19.4) 2/39(19.4) 19.4		E.		P = 0.0624
TUMOR : C-cell adenome	i			
8/50 (16.0)				
8/50(16.0) 7/50(14.0) 3/50(21.62 18.42 7/33(21.2) 7/38(18.4) 2/39(1) P = 1) P = 0.9933 1) P = 0.9933 4r(c) P = 0.0308*				
21. 62 18.42 18.42 18.33 19.53 19.53 19.63 19.53 19.63 19.63 19.63 19.64 19.64 19.64 19.64 19.64 19.64 19.64 19.64 19.64 19.64 19.64 19.64 19.64 19.64 19.64 19.64 19.64 19.64	8/50(16.0)	7/50 (14.0)	3/50(6.0)	2/50(4.0)
7/33 (21. 2) 7/38 (18. 4) 2/39 (p =	21.62	18. 42		5.13
(F)	7/33(21.2)	7/38(18.4)		2/39(5.1)
	= 0.9955 =			
	= = 0 0308*			
		E		P = 0, 0458*

AMAI VC 1C	
CTATICTION	
CE AND	
- INCLINENCE	
	3
7	

25 (e) (a (c)	3200 ppm	mdd 0008	
1/50(2.0) 3.03 1/33(3.0) 1/33(3.0) 1/33(3.0) 1/33(3.0) 1/33(3.0) P = 0.5587 P = 0.1512 1 1 1 2 2.2385 1 2 2.2385 2 2.32 8/33(2.1.2) 2 2 3.2 8/33(2.1.2) P = 0.5587 P = 0.5587 P = 0.5587 P = 0.5587 P = 0.9074 2 2 2 2 2 2 2 2 2			
1/50(2.0) 3.03 1/33(3.0) 1/33(3.0) 1/33(3.0) 1/33(3.0) 1/33(3.0) 1/33(3.0) 1/32			
1/33 (3.0) 1/33 (3.0) 1/33 (3.0) 1/33 (3.0) 1/34 (3.0) 1/3587 1/3585 1/3585 1/350 (18.0) 1/350 (18.0) 1/350 (18.0) 1/350 (2	2/50(4.0)	4/50(8.0)	
d) P = 0.5587 d(d) P = 0.1009 s(d) P = 0.1512 ttest(e) P = 0.2385 ITE : thyroid TUMOR : C-cell adenoma, C-cell carcinoma 9/50(18.0) 24.32 8/33(24.2) is s(d) P = 0.5587 d(d) P = 0.5587 ttest(e) P = 0.5736 t(e) SITE : adrenal gland TUMOR : pheochromocytoma 1/50(2.0) is d) P = 0.2736 t(e) P = 0.2736 t(f) P = 0.2736	5.13	10. 26	
P = 0.5587 P = 0.1009 P = 0.1009 P = 0.1512 STTE : thyroid TUMOR : C-cell adenoma, C-cell carcinoma 9/50(18.0) 24.32 8/33(24.2) P = 0.5587 P = 0.5587 P = 0.9074 STTE : adrenal gland TUMOR : pheochromocytoma 1/50(2.0) 2.56 0/33(0.0)	2/39(5.1)	4/39 (10.3)	
P = 0.5587 P = 0.2385 P = 0.1009 P = 0.1512 P = 0.1512 P = 0.2385 P = 0.5587 P = 0.5587 P = 0.5587 P = 0.9074 P = 0.5587 P = 0.2736 P =			
st(e) P = 0.1502 st(e) P = 0.2385 b) STTE : thyroid TUMOR : C-cell adenoma, C-cell carcinoma 9/50(18.0) 24.32 8/33(24.2) B = 0.5587 D = 0.5587 P = 0.5587 P = 0.2736 s) STTE : adrenal gland TUMOR : pheochromocytoma 1/50(2.0) 2.56 0/33(0.0)			
st(e) P = 0.2385 STTE : thyroid TUMOR : C-cell adenoma, C-cell carcinoma 9/50(18.0) 24.32 8/33(24.2) P = 0.5587 P = 0.9774 STTE : adrenal gland TUMOR : pheochromocytoma 1/50(2.0) 2.56 0/33(0.0)			
STTE : thyroid TUMOR : C-cell adenoma, C-cell carcinoma 9/50(18.0) 24.32 8/33(24.2) 8/33(24.2) 1)			
STTE : thyroid TUMOR : C-cell adenoma, C-cell carcinoma 9/50(18.0) 24.32 8/33(24.2) 1)	P = 0.5000	P = 0.1811	
UMOK			
9/50(18.0) 24.32 8/33(24.2) P = 0.5587 P = 0.9074 St(e) P = 0.2736 STTE : adrenal gland TUMOR : pheochromocytoma 1/50(2.0) 2.56 0/33(0.0)			
24.32 8/33(24.2) P = 0.5587 1) P = 0.8895 st(e) P = 0.2736 STTE : adrenal gland TUMOR : pheochromocytoma 1/50(2.0) 2.56 0/33(0.0)	(0 0)	(0 01) 01/ 0	
8/33(24.2) P = 0.5587 P = 0.8895 st(e) P = 0.9074 STTE : adrenal gland TUMOR : pheochromocytoma 1/50(2.0) 2.56 0/33(0.0)	10.01 10.05	0/50(12.0) 15 38	
P = 0.5587 P = 0.8895 P = 0.8895 P = 0.9074 P = 0.2736 P =	4/39(10.3)	6/39(15.4)	
P = 0.5587 P = 0.8895 P = 0.8895 P = 0.9074 P = 0.2736 P = 0.233 P = 0.256 P =			
P = 0.5587 P = 0.8895 P = 0.8895 P = 0.9074 St(e)			
D			
1)			
SITE : adrenal gland TUMOR : pheochromocytoma 1/50(2.0) 2.56 0/33(0.0)			
SITE : adrenal gland TUMOR : pheochromocytoma 1/50(2.0) 2.56 0/33(0.0)	0,000 0 1 0	CONTRACT (* 11.4)	
SITE : adrenal gland TUMOR : pheochromocytoma 1/50(2.0) 2.56 0/33(0.0)	l' V. 1940	1 = 0.2883	
TUMOR : pheochromocytoma 1/50(2.0) 2.56 0/33(0.0)			
1/50(2.0) 2.56 0/33(0.0)			
1/50 (2. 0) 2. 56 0/33 (0. 0) P =			
2.56 0/33(0.0) P =	5/50(10.0)	4/50(8.0)	
0/33(0.0) P =	12.82	10. 26	
	5/39(12.8)	4/39(10.3)	
method(d)			
4			
Combined analysis(d) $P = \frac{1}{2}$			
Cochran-Armitage test(e) $F = 0.865$ / $E = 0.855$	6001 0 = 6	0 - 0	

ANALYSIS
STATISTICAL
ONV
LESTONS-INCIDENCE
NEOPLASTIC

SITE Section Control L280 page Sign Sig	TOTAL .					rage .
SITE : adrenal gland TUMOR : phecochromocytoma, phecothromocytoma; malignant 2/50(4.0)	Group Name	Control	1280 ppm	3200 ppm	mdd 0008	
2/50(1.0) 9/50(18.0)			ochromocytoma:malignant			Transportations is a second se
1,33(3.0) 9/50(18.0)	mor rate					
1/33(3.0) 9/38(23.7) 1/33(3.0) 9/38(23.7) 1/3 P = 0.6512 1/3 P = 0.6512 1/3 SITE	verall rates(a) diusted rates(b)	2/50(4.0)	9/50(18.0)	5/50(10.0)	4/50(8.0)	
st(e) P = 0.6512 st(e) P = 0.6512 st(e) P = 0.6512 SITE : testis TUMOR : interstitial cell tumor 30/50(60.0) 72.73 24/33(72.7) 34/38(89.5) P = 0.4721 b) P = 0.4721 b) P = 0.6121 SITE : nammary gland TUMOR : fibroadenema 2/50(4.0) 6.06 2/33(6.1) 0/38(0.0) 0/38(0.0) 1) P = 0.1495 1) P = 0.6495 1) P = 0.1495 1) P = 0.4495 1) P = 0.4495 1) P = 0.4495 1) P = 0.4495	erminal rates(c)	1/33(3.0)	9/38(23.7)	5/39(12.8)	10.50	
st (e) P = 0.6512 1) P = 0.6512 1) P = 0.0256* SITE : testis TUMONR : interstitial cell tumor 30/50(60.0) 38/50(76.0) 38/50(76.0) 38/50(76.0) 30/50(60.0) 38/50(76.0) 1) P = 0.4721 1) P = 0.4721 1) P = 0.4721 24/33(72.7) 34/38(89.5) 1) P = 0.6121 2/50(4.0) 0/50(0.0) 6.06 0/38(0.0) 1) P = 0.1495 1) P = 0.1495	eto test					
P = 0.6512 P = 0.6512 P = 0.8232 SITE : testis TUMOR : interstitial cell tumor 30/50(60.0)	standard method(d)					
SITE : testis SITE : testis TUMOR : interstitial cell tumor 30/50(60.0)	Prevalence method(d) Combined analysis(d)	P = 0.6512 P =				
SITE : testis SITE : testis TUMOR : interstitial cell tumor 30/50(60.0) 38/50(76.0) 72.73 38/50(76.0) P = 0.4721 D) P = 0.4721 D) P = 0.4721 SITE : mammary gland TUMOR : fibroadenoma 2/50(4.0) 6.06 2/33(6.1) 0/38(0.0) P = 0.1495 D) P = 0.1495 D) P = 0.2744	ochran-Armitage test(e)	P = 0.8232				
SITE : testis TUMOR : interstitial cell tumor 30/50(60.0)	isher Exact test(e)		11		P = 0.3389	
30/50(60.0) 38/50(76.0) 72.73 24/33(72.7) 34/38(89.5) P = 24/33(72.7) 34/38(89.5) P = 0.4721 St(e) P = 0.6121 STIE : mammary gland TUMOR : fibroadenoma 2/50(4.0) 0/50(0.0) 2/33(6.1) 0/38(0.0) P = 0.1495 D = 0.2474	,		mor			
December 2013 (72.73	nor rate parall rates(a)	30/50(60.0)	0 32 /05/86	(0 04) 05/ 56	(0) (0) (0) (0)	
24/33(72.7) 34/38(89.5) P = 1)	ljusted rates(b)	20, 30 (30. 0)	30/30 (10:0) 89.74	39/50(70.0)	35/50(70.0)	
P =	rminal rates(c)	24/33(72.7)	34/38(89.5)	30/39(76.9)	32/39 (82.1)	
P = 0.4721 J) P = 0.4721 st(e) P = 0.6121 SITE : mammary gland TUMOR : fibroadenoma 2/50(4.0) 0/50(0.0) 1/50(2/33(6.1) 0/38(0.0) 1/39(J) P = 0.274 J) P = 0.2774	tistical analysis					
1)	tandard method(d)	d ====================================				
st (e) P =	revalence method(d)	P = 0.4721				
st(e) P = 0.6121 SITE : nammary gland TUMOR : fibroadenona 2/50(4.0)	combined analysis(d)	= d				
SITE : mammary gland TUMOR : fibroadenoma 2/50(4.0)	ochran-Armitage test(e) sher Exact test(e)	P = 0.6121	P = 0,0664	P = 0.2009	900% n = q	
SITE : mammary gland TUMOR : fibroadenoma 2/50(4.0)					2007:0	
TUMOR : fibroadenoma $ 2/50 (4.0) \\ 2/50 (4.0) \\ 0.0 $						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	mor rate					
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	verall rates(a)	2/50(4.0)			3/50(-6.0)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Justed rates(b)	6. 06		2. 50	M. 7.	
il) d) s;t (e)	erminai rates(c) atistical analysis	2/35(-0.1)		1/39(2.0)	2/39(5.1)	
	ore test					
	standard method(d)	= d				
	revalence method(d)	P = 0.1495				
	Combined analysis(d)	d				
	Cochran-Armitage test(e)	P = 0.2474	- 1			

2/3
53
\exists
$\overline{}$
\sim
4
<
3
=
<
೦
\rightarrow
_
5.7
2
$\overline{}$
-
\sim
\leftarrow
:/
$\overline{}$
ş
≤.
~
-
_
\circ
ラ
£23
$\overline{}$
≘
3
CID
NCID
CI
-INCID
-INCI
(S-INCID
-INCI
-INCI
IONS-INCI
IC LESIONS-INCI
IONS-INCI
TIC LESIONS-INCI
TIC LESIONS-INCI
TIC LESIONS-INCI
STIC LESIONS-INCI
LASTIC LESIONS-INCI
TIC LESIONS-INCI
OPLASTIC LESIONS-INCI
PLASTIC LESIONS-INCI
OPLASTIC LESIONS-INCI
WEOPLASTIC LESIONS-INCI
WEOPLASTIC LESIONS-INCI
WEOPLASTIC LESIONS-INCI
WEOPLASTIC LESIONS-INCI

: 0579 : RAT F344/DuCrlCrlj[F344/DuCrj] : MALE

STUBY No. ANIMAL SEX

8000 mdd	3/50(6.0) 7.14 2/39(5.1)	P = 0. 1212	4/50(8.0) 5.13 2/39(5.1) P = 0.1811	V C A V C
3200 ppm	1/50(2.0) 0.0 0/39(0.0)	P = 0.5000	3/50(6.0) 2.56 1/39(2.6)	
1280 ppm	and 4/50(8.0) 10.53 4/38(10.5)	P = 0, 0587	2/50(4.0) 5.26 2/38(5.3) P = 0.5000	
Control	SITE : preputial/clitoral glanc TUMOR : adenoma 0/50(0.0) 0.0 0/33(0.0) P = 0.3846	Y = 0.2054 P = 0.2175 P = 0.3822	SITE : peritoneum TUMOR : mesothelioma 1/50(2.0) 3.03 1/33(3.0) P = 0.0706 P = 0.3694 P = 0.1142 P = 0.1665	
Group Name	Tumor rate Overall rates(a) Adjusted rates(b) Torminal rates(c) Statistical analysis Peto test Standard method(d) Denoted	rrevalence method(d) Combined analysis(d) Cochran-Armitage test(e) Fisher Exact test(e)	Tumor rate Overall rates(a) Adjusted rates(b) Terminal rates(c) Statistical analysis Peto test Standard method(d) Prevalence method(d) Combined analysis(d) Cochran-Armitage test(e) Fisher Exact test(e)	(IIDT96AA)

⁽a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Boneath the control incidence are the P-values associated with the trend test.

Prevalence method : Incidental tumor test Standard method : Death analysis

Combined analysis: Death analysis + Incidental tumor test

⁽e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
?: The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
-----: There is no data which should be statistical analysis.
Significant difference; *: P ≤ 0.05 **: P ≤ 0.01

N.C.:Statistical value cannot be calculated and was not significant.

TABLE O 2

NEOPLASTIC LESIONS-INCIDENCE AND

STATISTICAL ANALYSIS: FEMALE

	_	
:	<	
	_	
* ** * * ** * * * * * * * * * * * * * *		
	7	
:	<	
***********	2	
1000		
17.17.1	1	
20.00	_	
	_	
	7	
10000	1	
5	=	

Group Name	Control	1280 ррт	3200 ppm	mdd 8000	
	SITE : spleen TUMOR : mononuclear cell leukemia	eukemia			
<pre>fumor rate Overall rates(a)</pre>	6/50(12.0)	2/50(4.0)	0/50(0.0)	1/50(2.0)	
Adjusted rates(b) Terminal rates(c) Statistical analysis	6. 98 2/42(- 4. 8)	2. 22 1/45(2. 2)	0.0 0/46(0.0)	0.0 0/10(0.0)	
Peto test Standard method(d) Prevalence method(d) Combined analysis(d)	P = 0.8073 P = 0.9867 P = 0.9804				
Cochran-Armitage test(e) Fisher Exact test(e)	l' = 0. 0492*	P = 0.1343	P = 0.0133*	P = 0.0559	
,	SITE : stomach TUMOR : squamous cell papilloma	lloma			AND
<pre>lumor rate Overall rates(a)</pre>	1/50(2.0)	1/50(2.0)	1/50(2.0)	25/50(50.0)	
Adjusted rates(b) Terminal rates(c)	2.38	2.22	2.17	58.54	
Statistical analysis Peto test					
Standard method(d) Prevalence method(d)	P = P < 0.0001**?				
Combined analysis(d) Cochran-Armitage test(e)	P = P < 0.0001**				
Fisher Exact test(e)	на нашинувана дапроложения от получения выполняться выполняться выполняться выполняться выполняться выполняться	P = 0.7525	P = 0.7525	l' < 0.0001**	
	SITE : stomach TUMOR : squamous cell papi	stomach squamous cell papilloma, squamous cell carcinoma			
<pre>fumor rate Overall rates(a)</pre>	1/50(2.0)	1/50(2.0)	1/50(2.0)	25/50(50.0)	
Adjusted rates(b) Terminal rates(c)	2.38 1/42(2.4)	2. 22 1/45(2. 2)	2.17	58.54 23/40 (57. 5)	
Statistical analysis					
Standard method(d)	P =				
Prevalence method(d) Combined analysis(d)	P < 0.0001**; P =				
Cochran-Armitage test(e) Fisher Exact test(e)	P < 0.0001**	P = 0.7525	P = 0, 7525	P < 0.0001**	

STEET STEE	ANIMAL : RAT F344/Ducri	RAT F344/DuCrlCrlj[F344/DuCrj] FEMALE			PAGE :
STIE Pituitary gland 1/50 (14.0) 10/50 (20.0) 1/50 (20.0) 1/50 (14.0) 10/50 (20.0) 1/50 (14.0) 10/50 (20.0) 1/50 (14.1.3) 1/50 (14.0) 1/50 (14.0) 1/50 (12.0) 1/50 (14.0)	Group Name	Control	1280 ppm	3200 ppm	8000 mdd
9/50(18.0)					
P = 0.5167 P = 0.5167 P = 0.5167 P = 0.2217 P = 0.2217 P = 0.2217 P = 0.2227 P = 0.	Tumor rate	(0 01 /02/0	(, , , , , , , , , , , , , , , , , , ,		
P = 0.5167 P = 0.5167 P = 0.5217 Str(a)	Adjusted rates(b)	3/ 50(15. 0) 14. 29	(/50(14.0)	10/50 (20.0)	10/50(20.0)
p = 0.5167 st(a) p = 0.2217 st(b) p = 0.267 SITE : pituitary gland TMMR : adenoma, adenoracinoma 9.50(18.0)	Terminal rates(c)	6/12(11.3)	6/45(13.3)	8/46 (17. 4)	8/40(20.0)
P = 0.5167	Statistical analysis Peto test				
st (a) P = 0.2217 st (b) P = 0.2217 SITE : pituitary gland TUMOR : addromat, addromat addromate; addromate, addromate;	Standard method(d)	P = 0.5167			
F = 0.2027 SITE : pituitary gland TUMOR : adenome, adenocarcinome 9/50(18. 0) P = 0.3048 P = 0.4178 P = 0.5000 P = 0.408 P = 0.408 P = 0.408 P = 0.408	Prevalence method(d)	P = 0.2217			
SITE : pituitary gland TUMOR : adenoms, adenocarcinoms 9/50(18.0) 14.29 16.42(14.3) 6/45(13.3) 10/50(20.0) 11.29 6/42(14.3) 6/45(13.3) 8/46(17.4) 19. P = 0.3048 19. P = 0.217 19. P = 0.2217 19. P = 0.4178 19. P = 0.5000 19. P = 0.4178 19. P = 0.4178 19. P = 0.5000 19. P = 0.4178 19. P = 0.5000	Cochran-Armitage test(e)	P = 0.2627 $P = 0.6008$			
SITE : pituitary gland 10MOR : adenoma, adenoracinoma 9/50(18.0)	Fisher Exact test(e)			P = 0.5000	P = 0.5000
9/50(18.0) 7/50(14.0) 10/50(20.0) 14.29 6/42(14.3) 6/45(13.3) 8/46(17.4) P = 0.3048 1) P = 0.217 P = 0.4178 P = 0.4178 SITE : thyroid TUMOR : C-cell adenoma 1/50(2.0)					
9/50 (18. 0) 7/50 (14. 0) 10/50 (20. 0) 13.33	Tumor rate				
14. 29	Overall rates(a)	9/50(18.0)	7/50 (14.0)	10/50(20.0)	11/50(22.0)
b	Adjusted rates(b)	14. 29	13.33	19.15	20.00
P = 0.3048 P = 0.217 p = 0.217 p = 0.4178 P = 0.4178 P = 0.3929 P = 0.5000 st(e)	Terminal rates(c)	6/42(14.3)	6/45(13.3)	8/46(17.4)	8/40(20.0)
P = 0.3048 st (e)	Statistical analysis				
st (e)	Feto test Standard mathod(4)	0 - 0			
P = 0.1830 P = 0.4178 P = 0.3929 P = 0.5000 P = 0.4708 P = 0.4708 P = 0.1022 P = 0.1830 P = 0.1830 P = 0.4708 P = 0.1830 P = 0.1820 P = 0.5000 P =	Dentical of me chou (d)	r = 0.30%0			
SITE : thyroid SITE : thyroid TUMOR : C-cell adenoma 1/50(2.0) 1/51(2.4) 1/42(2.4) 1/52(2.4) 1/52(3.4)	frevatence method(d)	P = 0.2211 $P = 0.1830$			
SITE : thyroid SITE : thyroid TUMOR : C-cell adenoma 1/50(2.0) 2.38 1/42(2.4) P = 0.1986 1) P = 0.1022 P = 0.5000	Cochran-Armitage test(e)	P = 0.4178			
SITE : thyroid TUMOR : C-cell adenoma 1/50(2.0)	Fisher Exact test(e)		E	P = 0.5000	P = 0.4016
$1/50(2.0) 5/50(10.0) 2/50(4.0) 2/50(4.0) 4.35 4.35 1/42(2.4) 5/45(11.1) 2/46(4.3) 2/46(4.3) 9 = \frac{1}{2} $					
1/50(2.0) $5/50(10.0)$ $2/50(4.0)$ 2.38 $11.11 11.11 $	Tumor rate				
2.38 11.11 4.35 1/42(2.4) 5/45(11.1) 2/46(4.3) 2/46(4.3) P =1986 3) P = 0.1986 3) P = 0.4708 P = 0.1022 P = 0.5000 P	Overall rates(a)	1/50(2.0)	5/50(10.0)	2/50(4.0)	4/50(8.0)
1/42(2. 4) 5/45(11. 1) 2/46(4. 3) P =	Adjusted rates(b)		11.11	4.35	10.00
method(d) P = 0.1986 analysis(d) P = 0.4708 intage test(e) P = 0.4708 P = 0.4708 P = 0.1022 P = 0.5000	Terminal rates(c) Statistical analysis		5/45(-11.1)	2/46(4.3)	4/40(10.0)
P = 0.1986 P = P = 0.4708 P = 0.4708 P = 0.1022 P = 0.1022	Peto test	1 2			
P = 0.4708 P = 0.1022 P = 0.5000	Standard method(d)	P = 0.1986			
P = 0.4708 $P = 0.1022$ $P = 0.5000$	Combined analysis(d)	= d			
P = 0.1022 $P = 0.5000$	Cochran-Armitage test(e)	P = 0.4708			
	Fisher Exact test(e)		P = 0.1022	P = 0.5000	P = 0.1811

(IIPT360A)

ANALYSIS
STATISTICAL
QNV :
CLESTONS-INCLDENCE
NEOPLASTIC

Group Name	Control	1280 ppm	3200 ppm	mdd 0008	
	SITE : thyroid TUMOR : C-cell adenoma, C-cell carcinoma	carcinoma			***************************************
Umor rate Overall rates(a)	2/50(4.0)	7/50 (14.0)	3/50(6.0)	4/50 (8.0)	
Adjusted rates(b) Terminal rates(c)	4. 55 1/42(2. 4)	15.56 7/45(_15.6)	6.52 3/46(6.5)	10.00	
Statistical analysis Peto test					
Standard method(d)	y == =================================				
Combined analysis(d)	r = 0.410/ P =				
Cochran-Armitage test(e) Fisher Exact test(e)	P = 0.9562	P = 0.0798	P = 0.5000	P = 0.3389	
	SITE : uterus TUMOR : endometrial stromal polyp	γρ			
Tumor rate					
Overall rates(a)	7/50(14.0)	6/50(12.0)	3/50(6.0)	4/50(8.0)	
Adjusted rates(b)	14. 58	13.33		92.66	
Terminal rates(c)	6/42(14.3)	6/45(13.3)	2/46(4.3)	3/40(7.5)	
Statistical analysis					
Peto test Standard method(d)	P = 0 3857				
Prevalence method(d)	P = 0 8391				
Combined analysis(d)	P = 0.8300				
Cochran-Armitage test(e)	P = 0.3089				
Fisher Exact test(e)		P = 0.5000	P = 0.1589	P = 0.2623	
	SITE : manmary gland TUMOR : fibroadenoma				
Tumor rate					
Overall rates(a)	7/50 (14.0)	6/50(12.0)	7/50 (14.0)	3/50(6.0)	
Adjusted rates(b)	14. 29	13.33	14.89	4.26	
Terminal races(c) Statistical analysis Polo teri	0/42 (-14. 3)	0/45(-15, 5)	6/46 (13. 0)	1/40(2.5)	
reto test Standard method(d)	P = 0 3207				
Prevalence method(d)	P = 0.9290				
Combined analysis(d)	P = 0.8944				
Cochran-Armitage test(e)	P = 0.1972				
Fisher Fract test(a)					

\simeq
S
~
\leq
Z
-
-
53
Ξ
S
Ţ
ΑŢ
S.
S
Š
ŧ.
ਹ
盃
\equiv
돐
×
⊣
Ś
8
\preceq
33
===
()
<u>~</u>
S
<
∽
0
邕

: 0579 : RAT F344/DuCrlJ;[F344/DuCrj] : FEMALE

STUDY No. ANIMAL SEX

SITE : memmery gland TUMOR : adences, Fibroadences TAGO (14.0) T	Group Name	Control	1280 ppm	3200 ppm	mdd 0008	
14.00 17.50 (14.0) 17.5		SITE : mammary gland TUMOR : adenoma.fibroadenoma				OPPOSITION AND ADDRESS OF THE PROPERTY OF THE
Trates (a) 7/50 (14.0) 6/50 (12.0) 7/50 (14.0) 4/50 (8.0) Trates (a) 1/4.29 6/45 (13.3) 6/46 (13.0) 7/50 (14.0) 6/50 (14.0) Trates (a) 1/4.29 6/45 (13.3) 6/46 (13.0) 2/40 (5.0) Trates (a) P = 0.3307 Exact test (a) P = 0.3304 Exact test (a) F = 0.3304 Exact test (b) F = 0.3007 Exact test (c) F = 0.3007 Trates (a) 7/50 (14.0) 7/50 (14.0) Trates (a) P = 0.3007 Exact test (b) P = 0.3000 Exact test (c) P	Tumor rate					
1.1.29	Overall rates(a)	7/50 (14.0)	6/50(12.0)	7/50(14.0)	4/50 (8.0)	
rates (c) 6/42 (14.3) 6/45 (13.3) 6/46 (13.0) 2/40 (5.0)	Adjusted rates(b)	14. 29	13.33	68 11	88. 99	
cal analysis eat analysis eat analysis eat manulysis eat method(d)	Terminal rates(c)	6/42(14.3)	6/45(13.3)	6/46(13.0)	2/40(5.0)	
ref method(d) P = 0.3207 ref method(d) P = 0.8506 red analysis(d) P = 0.8510 red analysis(d) P = 0.8510 red method(d) P = 0.85207 red method(d) P = 0.3594 red method(d) P = 0.3594 red method(d) P = 0.3594 red method(d) P = 0.3507 red method(d) P = 0.3207 red method(d) P = 0.8332 red method(d) P	Statistical analysis					
rd method (4)	Peto test					
entre method(d) P = 0.8510 Exact test(e) P = 0.8306 Exact test(e) P = 0.8306 Exact test(e) P = 0.8306 Exact test(e) P = 0.8304 SITE : mammary gland TUMOR : adenome, fibroadenome, adonocarcinome rates(a) 7/50(14.0) 7/50(14.0) 7/50(14.0) 4/50(8.0) 1 rates(b) 1.29 7/40(15.0) 6/42(14.0) 7/50(14.0) and rates(b) 1.29 7/46(15.0) 6/42(13.0) 2/40(5.0) entre method(d) P = 0.3207 entre method(d) P = 0.8760 ed analysis(d) P = 0.8332 -/Annitage test(e) P = 0.3030 Exact test(e) P = 0.3030 P = 0.6129 P = 0.6129 P = 0.6129 P = 0.6129 P = 0.6129 P = 0.6223 P = 0.2623	Standard method(d)	P = 0.3207				
Parameter Para	Prevalence method(d)	P = 0.8510				
Exact test(e) P = 0.3594 P = 0.5000 P = 0.6129 P = 0.2623 Exact test(e) Exact test(e) Exact test(e) Exact test(e) Exact test(e) P = 0.5000 P = 0.5000 P = 0.6129 P = 0.2623 SITE : mammary gland	Combined analysis(d)	P = 0.8036				
Exact test(e) P = 0.5000 P = 0.6129 P = 0.2623	Cochran-Armitage test(e)	P = 0.3594				
SITE : manmary gland TUMOR : adenome, fibroadenome, adonocarcinome rates(a) 7/50(14.0) 7/50(14.0) 4/50(8.0) d rates(b) 14.29 7/45(15.6) 6/46(13.0) 2/40(5.0) est analysis ret method(d) P = 0.3207 eluce method(d) P = 0.8760 ed analysis(d) P = 0.8760 Exact test(e) P = 0.3030 P = 0.6129	Firhor Groot tort(a)		0000	2000		
SITE : mammary gland TUMOR : adenoma, adenocarcinoma TUMOR : adenoma, fibroadenoma, adenocarcinoma TOFO(14.0) 7/50(14.0) 7/50(14.0) 4/50(8.0) d rates(a) 7/50(14.0) 7/50(14.0) 4/50(8.0) 15.56 14.89 6.38 17.45(15.6) 6/46(13.0) 2/40(5.0) est rect method(d) P = 0.3207 ence method(d) P = 0.3207 ence method(d) P = 0.8760 ed analysis(d) P = 0.8332 FAMILIAGE test(e) P = 0.3030 Exact test(e) P = 0.3030 Exact test(e) P = 0.6129 Exact test(e) P = 0.6129	realt bader teacte		I 0. 2000	l' = 0.6129	V = 0.2623	
SITE imammary gland TUMOR adenoma, adenocarcinoma TUMOR adenoma, fibroadenoma, adenocarcinoma TUMOR adenoma, fibroadenoma, fibroadenoma, fibroadenoma, adenoma, fibroadenoma, adenoma, fibroadenoma, adenoma, fibroadenoma, adenoma, fibroadenoma, adenoma, fibroadenoma, adenoma, fibroadenoma, fibroadeno					AN ARAMANA AND AN ARAMAN AND AN ARAMAN AND ANALYSIS AND A	ANALYSIS OF THE STREET OF THE
ate rates (a) 7/50(14.0) 7/50(14.0) 7/50(14.0) 4/50(8.0) 6.38 ad rates (b) 14.29 7/45(15.6) 6/46(13.0) 2/40(5.0) 6.38 al rates (c) 6/42(14.3) 7/45(15.6) 6/46(13.0) 2/40(5.0) 2/40(5.0) cal analysis exet (c) P = 0.3207 ence method (d) P = 0.8760 ed analysis (d) P = 0.832 Armitage test (e) P = 0.3030 P = 0.6129 P = 0.6129 P = 0.6129		SITE : mammary gland TUMOR : adenoma fibroadenoma	donocarcinoma			
rates (a) 7/50 (14.0) 7/50 (14.0) 7/50 (14.0) 4/50 (8.0) 6/38 6/42 (14.3) 7/45 (15.6) 6/46 (13.0) 7/50 (14.0) 4/50 (8.0) 6/38 6/42 (14.3) 7/45 (15.6) 6/46 (13.0) 2/40 (5.0) 2/40 (5.0) 6/45 (13.0) 7/45 (15.6) 6/46 (13.0) 7/45 (15.6) 6/46 (13.0) 7/45 (15.6) 6/46 (13.0) 7/45 (15.6) 6/46 (13.0) 7/45 (15.6) 6/46 (13.0) 7/45 (15.6) 6/46 (13.0) 7/45 (15.6) 7/	Timor rate	tomore account to the control of the	COLOCOL CALICING			
rates (a) 7/50 (14.0) 7/50 (14.0) 4/50 (8.0) d rates (b) 11.29 7/50 (14.0) 7/50 (14.0) 4/50 (8.0) d rates (b) 12.29 7/45 (15.6) 6/46 (13.0) 7/45 (15.0) est analysis est rate method (d) P = 0.3207 ence method (d) P = 0.8760 ence method (d) P = 0.8760 ence method (d) P = 0.8332 -Armitage test (e) P = 0.3030 P = 0.3030 P = 0.6129 P = 0.6129	I Tarre	i t				
11.29	Overall rates(a)	(/50([4.0)	7/50(14.0)	7/50(14. 0)		
rates (c) 6/42 (14.3) 7/45 (15.6) 6/46 (13.0) 2/40 (5.0)	Adjusted rates(b)	14. 29	15. 56	14.89	6, 38	
cal analysis est rd method(d) P = 0.3207 ence method(d) P = 0.8760 ence method(d) P = 0.8750 -dramitage test(e) P = 0.3030 Exact test(e) P = 0.3030 P = 0.6129 P = 0.6129	Terminal rates(c)	6/42(14.3)	7/45(15.6)	6/46(13.0)		
rest red method(d) P = 0.3207	Statistical analysis					
rd method(d) $P = 0.3207$ euce method(d) $P = 0.8760$ ed analysis(d) $P = 0.8332$ r-Armitage test(e) $P = 0.3030$ $P = 0.6129$ $P = 0.6129$ $P = 0.6223$	Peto test					
ed analysis(d) P = 0.8760 ed analysis(d) P = 0.8332 -'Armitage test(e) P = 0.3030 Exact test(e) P = 0.6129 P = 0.6129 P = 0.623	Standard method(d)	$\Gamma = 0.3207$				
ed analysis(d) $P = 0.8332$	Prevalence method(d)	P = 0.8760				
-Armitage test(e) P = 0.3030 P = 0.6129 P = 0.6129 P = 0.6129	Combined analysis(d)	P = 0.8332				
Exact test(e) P = 0.6129 P = 0.6129 P = 0.623	Cochran-Armitan tart(a)	0 3030				
Exact test(e) $\Gamma = 0.2623$	contrain Atmittage restrie/	0.0000	-	4		
	fisher Exact test(e)		P = 0.6129	P = 0.6129	P = 0.2623	
	/ TTO COLUMN COL					M delta behades des de desenvers son escriber de la company de la compan

⁽a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.

Standard method : Death analysis

Prevalence method : Incidental tumor test

Combined analysis: Death analysis + Incidental tumor test

(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.

?: The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.

?: The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.

-----: There is no data which should be statistical analysis.

Significant difference; *: P \(\leq 0.05 \) **: P \(\leq 0.01 \)

N.C. Statistical value cannot be calculated and **as not significant.

TABLE Q 1

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER: $F344/DuCrlCrlj\ MALE\ RATS$

TABLE Q1 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER: F344/DuCrlCrlj MALE RATS

Organs	No. of animals	No. of animals	Incidence	Min Max.
Tumors	examined	bearing tumor	(%)	(%)
Stomach	2249			
Squamous cell papilloma 1)		5	0.2	0 - 2
Squamous cell carcinoma 2)		4	0.2	0 - 2
1)+2)		9	0.4	0 - 2
Urine bladdar	2249			
Transitional cell papilloma		11	0.5	0 - 4
Transitional cell carcinoma		0	0.0	0 - 0
Spleen	2249			
Mononuclear cell leukemia		264	11.7	2 - 22
Thyroid	2243			
C-cell adenoma	2210	317	14.1	2 - 30
Adrenal	2249			
Pheochromocytoma		258	11.5	0 - 40
Pheochromocytoma:malignant		37	1.6	0 - 8

45 carcinogenicity studies examined in Japan Bioassay Research Center were used.

Study No.:

 $0043,\,0059,\,0061,\,0063,\,0065,\,0067,\,0095,\,0104,\,0115,\,0130,\,0141,\,0158,\,0162,\,0189,\\0205,\,0210,\,0224,\,0242,\,0246,\,0267,\,0269,\,0278,\,0284,\,0288,\,0294,\,0296,\,0318,\,0328,\\0342,\,0347,\,0365,\,0371,\,0396,\,0399,\,0401,\,0407,\,0417,\,0421,\,0437,\,0448,\,0457,\,0461,\\0407,\,0477$

0497, 0535, 0560

TABLE Q 2

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER: F344/DuCrlCrlj FEMALE RATS

TABLE Q2 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : F344/DuCrlCrlj FEMALE RATS

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min Max. (%)
Stomach Squamous cell papilloma	2097	5	0.2	0 - 2
Squamous cell carcinoma		0	0.0	0 - 0
Spleen Mononuclear cell leukemia	2097	267	12.7	2 - 26

42 carcinogenicity studies examined in Japan Bioassay Research Center were used.

Study No.:

 $0043,\,0059,\,0061,\,0063,\,0065,\,0067,\,0095,\,0104,\,0115,\,0130,\,0141,\,0158,\,0162,\,0189,\\0205,\,0210,\,0224,\,0242,\,0246,\,0267,\,0269,\,0278,\,0284,\,0296,\,0303,\,0318,\,0328,\,0342,\\0347,\,0365,\,0371,\,0399,\,0401,\,0417,\,0421,\,0437,\,0448,\,0457,\,0461,\,0497,\,0535,\,0560$

TABLE R

CAUSE OF DEATH OF RATS IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL

Y NO. AL	: 0579 : RAT F344/DuCrlCrlj[F344/DuCrj]	r.j.]		COUSE OF DEATH (SUMMARY) (0-105#)	
SEX : MALE				PAGE:	. H
Group Name	Control	1280 ppm	3200 ppm	8000 ppm	
Number of Dead and Moribund Animal	17	12	11	11	
no microscop confirm	3	2	1	2	
cardiovascular les	0	0	0	_	
adrenal lesion	ı	0	0	0	
tumor d:leukemia	ಣ	63	0	_	
tumor disubcutis		_	2	0	
tumor d:tongue	0	0	-	0	
tumor dipituitary	£Ç.	2	m	ಎ	
tumor d:thyroid	0		0	0	
tumor d:prep/cli gl	0	0			
tumor dispinal cord	1	0	0	0	
tumor d:Zymbal gl	2	0	0	0	
tumor d:bone	0	0	0	4	
tumor d:vertebra	1	0	0	0	
tumor diperitoneum	0	_	2	S	
tumor diretroperit	0	0	-1	0	

STUDY NO. : 05/9 ANIMAL : RAT F344/D	: 05/9 : RAT F344/DuCrlCrlj[F344/DuCrj]	0r.j]		COUSE OF DEATH (SUMMARY) (0-105W)	
SEX : FEMALE					PAGE: 2
Group Name	Control	1280 ppm	3200 ppm	8000 pmq	
Number of Dead and Moribund Animal	ဘ	5	4	10	
no microscop confirm	0	1	0	0	THE R. P. LEWIS CONTRACTORS AND ADDRESS OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE PROPERTY OF THE
tumor d:leukemia	4	_	0	I	
tumor disubcutis	0	0	0	-	
tumor d:kidney	0	0	_	0	
tumor dipituitary	ಞ	_		m	
tumor d:uterus	0	_	7	ന	
tumor dimammary gl	1	0	0	1	
tumor dibrain	0	1	0		
(BT0120)	THE REAL PROPERTY OF THE PROPE		O-Accessa de Calabados e de presenta por en		BAIS4

FIGURES

FIGURE 1 SURVIVAL ANIMAL RATE OF MALE RATS IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL SURVIVAL ANIMAL RATE OF FEMALE RATS IN THE 2-YEAR FEED FIGURE 2 STUDY OF 2-AMINO-4-CHLOROPHENOL BODY WEIGHT CHANGES OF MALE RATS IN THE 2-YEAR FEED FIGURE 3 STUDY OF 2-AMINO-4-CHLOROPHENOL BODY WEIGHT CHANGES OF FEMALE RATS IN THE 2-YEAR FEED FIGURE 4 STUDY OF 2-AMINO-4-CHLOROPHENOL FIGURE 5 FOOD CONSUMPTION CHANGES OF MALE RATS IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL FOOD CONSUMPTION CHANGES OF FEMALE RATS IN THE FIGURE 6 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL




FIGURE 1 SURVIVAL ANIMAL RATE OF MALE RATS IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL




FIGURE 2 SURVIVAL ANIMAL RATE OF FEMALE RATS THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL




FIGURE 3 BODY WEIGHT CHANGES OF MALE RATS IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL




FIGURE 4 BODY WEIGHT CHANGES OF FEMALE RATS IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL




FIGURE 5 FOOD CONSUMPTION CHANGES OF MALE RATS IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL






FIGURE 6 FOOD CONSUMPTION CHANGES OF FEMALE RATS IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL



Photograph 1

Forestomach: nodule (arrows)


Rat, Male, 8000 ppm, Animal No. 0579-1304



Photograph 2

Forestomach: Squamous cell hyperplasia


Rat, Male, 8000 ppm, Animal No. 0579-1340 (H&E)



Photograph 3

Forestomash: Squamous cell papilloma


Rat, Male, 8000 ppm, Animal No. 0579-1336 (H&E)



Photograph 4

Forestomash: Squamous cell carcinoma


Rat, Male, 8000 ppm, Animal No. 0579-1344 (H&E)



Photograph 5

Urinary bladder: Transitional cell carcinoma

Rat, Male, 8000 ppm, Animal No. 0579-1329 (H&E)



Photograph 6

Higher magnification of photograph 5

Urinary bladder: Transitional cell carcinoma

Rat, Male, 8000 ppm, Animal No. 0579-1329 (H&E)